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Abstract 
Collagens are a family of extracellular matrix proteins that are critically important for 
providing structural support to tissues and for regulating cell behaviour. The thesis 
describes the biochemical analysis of collagen binding by two globular proteins that 
profoundly influence collagen fibril formation in vivo, decorin and SPARC. 
Decorin is the archetypal small leucine-rich repeat proteoglycan and an important 
regulator of collagen fibrillogenesis. The crystal structure of decorin, published in 2004, 
revealed a dimeric structure in which the presumed collagen binding site was not 
accessible. Whether the dimer is functional has been controversial, however, and it has 
been claimed that biologically active decorin is monomeric. In order to resolve this 
controversy, I designed a number of decorin mutants to disrupt the crystallographic 
dimer, including two mutants which introduced glycosylation sites into the dimer 
interface. Size exclusion chromatography with multi-angle laser light scattering and 
analytical ultracentrifugation were used to determine the oligomeric states of decorin 
and the designed mutants. I found that wild-type decorin dimerises in solution with a 
dissociation constant of ~1 μM. The mutants with engineered glycosylation sites were 
pure monomers while other mutants remained dimeric. Thermal unfolding experiments 
showed that the engineered decorin monomers were as stable as wild-type decorin. 
Mutations on the concave face of decorin abolished collagen binding, regardless of 
whether the mutant proteins retained the ability to dimerise or not. Thus the concave 
face of decorin is involved in collagen binding and the dimer must dissociate in order to 
bind collagen.  
 
The crystal structure of human SPARC bound to a collagen-like triple-helical peptide 
was determined in the Hohenester lab in 2008. The key collagen binding residues are 
conserved between human and invertebrate (Drosophila and C. elegans) SPARCs. There 
is a key difference between the orthologues, however: high-affinity collagen binding to 
human SPARC requires proteolytic cleavage of an inhibitory loop that is absent from 
invertebrate SPARCs. To investigate the functional consequences of this structural 
difference for collagen binding, I compared the interactions of the different SPARCs with 
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collagen I and IV, using solid-phase assays and surface plasmon resonance. I found that 
invertebrate SPARCs did not bind collagen more tightly than human SPARC, suggesting 
that the absence of the inhibitory loop does not confer a higher affinity for collagen in 
invertebrate SPARCs. I made several unsuccessful attempts to crystallise an 
invertebrate SPARC, including experiments in which the glycan was trimmed by 
endoglycosidase digestion or removed by mutagenesis of acceptor sites. 
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Chapter 1. Introduction 
 
Collagen-rich extracellular matrices are critically important not only for providing 
structural support to cells but also in cell adhesion, signalling, regulation of tissue 
remodelling during growth, differentiation and wound healing (Myllyharju and 
Kivirikko, 2004).  While the basic structure of the collagen triple helix has been known 
for half a century, protein-collagen interactions remain poorly understood at the atomic 
level. In the projects outlined in this thesis, I have studied collagen binding by two 
secreted proteins, mouse decorin and invertebrate SPARC. This introduction will first 
provide a brief outline of the environment of these two proteins i.e. the extracellular 
matrix. The basic structure and composition of two subclasses of the collagen 
superfamily will be discussed. This will be followed by an overview of our current 
understanding of the structure and biological roles of the two proteins under study.  
 
1.1 The extracellular matrix (ECM) 
The ECM is a complex network of macromolecules (structural proteins, proteoglycans, 
growth factors and matricellular proteins) that provide structural support to tissues 
while regulating cell behaviour and function including cell migration and proliferation, 
homeostasis, and developmental patterning (Frantz et al., 2010). ECM proteins are large 
multidomain molecules - the domains are often repeated and in tandem within the same 
molecule such that adjacent domains can cooperate in biological activities (Hohenester 
and Engel, 2002). Different tissues have unique ECM compositions. The ECM is dynamic 
and continuously remodelled to adapt to the functional requirements of tissues 
(Bosman and Stamenkovic, 2003). Genetic abnormalities in ECM proteins can give rise 
to a wide range of diseases (Frantz et al., 2010, Bateman et al., 2009).  
A list of core ECM proteins which form the “core matrisome” have been identified - 
consisting of almost 300 proteins, including 43 collagen subunits, 200 glycoproteins and 
three dozen proteoglycans (Hynes and Naba, 2012). In addition, there are various “ECM-
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affiliated” proteins (Naba et al., 2012), ECM-modifying enzymes such as proteases and 
cross-linking enzymes and growth factors that are present in the ECM. The main 
molecular components can be divided into two groups: fibrous proteins such as collagen 
and fibronectin and b) proteoglycans (PGs) such as those with leucine rich repeats 
(LRRs), perlecan and agrin (Schaefer and Schaefer, 2010).  
 
1.1.1 The basement membrane 
Basement membranes (BM) or basal laminae are a specialised form of sheet-like ECM 
underlying epithelial cells and surrounding endothelial, muscle, fat and peripheral 
nerve cells (Rowe and Weiss, 2008). BM genes are very ancient: they originated early 
during metazoan evolution and are highly conserved (Hynes, 2012). The discovery of 
the basement membrane-rich mouse Engelbreth-Holm-Swarm (EHS) tumour in the late 
1970s led to the identification of a set of proteins that form a typical 50-100 nm thick 
lamina: cross-linked type IV collagen which makes up 50% of all BM proteins; laminin, a 
heterotrimer made up of related α, β and γ subunits; nidogen, a laminin-binding 
glycoprotein and perlecan and agrin, heparan sulphate proteoglycans (Figure 1.1) 
(Yurchenco, 2011). These molecules are large, ranging from ~ 75 nm to ~400 nm in 
length. BM also often contains the ubiquitous extracellular matrix components SPARC, 
fibulins, and fibronectin (Erickson and Couchman, 2000). Some specialised BMs are 
thicker, e.g. those of the extra-embryonic Reichert’s membrane, the kidney glomerulus 
and the EHS tumour matrix. A clear understanding of BM architecture by imaging in situ 
is difficult as it involves harmful extraction from tissues (Hohenester and Yurchenco, 
2013). All BMs appear similar under the electron microscope but their detailed 
molecular compositions are unique in each tissue (Kalluri, 2003).  
Unlike other components of the BM, laminin and collagen IV can self-assemble to form 
polymers (Yurchenco et al., 1992). BM components are assembled into functional units 
and secreted by cells. The α, β and γ chains of laminin twist around each other to form a 
cruciform trimer with three short arms and one long arm stabilised by disulphide bonds 
(Beck et al., 1990). Laminin polymers are initially deposited and these are anchored to 
the cell surface by interactions via cell surface receptors such as integrins, α-
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dystroglycan and sulphated glycolipids/sulphatides (Figure 1.1B). This is followed by 
accumulation of non-laminin components such as heparan sulphate proteoglycans, 
agrin and perlecan, which provide collateral linkages to tether laminins to the cell 
surface. Collagen IV polymers are subsequently deposited on the cell surface. The 
laminin and collagen networks are bridged by nidogens 1 and 2 (BM glycoproteins).  
Studies with nidogen-deficient mice have shown that these proteins are not crucial for 
bridging laminin and collagen so other proteins must also be involved in this process 
(Bader et al., 2005). Other components of the BM such as heparan sulphates act in 
concert with nidogen and interact with this scaffold to form a fully functional BM 
(Hohenester and Yurchenco, 2013).  
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Figure 1.1 The basement membrane. A. Scanning electron micrograph of the basal lamina of 
the cornea of the chick embryo. The upper surface of the sheet-like basal lamina is exposed by 
removal of some of the epithelial cells. A network of collagen fibrils in the underlying connective 
tissue interacts with the lower face of the lamina (Alberts, 2002) B. Schematic of binding 
interactions between basement membrane components. Laminins anchor to the cell surface by 
interacting with receptors such as integrins, α-dystroglycan and sulphatides, using their long 
arms. Agrin and perlecan provide collateral linkages to cell surfaces. Type IV collagen forms an 
independent network, through interactions of its N-terminal 7S and C-terminal NC1 domains, as 
well as through lateral associations of the triple helices. The laminin and collagen networks are 
linked by nidogen and heparan sulphates (black double-headed arrows). Taken from 
Hohenester and Yurchenco (2013). 
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BMs separate the epithelium from the stroma of tissues. They function to provide 
structural support to adherent epithelial cells, and also influence cell behaviour such as 
providing cues to influence cell polarity. BMs are important in cell adhesion, growth, 
differentiation, tissue repair and molecular ultrafiltration (Sundaramoorthy et al., 
2002). With a pore size in the order of ~ 50 nm, BMs only allow small molecules to 
passively diffuse through them, thus acting as selective barriers (Rowe and Weiss, 
2008). 
Many genetic and vascular diseases are caused by defects in BM proteins. For example, 
mutations in type IV collagen α5 chain causes Alport syndrome, which is characterised 
by a defective glomerular BM. Goodpasture syndrome - an autoimmune disease, is 
caused by auto-antibodies formed against type IV collagen α3 chain (Kalluri, 2003).  
 
1.2 Collagen 
Collagens are the most abundant proteins in mammals where they account for ~30% of 
the total protein mass. This family of extracellular proteins is characterised by the 
presence of a triple-helix that can make up most of their structure (96% of collagen I) or 
just a fraction (less than 10% in collagen XII) (Ricard-Blum, 2011). All collagen 
molecules consist of three polypeptide (α) chains that coil around each other to form a 
right-handed triple helix with a one-residue stagger between adjacent α chains (Figure 
1.2). Each polypeptide chain contains repeating peptide triplets of glycine-X-Y. X and Y 
can be any amino acid but are often proline and 4-hydroxyproline respectively. The 
presence of glycine, the smallest amino acid, as every third residue allows close packing 
of the chains within the triple helix. Hydroxyproline is important for stability of the 
triple helix, which is further stabilised by hydrogen bonds and water bridges and 
electrostatic interactions involving lysine and aspartic acid (Brodsky and Ramshaw, 
1997). All three polypeptide chains in a triple helix can be identical, which is true for 
most collagens (homotrimers), or may differ, consisting of two or three different α 
chains (heterotrimers) (Kadler et al., 2007). For example, type I collagen is made up of 
two α1 chains and one α2 chain wound into a triple helix whereas collagen II consists of 
three identical α chains. The primary structure of α1 chain of one type of collagen 
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differs from that of the α1 chain of another type of collagen. All collagens also contain 
non-collagenous (NC) domains that are numbered from the C-terminus (Kadler et al., 
2007).  
 
 
 
 
Figure 1.2 The collagen triple helix. Collagen is initially synthesised as pro-collagen with the 
triple-helical domain flanked by N- and C- terminal propeptides. These propeptides are 
eventually cleaved by enzymes (N- and C- proteinases). The mature collagen still contains non-
triple helical short peptides called N- and C-telopeptides, and are subsequently assemble into 
fibrils. Taken from Boudko et al. (2012). 
 
Collagens are mostly synthesised by cells in the ECM: fibroblasts, myofibroblasts, 
osteoblasts and chondrocytes (Bosman and Stamenkovic, 2003). Vertebrates have at 
least 28 different collagen types but the existence of several isoforms of the same 
collagen type gives rise to further diversity (Ricard-Blum, 2011). In addition, there 
exists a large group of collagen-like proteins such as C1q, ficolin, surfactant protein and 
macrophage scavenger receptor (Myllyharju and Kivirikko, 2001). The function of the 
collagens depends on the proper supramolecular assembly of the triple helices (Gordon 
and Hahn, 2010). Collagens can be subdivided into subfamilies based on their 
supramolecular assemblies: fibril- forming collagens, network-forming collagens, fibril-
associated collagens with interrupted triple helices (FACITs), anchoring fibrils and 
beaded filaments (Ricard-Blum, 2011).  
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1.2.1 Fibril-forming collagens: collagen I 
Tissues such as tendon, bone, cartilage and skin, which have to resist tensile and shear 
forces, contain collagen that are arranged into fibrils (Bosman and Stamenkovic, 2003). 
Members of this family include collagen types I, II, III, V and XI, type I being the 
archetypal collagen and the most abundant. With the exception of collagens XXIV and 
XXVII, the Gly-X-Y triple helical domain of fibril-forming collagens contains ∼1000 
residues and is uninterrupted (Kadler et al., 2007). Figure 1.3 shows how trimeric 
collagen molecules assemble into fibrils. Each triple helix is staggered from its 
neighbour by 67 nm in the direction of the helix and laterally, the fibrils are arranged 
quasi-hexagonally with respect to each other within the fibril (Perumal et al., 2008) and 
are connected by intermolecular covalent cross-links. The quarter-stagger gives rise to 
the banded pattern of fibrils in electron micrographs. The D-period, which is ~67 nm 
long, forms the basic morphological structure of the fibril. It is composed of a gap zone 
and an overlap zone and each D-period contains the complete monomer sequence from 
elements of five monomers (Sweeney et al., 2008). 
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Figure 1.3 The collagen fibril. A. A single type I collagen triple helix (monomer). Type I 
collagen is secreted as a procollagen monomer 300 nm long, extracellularly, the N- and C-
propeptides are cleaved by proteinases (dashed vertical lines), B) the tropocollagen monomers 
assemble in a staggered fashion into collagen fibrils (C) where one D-period repeat (67 nm 
segment of microfibril, box) contains the complete collagen sequence from elements of the five 
monomers and includes an overlap and gap zone. (D). Collagen fibrils appear as periodic 
banded structures by electron microscopy; arrow, left border of overlap zone; heparin-albumin 
gold conjugates, which appear as circular dark objects, were used to map the heparin-binding 
site (E). Taken from Sweeney et al. (2008).  
 
Fibril-forming collagens are synthesised as pro-collagens in the endoplasmic reticulum 
(ER) having N- and C- propeptides, short non-helical N- and C- telopeptides, and a 
central triple helix (Ricard-Blum, 2011). The intracellular steps in collagen biosynthesis 
involve a number of post-translational modifications including hydroxylation of certain 
proline and lysine residues to 4-hydroxyproline, 3-hydroproline and hydroxylysine, 
glycosylation of some of the hydroxylysine residues and formation of some intra-chain 
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and inter-chain disulphide bonds catalysed by protein disulphide isomerase (PDI) 
(Myllyharju and Kivirikko, 2004). These processes are stopped by the formation of the 
triple helix. This happens when the C- propeptides associate and the triple helix is 
propagated in a zipper-like fashion towards the N-terminus (Myllyharju and Kivirikko, 
2001). The chaperone, Hsp47, binds to procollagen the ER and it has been suggested 
that intracellular secreted protein acidic and rich in cysteine (SPARC) also acts as a 
chaperone in concert with Hsp47 to ensure that correctly folded procollagen exits the 
ER (Martinek et al., 2007). The secretion of procollagen fibres requires formation of 
large COPII vesicle coats which can accommodate these macromolecules (Jin et al., 
2012). Once outside the cell, the propeptides of procollagen are cleaved. The N-
propeptides are cleaved by procollagen N- proteinases which are disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS)-2, -3 and -14 proteinases. 
The C-propeptides are cleaved by procollagen C-proteinases which are bone 
morphogenetic protein-1 (BMP-1) proteinases (Kadler et al., 2007). Meprin α and 
meprin β also act as both C- and N- proteinases for type I procollagen (Broder et al., 
2013). The cleavage of the N- and C- propeptides exposes the telopeptides which are 
non-helical regions containing binding sites for fibrillogenesis – they form non-
reducible covalent cross-links with neighbouring triple helices so molecules can form 
fibrils in a quarter-staggered arrangement (Eyre et al., 1984). This process is catalysed 
by lysyl oxidase and gives collagen its tensile strength. The inhibition of this enzyme 
does not affect fibril formation. However, cross-link-deficient collagen is more likely to 
be degraded than cross-linked collagen. Thus lysyl oxidase inhibitors have potential to 
be used as anti-fibrotic drugs (Myllyharju and Kivirikko, 2001). 
Collagen fibrils often contain more than one collagen type. For e.g. type I collagen may 
contain small amounts type III, V and XII. Collagen II, the principal component of 
cartilage, contains small amounts of collagen XI in its core and collagen type IX on its 
surface (Myllyharju and Kivirikko, 2004). In vitro, collagen fibrillogenesis is a self-
assembly process that does not require the presence of cells. In vivo, noncollagenous 
molecules are required to initiate fibrillogenesis (Kadler et al., 2008). Nearly 50 
molecules have been found to interact with type I collagen in vivo (Di Lullo et al., 2002) 
which may generate a variety of fibril patterns from parallel bundles in tendon and 
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ligament to orthogonal arrangements in cornea. The initial site of fibril formation has 
not been defined so far (Ricard-Blum, 2011). In embryonic development, cells may 
control fibril formation extracellularly by localising this process to cell membrane 
through fusion of collagen fibril intermediates (Birk and Trelstad, 1986, Zhang et al., 
2005) or they may start intracellularly in Golgi-to-membrane carriers that transport 
procollagen to cell membrane protrusions called fibripositors  (Canty et al., 2004). 
There are speculations that fibronectin and integrins may bind collagen and induce a 
conformational change to accelerate fibrillogenesis (Kadler et al., 2008). Collagen type V 
and type XI (which is homologous to collagen V) are used to nucleate collagen fibrils. 
Using mouse models of Ehlers-Danlos syndrome, a hereditary connective tissue 
disorder resulting from mutations in COL5A1 and COL5A2 genes, it has been shown that 
collagen V controls initiation of collagen fibril assembly in vivo (Wenstrup et al., 2004). 
Mice lacking collagen V do not contain collagen fibrils and die at embryonic day 10. Mice 
deficient in small leucine-rich repeat proteoglycans (SLRPs) that bind collagen including 
decorin, biglycan, lumican and fibromodulin, also exhibit defects in collagen fibril size 
and morphology (Schaefer and Iozzo, 2008) (more on this in later sections).  
The collagen triple helix is resistant to proteolytic cleavage by pepsin, trypsin and 
papain (Kadler et al., 2007). Matrix metalloproteinases MMP-1, -8 and -13 cleave fibril-
forming collagens I, II and III, generating three-quarter and one-quarter fragments 
(Ricard-Blum, 2011) as part of the ECM degradation and remodelling process. 
 
 
1.2.2 Network-forming collagens: Collagen IV 
The second class of collagens are the network-forming collagens which include collagen 
types IV, VI, VIII, and X. The ability to self-assemble into organised networks 
distinguishes these collagens from fibrillar ones. Type IV collagen is unique among the 
collagen superfamily since it is only found in BMs. It is the ancestral type of collagen 
from which the other 27 vertebrate collagen types have evolved (Pastor-Pareja and Xu, 
2011). Six genes encoding six polypeptide α chains, α1(IV) – α6(IV) have been identified 
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(Khoshnoodi et al., 2008). These chains are closely related (50 – 70% identity at the 
amino acid level) and can assemble into unique heterotrimers in specific 
stoichiometries to make three different types of network-forming building blocks called 
protomers. These include the (α1)2α2, α3α4α5 and (α5)2α6 protomers (Miner, 2012). 
The most common variant is (α1)2α2, found nearly in all BMs, whereas α3α4α5 and 
(α5)2α6 are found in alveolar and glomerular BMs (Yurchenco, 2011). The existence of 
different α chains for collagen IV and their restricted tissue distribution determine the 
structural and functional specificity of BMs (Ortega and Werb, 2002). Each α chain is 
~400 nm long and contains three domains: a middle triple helical domain flanked by a 
cysteine-rich N-terminal 7S domain and a C-terminal globular NC1 domain which is 
about 200 amino acids in length (Kalluri, 2003). The triple-helical region is ~1,400 
amino acids in length, but unlike most other collagen types, the collagenous Gly-X-Y 
repeats have 21-26 interruptions in which glycine does not occur in every third 
position, presumably to make a more flexible trimer and to serve as cell-binding sites 
(Khoshnoodi et al., 2008). The interruptions do not disturb the folding of the triple helix 
but give rise to kinks in the rod-like helix (Boudko et al., 2012). As demonstrated by 
electron microscopy, trimer assembly begins at the C-terminus when NC1 domains from 
three α chains interact and trimerisation proceeds from C- to N-terminus in a zipper-
like fashion to form a protomer (Figure 1.4). This is followed by two trimers interacting 
via the C-terminal NC1 domains to form an NC1 hexamer. The crystal structure of the 
NC1 domain reveals that it exposes a flat face to its opposite trimer for dimerisation and 
becomes stabilised through an unusual covalent linkage between the side chains of a 
Met residue on one chain and a Lys residue on the opposite chain (Sundaramoorthy et 
al., 2002, Than et al., 2002). (Bhave et al., 2012) have shown that the BM enzyme, 
peroxidasin, catalyses the formation of this bond and Drosophila peroxidasin mutants 
show BM defects due to fewer collagen IV crosslinks. Next, two protomers associate 
through the N-terminal 7S domains to form a tetramer. In this way, a collagen scaffold is 
formed which has been compared with a chicken-wire fence, although the molecules 
further interact to form supramolecular assemblies by lateral association of collagenous 
domains (Boudko et al., 2012). 
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Figure 1.4 Type IV collagen network formation. Each α chain is made up of a 7S domain, a 
triple-helical domain and an NC1 domain. Trimer assembly is initiated by interaction of NC1 
domains. The triple-helical protomer forms. Two trimers interact head to head through their 
NC1 domains, then four trimers associate through their 7S domains. Several trimers can also 
laterally associate via their triple-helical domains. Adapted from Kalluri (2003). 
 
Type IV collagens are present in mammalian BMs throughout development and 
adulthood. However, in invertebrate BMs, collagen IV is deposited much later in 
development, around the time of early muscle contractions, suggesting that collagen IV 
is not required for initial BM assembly but BMs need collagen IV to withstand 
mechanical stress (Yurchenco et al., 2004).  In Drosophila, dorsal-ventral patterning is 
regulated by a host of secreted proteins such as Dpp  that form a concentration gradient. 
There are two type IV collagen proteins in Drosophila: Viking (Vkg) and Cg25C. It has 
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been shown that collagen IV promotes gradient formation by binding Dpp in early 
Drosophila embryo (Wang et al., 2008).  
 
1.3 Small leucine rich repeat proteoglycans (SLRPs) 
1.3.1 SLRPs: characteristics and classification 
Proteoglycans are glycoproteins composed of covalently linked diverse carbohydrate 
chains called glycosaminoglycans (GAGs) attached to serine residues of a protein core 
(Schaefer and Schaefer, 2010). GAGs are linear, consisting of repeating units of 
disaccharides with carboxyl and sulphate groups attached. They consist of an amino 
sugar, N-acetylglucosamine or N-acetylgalactosamine and a second sugar which is 
usually a uronic acid, iduronic or glucuronic acid (Kjellen and Lindahl, 1991). GAGs can 
vary in size, number, sulphation and epimerisation in various tissues (Chen and Birk, 
2013). Owing to their negative charge, GAGs cause proteoglycans to be extended in 
conformation and enable them to bind water and divalent cations such as calcium, thus 
conferring space-filling and hydration functions (Hynes and Naba, 2012). In addition to 
the GAG chains, most core proteins of proteoglycans carry N- and/or O-linked 
oligosaccharides (Kjellen and Lindahl, 1991). 
Mammalian genomes encode roughly three dozen ECM proteoglycans. They can be 
broadly divided into two families: modular proteoglycans and small leucine-rich repeat 
proteoglycans (SLRPs). Modular proteoglycans, such as aggrecan, perlecan and agrin, 
are multidomain assemblies which are relatively elongated and often highly 
glycosylated (Iozzo and Murdoch, 1996). Unlike modular proteoglycans, SLRPs have 
relatively smaller protein cores (36-42 kDa) (Schaefer and Iozzo, 2008). 
SLRPs belong to the leucine-rich repeat (LRR) superfamily of proteins (Hocking et al., 
1998). The SLRP gene family encodes 18 genes mapped onto relatively few (7) 
chromosomes, suggesting that some degree of functional redundancy has been 
generated during evolution (Chen and Birk, 2013, Iozzo, 1998).  At the protein level, 
SLRPs are characterised by a central LRR region flanked by cysteine-rich clusters on the 
N- and C- termini and at least one GAG chain. The LRRs are 20-29 amino acids long, the 
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most common length being 24 residues, with a conserved motif of LxxLxLxxNxL, where 
L is leucine, isoleucine or valine and x is any amino acid (McEwan et al., 2006). The LRR 
motif has been found in >100 intracellular, extracellular, and cell surface proteins (Scott 
et al., 2006). The LRRs adopt a curved solenoid structure with convex and concave faces 
that allow protein-protein interactions (Kresse and Schonherr, 2001). All SLRPs have 
four cysteines with class-conserved internal spacing at the N-terminus and two cysteine 
residues at the C-terminus (Chen and Birk, 2013). Another hallmark of SLRPs is the 
presence of the C-terminal ‘ear repeat’, a long repeat that extends laterally away from 
the protein core. LRR-XI contains one of the cysteine residues which forms a disulphide 
bond with the other cysteine residue on LRR-XII (McEwan et al., 2006).  
The SLRP family can be divided into five classes (Classes I-V) based on conservation and 
homology at the genomic and protein levels and the spacing of cysteine residues at the 
N-terminus (Table 1) (Schaefer and Iozzo, 2008). SLRPs are closely related but are 
differentially expressed and have acquired special functions (Kalamajski and Oldberg, 
2010). Figure 1.5 is a sequence-based evolutionary tree (dendogram) of the SLRP 
family.   
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Phylogenetic tree of SLRPs. Evolutionary tree based on a multiple sequence 
alignment by ClustalW. Adapted from McEwan et al. (2006). 
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Table 1 Classification and properties of SLRPs including size, type of GAG, binding partners and 
knockout-mice phenotypes (where available). Adapted from (Kalamajski and Oldberg, 2010, Chen 
and Birk, 2013) 
SLRPs 
Size 
(kDa)
a
 
Type 
of 
GAG
b
 
Abundant in Binding partners 
Knock-out mice 
phenotype 
Class I 
Decorin 36 CS/DS 
Skin, tendon, 
cartilage, kidney, 
muscle, predentin 
and PDL 
Collagen I; collagen II and III; 
collagen V; collagen VI; 
collagen XII; collagen XIV; 
ﬁbronectin; 
thrombospondin-1; 
microﬁbril-associated 
glycoprotein-1 and ﬁbrillin-1; 
tenascin-X  
Fragile skin, weak 
tendons, lower 
airway resistance, 
slow wound 
healing and 
angiogenesis 
Biglycan 38 CS/DS 
Skin, tendon, bone, 
cartilage, kidney, 
muscle, predentin 
and PDL 
Collagen I; collagen II; 
collagen III; collagen VI; 
collagen IX and biglycan; 
collagen II and VI complex; 
tropoelastin and microﬁbril-
associated glycoprotein-1 
Bone mass 
reduction, aortic 
rupture, and weak 
tendons 
Asporin 42 * 
Liver, heart, aorta, 
uterus, 
perichondrium, 
periosteum, 
predentin and PDL 
Collagen I  
Class II 
Fibromodulin 42 KS 
Tendon, ligament, 
cartilage, predentin 
and PDL 
Collagen I; collagen II; 
collagen VI; collagen IX; 
collagen XII 
Weak tendons and 
osteoarthritis 
Lumican 38 KS 
Widespread, 
predentin, and PDL 
Collagen I; aggrecan; β1 
integrin; β2 integrin; α2β1 
integrin  
Fragile skin and 
opaque cornea 
Osteoadherin 42 KS Mineralised bone 
αvβ3 integrin; Non-
collagenous domain 4 of 
collagen IX 
 
PRELP 44 KS 
Cartilage, lung 
kidney, and skin 
Perlecan and collagen  
Class III 
Osteoglycin 35 KS Cornea and skin Collagen I 
Slight skin fragility, 
but clear (normal) 
cornea 
Opticin 35-45 * Vitreous (eye) 
Heparan and chondroitin 
sulphate proteoglycans, 
collagen 
 
Class IV 
Chondroadherin 36 KS 
Cartilage, cornea, 
lens, and retina 
α2β1 integrin; collagen II  
Class V 
Podocan 70   Collagen I  
a
Approximate molecular mass of the protein core without post-translational modifications   
b
Type of 
glycosaminoglycan - (CS chondroitin sulphate, DS dermatan sulphate, KS keratan sulphate)  *These SLRPs are 
non-glycanated but may have acidic regions (e.g. poly Asp in asporin) or sulphated tyrosine residues 
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Class I SLRPs – This family includes decorin, biglycan and asporin (Table 1). These are 
encoded by eight exons with highly conserved intron/exon junctions (Schaefer and 
Iozzo, 2008). They contain 10-12 LRRs and a defined N-terminal cysteine sequence 
(CX3CXCX6C) which forms two disulphide bonds (Ameye and Young, 2002). Biglycan 
and decorin share 57% sequence identities (Iozzo, 1998). They contain one or two 
dermatan or chondroitin sulphate chains, respectively; the choice of chains is tissue-
specific (Hocking et al., 1998). Asporin, on the other hand, does not contain GAG chains, 
so is not a classical proteoglycan but has been placed in this class based on sequence 
homology (Schaefer and Iozzo, 2008). Biglycan and decorin are secreted containing N-
propeptides of 21 and 14 residues respectively, which can be cleaved by BMP-1 to 
release the mature forms in certain tissues (Scott et al., 2000). Figure 1.6 is a schematic 
of the structures of class I SLRP members, decorin and biglycan.  
 
 
Figure 1.6 Schematic of Class I SLRPs, decorin and biglycan. Multiple LRRs (shown as green 
boxes) in the central domain make up about 70% of each core protein. The LRRs are flanked by 
cysteine-rich clusters on two sides that can form disulphide bonds (S-S) (arrows). Decorin 
carries one and biglycan carries two dermatan sulphate or chondroitin sulphate 
glycosaminoglycans in the N-terminal region (red wavy lines). Potential N-linked glycosylation 
sites are shown as red dotted lines.  
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Class II SLRPs – This group comprises of fibromodulin, lumican, osteoadherin and 
PRELP. These are encoded by three exons, with a large central exon encoding almost all 
LRRs (Ameye and Young, 2002). They have a conserved N-terminal cysteine sequence 
(CX3CXCX9C) and contain sulphated tyrosine residues at the N-terminal end making 
them polyanionic. They primarily carry keratan sulphate proteoglycans (Schaefer and 
Iozzo, 2008).   
Class III SLRPs – This class includes osteoglycin, epiphycan and opticin. These are 
encoded by seven exons and consist of seven LRRs which are encoded by the last 3 
exons. The N-terminal cysteine sequence is CX2CXCX6C. They also contain N-terminal 
sulphated tyrosine residues (Ameye and Young, 2002).  
Class IV SLRPs – This family contains two members, chondroadherin and nyctalopin, 
which are non-canonical SLRPs. They do not have ‘ear repeats’ but contain four C-
terminal cysteines forming two disulphide bonds (McEwan et al., 2006). Interestingly, 
nyctalopin is the first described glycosylphosphatidylinositol-anchored SLRP (Schaefer 
and Iozzo, 2008).  
Class V SLRPs – This class of non-canonical SLRPs includes podocan. It contains a 
relatively large number of LRRs (22) and is the only SLRP not to have a disulphide-
bonded C-terminal cap (McEwan et al., 2006). Hence, it is not a ‘classical’ SLRP but is 
classed as one due to functional commonality with other SLRP members such as binding 
to collagen I (Schaefer and Iozzo, 2008).  
In the ECM, SLRPs are found ubiquitously but their distribution is regulated temporally 
and spatially during development. For example, the corneal stroma contains decorin 
and biglycan but biglycan expression decreases significantly postnatally whereas 
decorin expression remains stable. Lumican is expressed throughout the corneal stroma 
during development but restricted to the posterior stroma in the adult (Chakravarti et 
al., 2006). Fibromodulin, which is not considered to be a corneal component, is 
expressed briefly into the central cornea during early postnatal development (Chen and 
Birk, 2013). 
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1.3.2 Biological functions of SLRPs  
One of the major functions of SLRPs involves regulating collagen fibril assembly as 
evidenced by the presence of disorganised fibrils leading to defective connective tissue 
phenotypes in SLRP knockout mice (Table 1) (Kalamajski and Oldberg, 2010). Various 
SLRPs cooperate to modulate the process of fibrillogenesis. SLRPs belonging to the 
same class have the same binding site on collagen and therefore compete with one 
another for collagen binding (for e.g. lumican competes with fibromodulin) (Chen and 
Birk, 2013). This gives rise to some level of functional redundancy within SLRP 
members. For example, mice deficient in either decorin or biglycan show a mild corneal 
stromal phenotype, but decorin-biglycan double knockout mice have a severe skin 
phenotype, indicating that the two SLRPs are sufficiently similar to compensate for the 
loss of either of the two (Zhang et al., 2009). It is generally accepted that SLRPs bind 
collagen fibrils via their concave faces. For example, lumican and fibromodulin binding 
to collagen type I is mediated by a homologous sequence in LRR 5-7 (Kalamajski and 
Oldberg, 2009). The sulphated GAG chains extend outwards into the inter-fibril space 
and are involved in hydration of the matrix (Chen and Birk, 2013). However, SLRP core 
proteins can regulate fibrillogenesis in vitro in the absence of GAGs (Rada et al., 1993).  
How exactly the SLRPs regulate collagen fibrillogenesis is not known. (Kalamajski and 
Oldberg, 2010) suggest three possible mechanisms: a) they bind to collagen and prevent 
uncontrolled fibril assembly by sterical hindrance, b) SLRPs with more than one binding 
site can add collagens to the multimers and bridge fibrillar and FACIT collagens or, c) 
they may hinder access to potential cross-linking lysine residues on collagen monomers.  
Apart from their role in collagen fibril assembly, SLRPs are involved in modulating 
signalling pathways including those of the BMP/TGFβ superfamily (Schaefer and Iozzo, 
2008). At least three SLRPs (decorin, biglycan and fibromodulin) bind TGFβ, a cytokine 
involved in inflammation, control of cell proliferation, and apoptosis, via their protein 
cores (Hildebrand et al., 1994). Mice deficient in biglycan show age-dependent 
osteopenia as a result of defective osteoblast differentiation due to reduced BMP-4 
binding, indicating a modulating role of biglycan on BMP-4 binding (Chen et al., 2004). 
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Decorin binds to four different receptor tyrosine kinases (RTKs) (Iozzo and Schaefer, 
2010): it activates the epidermal growth factor receptor (EGFR) leading to growth 
suppression (Iozzo et al., 1999); it binds to insulin-like growth factor-1 receptor (IGF-
IR) on endothelial cells (Schonherr et al., 2005); it binds to vascular endothelial growth 
factor receptor 2 (VEGFR2) and antagonises proliferation and migration of extravillous 
trophoblast (EVT) cells (Khan et al., 2011); and it acts as a novel antagonistic ligand of 
the Met receptor (Goldoni et al., 2009). These interactions have potential to be exploited 
as protein-based therapies for various cancers and inflammatory disorders (Schaefer 
and Iozzo, 2008). 
 
1.4 Decorin 
1.4.1 Structure 
Decorin is the archetypal SLRP, so named because it “decorates” collagen fibrils. It is 
almost ubiquitously expressed in connective tissues and is conserved across species. It 
is synthesised mainly by fibroblasts, stressed vascular endothelial cells, and smooth 
muscle cells (Neill et al., 2012). It consists of a signal sequence, a short cleavable 
propeptide, a single N-terminal dermatan/chondroitin sulphate GAG chain attached to a 
serine residue, and a core protein of ~45 kDa containing 12 LRRs (numbered I-XII), 
flanked by disulphide-bonded sequences (Figure 1.7). The crystal structure of the 
decorin core protein, determined by Scott et al., 2004, revealed that the twelve LRRs 
form a right-handed curved solenoid which is “banana-shaped”, in contrast to the more 
closed “horseshoe-shaped” porcine ribonuclease inhibitor crystal structure (Kobe and 
Deisenhofer, 1993), which had previously been used to generate homology models for 
decorin (Weber et al., 1996).  The 12 LRRs are in tandem array and vary in length from 
21 to 30 amino acids, following a short-long-long regular pattern throughout the 
molecule (Scott et al., 2004). The first nine LRRs have a 21-24-24 repeating structure, 
except LRR-VI which is 26 residues long. The last three LRRs show a 23-30-27 pattern 
(McEwan et al., 2006).  The inner concave face is made up of parallel β-sheets and the 
convex back consists of irregular loops and single helical turns. Differences in the length 
of the LRRs and secondary structure elements forming the convex face gives rise to the 
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variation in molecular curvature. The core proteins of bovine and mouse decorin have 3 
and 4 consensus sites for N-linked glycosylation, respectively. The presence of decorin 
core protein without a GAG chain has been reported in some tissues but its relevance is 
unknown (Seo et al., 2005). Two distinctive features of SLRPs also present in decorin 
include a) the N-terminal capping motif which forms where four cysteine residues form 
a disulphide knot which buries the hydrophobic core of the first LRR and, b) the C-
terminal “ear-repeat” where LRR-XII extends laterally and a conserved cysteine residue 
forms a disulphide bond with another one on the last LRR (Scott et al., 2004). The 
decorin crystal structure revealed that two monomers associate through their concave 
faces, burying a large surface area (~ 2,300 Å2) to form an antiparallel dimer. 
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LRR  Length Sequence 
 G P V C P F R C Q C H  22-32 
I L R V V Q C S D L G L E K V P K D L P P D 21 33-53 
II T A L L D L Q N N K I T E I K D G D F K N L K N 24 54-77 
III L H T L I L I N N K I S K I S P G A F A P L V K 24 78-101 
IV L E R L Y L S K N Q L K E L P E K M P K T 21 102-122 
V L Q E L R V H E N E I T K V R K S V F N G L N Q 24 123-146 
VI M I V V E L G T N P L K S S G I E N G A F Q G M K K 26 147-172 
VII L S Y I R I A D T N I T T I P Q G L P P S 21 173-193 
VIII L T E L H L D G N K I T K V D A A S L K G L N N 24 194-217 
IX L A K L G L S F N S I S A V D N G S L A N T P H 24 218-241 
X L R E L H L N N N K L V K P G G L A D H K Y 23 242-264 
XI I Q V V Y L H N N N I S A I G S N D F C P P G Y N T K K A S 30 265-294 
XII Y S G V S L F S N P V Q Y W E I Q P S T F R C V Y V R 27 295-321 
    A A V Q L  322-326 
 
Figure 1.7 Schematic of bovine decorin core protein and its internal organisation. Green 
arrows represent β-strands, red ribbons show α-helical loops and glycosylation sites are shown 
in cyan. The N- and C- termini are labelled. The figure was generated using PyMOL 
(http://www.pymol.org), from the PDB entry: 1xku. Adapted from Scott et al. (2004). Amino 
acid sequences for the 12 LRRs are tabulated. LRR consensus sequences are highlighted in 
green. 
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1.4.2 Function in extracellular assembly 
Several important functions have been attributed to decorin, based on the interaction of 
the core protein with other proteins, including regulation of collagen fibrillogenesis, 
corneal transparency, tensile strength of skin and tendon, and tumour repression 
(Keene et al., 2000). The main driving force behind fibril formation is the collagen 
structure itself but SLRPs seem to be important in the process as well. One of the main 
roles of decorin is to regulate collagen fibril formation; it does so by delaying fibril 
assembly and reducing fibril diameter (Figure 1.8) (Chen and Birk, 2013, Kalamajski 
and Oldberg, 2010). Decorin has been shown to bind collagen types I and II, III, VI and 
XIV (Vogel et al., 1984, Bidanset et al., 1992, Douglas et al., 2006). The concave face is 
thought to be involved in protein-protein interactions (Kobe and Kajava, 2001).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Transmission electron micrographs of dermal collagen of the skin from the 
decorin (Dcn)-deficient mice. (A and B) Dcn -/- and (C) Dcn+/+ mice. Dcn -/- shows larger 
(>200 nm) and irregular fibrils (A and B, asterisks) in addition to smaller (30–40 nm) fibrils (A, 
circles). Arrowheads in B indicate coarser fibrils showing lateral fusion to an adjacent tapered 
segment. C. Collagen from the wild-type mouse shows a more compact and uniform pattern of 
fibril diameter and distribution. Adapted from Danielson et al. (1997).  
43 
 
Decorin knock-out mice are viable and grossly normal but have fragile skin, with 
reduced tensile strength and a thinner than normal dermis. The collagen defects are 
very similar to the cutaneous defects observed in human Ehlers-Danlos syndrome (EDS) 
(Ameye and Young, 2002). Compared to wild-type mice, decorin-deficient mice have 
significantly delayed dermal wound healing, indicating that decorin has a role in tissue 
repair (Jarvelainen et al., 2006). Targeted disruption of the decorin gene in the 
periodontal ligament (PDL) of mice shows collagen fibrils with abnormal morphology 
arranged in a random orientation instead of the normal parallel orientation (Hakkinen 
et al., 2000). Mice lacking decorin or biglycan show changes in collagen fibril size and 
shape in bone. However, there are no changes in bone mass or other skeletal 
phenotypes in decorin-deficient mice, unlike biglycan-deficient animals, indicating that 
despite their high level of homology, the two SLRPs have different functions in vivo 
(Corsi et al., 2002). Decorin-deficient mice have higher biglycan expression, but the 
reverse is not the case. Decorin-biglycan double-KOs show severely disrupted collagen 
fibril structures in the cornea, indicating that biglycan compensates for the loss of 
decorin (Zhang et al., 2009). Three frameshift mutations at the C-terminus of the 
decorin gene have been associated with a human disease called congenital stromal 
corneal dystrophy (Bredrup et al., 2005) that leads to corneal opacity, which has also 
been observed in mouse models of this disease (Chen et al., 2011).  
Decorin can act as an adhesion site for Borrelia burgdorferi, the causative agent of Lyme 
disease, which resides in the ECM and expresses two surface-exposed decorin-binding 
adhesins (Guo et al., 1995). Decorin-deficient mice are more resistant to the disease 
(Brown et al., 2001).  
 
1.4.3 Decorin: role in cell signalling and cancer 
In addition to being a structural protein, decorin is recognised as having key roles in cell 
signalling with its ability to regulate downstream signalling indirectly via sequestration 
of growth factors, and directly by binding and down-regulating several RTKs, which are 
often overexpressed in cancer cells (Neill et al., 2012). When expressed in tumour 
xenograft-bearing mice or injected systemically, decorin inhibits both primary tumour 
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growth and metastatic spreading (Goldoni and Iozzo, 2008). The potential of decorin as 
a novel biological target for the treatment of tumours is being investigated these days 
by many researchers (Sofeu Feugaing et al., 2013). 
Yamaguchi et al. (1990) first discovered that the stable transfection of decorin causes 
growth arrest in Chinese hamster ovary cells and this was due to the anti-proliferative 
effect of decorin, i.e. its ability to bind and block TGF-β (Neill et al., 2012). Decorin 
directly interacts with EGFR, causing rapid phosphorylation of the EGFR in squamous 
carcinoma cells, leading to activation of the MAP kinase signal pathway, induction of 
endogenous p21 and growth suppression (Iozzo et al., 1999). This signal transduction 
process leads to down-regulation of the receptor (Csordas et al., 2000), endocytosis of 
decorin-bound EGFR and ultimately to lysosomal degradation of the internalised 
decorin (Zhu et al., 2005). Decorin interaction with the EGFR is mediated by LRR-7 of 
the decorin protein core (Santra et al., 2002). A stoichiometry of 1:1 for the decorin 
protein core and EGFR is likely, due to structural constraints of the EGFR binding 
region, suggesting that biologically active decorin is a monomer (Iozzo and Schaefer, 
2010, Goldoni et al., 2004). Decorin also binds Met, the receptor for hepatocyte growth 
factor, with high affinity (Goldoni et al., 2009). This interaction leads to transient 
activation of the receptor, recruitment of the E3 ubiquitin ligase c-Cbl, followed by rapid 
intracellular degradation of Met. Signalling through Met leads to suppression of β-
catenin, a downstream Met effector, leading to inhibition of tumour growth and 
metastasis (Goldoni et al., 2009). It has been shown that ~30% of decorin-null mice 
develop intestinal tumours, associated with up-regulation of β-catenin signalling (Bi et 
al., 2008). In normal cells, decorin exerts proliferative effects and a prosurvival 
response, favouring cell growth, via its effects on IGF-IR (Iozzo and Schaefer, 2010). 
Decorin binds to IGF-IR in endothelial cells and also binds to and sequesters IGF, the 
natural ligand for IGF-IR. Decorin addition causes IGF-IR phosphorylation and 
activation, which is followed by receptor down-regulation. These effects are caused by 
the core protein of decorin, and the binding region could be mapped to the N terminus 
of the molecule. Binding to IGF-IR leads to phosphorylation of protein kinase B, 
induction of p21, resulting in inhibition of apoptosis in endothelial cells (Schonherr et 
al., 2005). Figure 1.9 summarises the roles of decorin in tumour progression.  
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Figure 1.9 Role of decorin in tumour progression. Decorin is produced and secreted by 
fibroblasts of the tumour stroma (light yellow spindle-shaped cells) and affects tumour cells 
(centre) via multiple pathways: (1) decorin affects signal transduction via multiple RTKs, thus 
modulating cell proliferation, cell cycle progression and apoptosis. For example, interaction of 
the decorin with erbB family receptors leads to signal transduction characterised by stimulation 
of MAP kinases, up-regulation of p21, an inhibitor of cyclin-dependent kinases, and ultimately to 
growth suppression. (2) Decorin induces endocytosis of the EGFR, leading to receptor 
downregulation and a reduction in extracellular decorin. (3) Decorin promotes matrix 
organisation (collagen fibrillogenesis) which constitutes a physical barrier against 
migration/motility of cancerous cells, thus preventing metastasis (4) Decorin can negatively 
regulate signal transduction by interfering with growth factor binding, such as TGF-β. As a 
result, synthesis of matrix molecules and growth factor-dependent modulation of cell 
proliferation and migration are inhibited. (5) Decorin affects tumour angiogenesis via the VEGF-
R, PDGF-R and FGF-R pathways. Taken from Sofeu Feugaing et al. (2013). 
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1.4.4 Decorin: monomer or dimer? 
Ultrastructural studies of tissue-derived collagen fibrils using stains such as 
Cupromeronic blue (Scott and Orford, 1981) and antibodies against the decorin core 
protein (Pringle and Dodd, 1990) have shown that decorin binds in the gap zone of the 
D-period. Keene et al. (2000) mapped the binding site of decorin core protein to a 
narrow region in the C-terminus of the collagen type I triple helix, very close to one of 
the major intermolecular cross-linking sites, using rotary shadowing electron 
microscopy and photoaffinity labelling. Interaction studies using peptides derived by 
cyanogen bromide (CNBr) cleavage of type I and type II collagen with decorin extracted 
from bovine tendon showed that decorin makes contacts with multiple sites in type I 
collagen and probably also in type II collagen and that some collagen Lys/Hyl residues 
are essential for the binding (Tenni et al., 2002).  
Several structural and biophysical studies have indicated that decorin and other SLRPs 
form stable dimers, that monomeric decorin cannot exist in solution and that 
dimerisation is mediated by the concave face, potentially making this surface 
unavailable for ligand binding (Scott et al., 2003, Scott et al., 2004, Scott et al., 2006). In 
contrast to this view, Goldoni et al. (2004) have claimed that biologically active decorin 
is monomeric and dimerisation is an artefact of lyophilisation. Other researchers have 
found that like most SLRPs, decorin-collagen interactions appear to be mediated via the 
concave face of the core protein, buried in the dimer interface, which is also the most 
conserved region. Using chimeras of recombinant decorin and biglycan, it has been 
shown that the decorin binding sites for collagen I are located in LRRs 5-6 (Svensson et 
al., 1995). A critical role of Glu-180 residue in LRR-6 has been suggested by studying 
interactions of recombinant decorin, expressed in mammalian cells, with collagen type I 
(Kresse et al., 1997). Site-directed mutagenesis studies have further localised the 
binding site to the sequence, SYIRIADTNIT, in LRR-6 (Kalamajski et al., 2007). It is to be 
noted that these studies have a slightly different numbering system for the LRRs than 
that used in Figure 1.7 since the presence of the first LRR only became evident after the 
elucidation of the crystal structure.  Molecular modelling studies of the interactions 
between decorin core protein and type I collagen fibrils were investigated using their 
respective X-ray diffraction structures (Orgel et al., 2009, Weber et al., 1996). The 
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monomeric form of decorin core protein showed the most appropriate shape 
complementarity with the collagen fibril surface and favourable calculated energies of 
interaction (Orgel et al., 2009).  
These data raise questions about the oligomeric state of decorin and its impact on 
collagen binding. Hence, the aim of my project was to resolve this controversy by 
determining the oligomeric state of decorin and studying its interactions with collagen 
using various biophysical and biochemical techniques. 
 
1.5 SPARC 
Matricellular proteins are ECM molecules that have no primary structural roles in the 
ECM but are involved in mediating cell-matrix interactions (Brekken and Sage, 2000). 
Members of this family of extracellular proteins include thrombospondin (TSP) 1 and 2, 
SC1/hevin, tenascin C and X and SPARC (also known as osteonectin or BM-40). Some 
distinguishing characteristics of matricellular proteins are: a) they are expressed at high 
levels during embryogenesis and in response to injury, declining postnatally; b) they 
bind to many cell-surface receptors, the ECM, growth factors, cytokines and proteases; 
c) they generally induce de-adhesion of anchorage-dependent cells; and d) in most 
cases, targeted gene disruption in mice produces either a grossly normal or a subtle 
phenotype that is exacerbated upon injury (Bornstein and Sage, 2002, Aszodi et al., 
2006).  
SPARC is a matricellular glycoprotein that is conserved in all animals from C. elegans 
and Drosophila, to mammals (Bradshaw, 2009). It was first described as a major 
component of human and bovine bone and as a protein secreted by proliferating cells in 
vitro (Lane and Sage, 1994). SPARC is expressed by many different cell types including 
endothelial cells, fibroblasts, osteoblasts and macrophages (Trombetta-Esilva and 
Bradshaw, 2012). It has been shown to induce cell rounding in endothelial cells, 
fibroblasts and smooth muscle cells and functions as a counter-adhesive protein (Sage 
et al., 1989). A third function of SPARC is in the regulation of the ECM production and 
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turnover through its effects on collagen and extracellular proteases (Bradshaw and 
Sage, 2001).   
 
1.5.1 SPARC: general structure 
In both vertebrates and invertebrates, SPARC is a single copy gene that is highly 
conserved (Table 2). The murine SPARC gene has 10 exons whereas the C. elegans 
homologue only contains 6 exons, as a result of which the nematode protein is 
truncated in its first acidic module. However, this truncation does not affect the 
protein’s ability to bind Ca2+ and collagen (Brekken and Sage, 2000). In contrast to C. 
elegans, Drosophila SPARC is longer than vertebrate SPARCs, mainly due to additional 
amino acid residues in the N-terminal domain. Whether these additional residues confer 
unique functions to Drosophila SPARC remains to be determined (Martinek et al., 2002).  
Human SPARC protein is 32 kDa in size and has 303 amino acids, with the initial 17 
amino acids containing the signal sequence, which is removed upon secretion. The  
mature SPARC protein has 286 amino acids with three distinct modular domains: i) an 
N-terminal acidic domain (residues 1-52) which binds several Ca2+ ions with low 
affinity and also to hydroxyapatite, ii) a central follistatin-like (FS) domain (residues 53-
137) and iii) an α-helical extracellular high affinity Ca2+-binding (EC) domain (residues 
138-286) containing a pair of EF-hands and the collagen binding site (Figure 1.10) 
(Bradshaw and Sage, 2001). This domain organisation is phylogenetically conserved 
(Martinek et al., 2002). 
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Table 2: Amino acid sequence identities of SPARC from different organisms; Adapted from 
Brekken and Sage (2000) 
 Accession no.  from 
NCBI databank 
SPARC % amino acid sequence identity 
Human 
SPARC   
99 
92 
30 
                                        31 
Bovine AAA30678 
Mouse  CAA27642 
Drosophila CAB39319 
C. elegans AAA16827 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Schematic of the modular domains of SPARC protein  The follistatin-like 
domain is shown in red and the EC module (aa 138-286) is shown in blue. The FS domain 
contains the peptide 2.1 shown in green; The (K)GHK angiogenic peptide shown in black; The 
EC domain contains peptide 4.2 (aa 255–274) shown in yellow. Taken from (Brekken and Sage, 
2000), originally drawn from PDB entry 1BMO  (Hohenester et al., 1997). 
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The FS domain contains 10 cysteines and an N-linked glycan at Asn99. It has an 
elongated structure consisting of an N-terminal β-hairpin and a small core of mixed α/β 
structure. The structure is homologous to a repeated domain in follistatin, a protein that 
binds to members of the TGF-β family, and to domains in agrin. The N-terminal β-
hairpin is very similar to that of EGF and the core resembles a serine protease inhibitor 
of the Kazal family (Hohenester et al., 1997). The FS domain also contains peptides that 
exert different effects on endothelial cells. Peptide 2.1 inhibits the proliferation of 
endothelial cells whereas peptide 2.3 stimulates endothelial cell proliferation (Figure 
1.10) (Funk and Sage, 1993).  
The EC domain is a compact, highly α-helical structure that contains two EF-hand 
motifs, which bind Ca2+ with high affinity (Hohenester et al., 1996). Binding of Ca2+ to 
the EF-hands increases the α-helical secondary structure content in SPARC, which is 
dependent on cooperative interactions between the EF-hands and FS domain (Maurer 
et al., 1995). The fibril-forming collagen types I, III, and V, and the basement membrane 
collagen type IV, bind this domain in a Ca2+-dependent fashion (Termine et al., 1981, 
Sage et al., 1989, Mayer et al., 1991, Maurer et al., 1995). This domain contains peptide 
4.2 which has been shown to inhibit endothelial cell proliferation (Brekken and Sage, 
2000).  
 
1.5.2 SPARC – growth factor interactions 
SPARC modulates the activity of at least three growth factor/cytokine signalling 
pathways, mediated by cell surface receptors including vascular endothelial growth 
factor (VEGF) receptor, basic ﬁbroblast growth factor (bFGF, FGF2), and TGF-β1 
(Bradshaw, 2012). SPARC directly interacts with VEGF-A and prevents it from inducing 
VEGFR1 activity in cultured endothelial cells and in vivo. SPARC inhibits the FGF2-
induced activation of endothelial cells in vitro. Another growth factor crucial for 
vascular homeostasis is TGF-β1. Genetic ablation of TGF-β1 results in abnormal vessel 
formation and embryonic lethality in mice (Rivera et al., 2011). Whether TGF-β1 and 
SPARC interact directly is unknown but TGF-β1 induces expression of SPARC in a 
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variety of cell types including ﬁbroblasts and mesangial cells (Francki et al., 1999). 
Conversely, SPARC also regulates expression of TGF-β1.  
In Drosophila, SPARC is upregulated by “loser” cells – cells proximal to “killer” or 
“winner” cells, during cell competition (Portela et al., 2010). The loser cells are induced 
to undergo apoptosis by a secreted factor from winner cells. SPARC expression by loser 
cells prolongs the life of these cells by inhibiting an unidentiﬁed secreted killing signal 
and preventing, at least temporarily, apoptosis of the loser cell (Bradshaw, 2012).  
 
1.5.3 SPARC – collagen interactions 
The binding of SPARC to collagen is specific to the collagen triple helix as it is abolished 
by heat denaturation of collagen (Giudici et al., 2008). Proteolytic cleavage of full-length 
SPARC or the EC module by several MMPs at the peptide bond between Leu197-Leu198 
in helix-αC results in a 10-fold increase in collagen affinity. Cleavage of helix-αC exposes 
the collagen binding site on helix-αA, thereby increasing binding affinity (Sasaki et al., 
1997). Deletion of helix-αC in recombinant SPARC gives a similar increase in binding 
affinity (Sasaki et al., 1998). Differentially glycosylated forms of SPARC may have 
different functional roles in vivo. Bone SPARC carrying high-mannose structures binds 
collagen I with higher affinity than platelet SPARC carrying bi-antennary and tri-
antennary glycans (Kaufmann et al., 2004). On the other hand, a single N99Q mutation 
to prevent N-glycosylation causes no significant change in the binding of SPARC to 
collagens I and IV (Sasaki et al., 1997).  
The SPARC binding site on collagen I has been mapped in two separate studies. Wang et 
al. (2005) identified a broad distribution of SPARC binding sites, with a primary binding 
site ~1/3 (87.5 – 125nm) from the C-terminus of procollagen I, using tapping-mode 
atomic force microscopy. Another study by Giudici et al., using rotary shadowing 
followed by electron microscopy, found a major site located ~180nm from the C-
terminus and a less preferred site 60-100nm from the C-terminus. The discrepancy 
between the two studies could be due to the different sources of SPARC and 
procollagen, and the different experimental methods used (Giudici et al., 2008). 
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The crystal structure of human SPARC FS-EC bound to a 33-residue collagen-like triple 
helical peptide has been recently determined (Figure 1.11) (Hohenester et al., 2008). 
The peptide represents residues 564-590, the major binding site identified by Giudici et 
al. SPARC has been shown to bind the GVMGFO (O stands for hydroxyproline) motif of 
the middle and trailing collagen chains, burying a total of 720 Å2 of solvent-accessible 
collagen surface. This motif also binds two other unrelated proteins: von Willebrand 
factor and discoidin domain receptor 2. The structure revealed that the collagen triple 
helix is not distorted upon SPARC binding. In contrast, the conformation of SPARC is 
significantly altered, resulting in a deep pocket that accommodates the phenylalanine 
residue of the trailing collagen chain (Hohenester et al., 2008).  
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Figure 1.11 Crystal structure of SPARC FS-EC Δα-C (inhibitory loop removed) bound to a 
33-residue collagen peptide. The FS and EC domains are in green and blue respectively. The 
glycan attached to N99 is in cyan. The collagen peptide is shown as a ribbon with individual 
chains in magenta, red and yellow. The figure was generated using PyMOL from PDB entry 2V53 
(Hohenester et al., 2008).  
 
 
1.5.4 SPARC in ECM assembly 
The phenotype of SPARC-null mice is grossly normal except that they display some 
abnormalities in the ECM: a) early onset cataract formation and rupture of the lens 
capsule (Gilmour et al., 1998); b) osteopenia, with decreased bone formation and 
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decreased osteoblast and osteoclast surface and number (Delany et al., 2000); and c) 
accelerated cutaneous wound closure (Bradshaw et al., 2002). These phenotypes can be 
attributed to significant changes in collagen fibril morphology and decreases in collagen 
concentrations in SPARC-null mice compared with wild-type animals (Bradshaw, 2009). 
The skin of SPARC-null mice has roughly half the amount of collagen in comparison with 
wild-type, as measured by hydroxyproline analysis (Bradshaw et al., 2003). SPARC and 
collagen I may be involved in ECM remodelling. For example, Mov-13 mice carry a 
mutation in the collagen α1(I) gene and do not express collagen I in the ECM. These 
mice have impaired deposition of SPARC within the ECM, suggesting that collagen I 
influences the spatial distribution of SPARC (Iruela-Arispe et al., 1996).  
SPARC also interacts with collagen IV and influences basal lamina assembly.  Studies 
with SPARC-GFP fusion protein show that the protein is localised to most BMs along 
body wall and sex muscles and overlaps with the distribution of collagen IV in C. 
elegans. Elimination of SPARC by RNA interference results in embryonic or larval 
lethality (Fitzgerald and Schwarzbauer, 1998). This may be due to the fact that unlike 
vertebrates, C. elegans does not contain any SPARC homologues so there is no functional 
compensation.  Collagen IV is required during development to provide mechanical 
strength in order to withstand contractile forces during embryonic movements 
(Yurchenco et al., 2004, Martinek et al., 2008). SPARC and other BM components such as 
network-forming collagen IV are synthesised and secreted by haemocytes and 
assembled in BMs mid-embryogenesis in Drosophila (Martinek et al., 2002). Inhibition 
of SPARC expression in Drosophila leads to the absence of collagen IV in the BM of 
certain structures such as the ventral nerve chord, resulting in embryonic lethality 
(Martinek et al., 2008). SPARC mutants and collagen IV mutants also show striking 
phenotypic similarity in flies suggesting a mutual dependence of the two proteins 
(Martinek et al., 2008).  It has been proposed that intracellular SPARC acts as the 
principal collagen IV chaperone in invertebrates, which do not have other molecular 
chaperones such as Hsp47, thus ensuring stability of the triple helix prior to export from 
the endoplasmic reticulum (Martinek et al., 2002).  Martinek et al. (2002) have further 
hypothesised that SPARC promotes collagen fibril assembly by modulating the binding 
of molecules such as decorin.                                                   
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1.5.5 Collagen binding by vertebrate and invertebrate SPARC 
Although the collagen binding residues between human and invertebrate SPARC 
(Drosophila (dSPARC) and C. elegans (cSPARC)) are highly conserved (Appendix 1), 
there is one difference between the orthologues: collagen binds to human SPARC 
following proteolytic nicking of an inhibitory loop which is not present in invertebrate 
SPARC. Lacking helix αB, invertebrate SPARCs have a much shorter connection between 
helices αA and αD (Hohenester et al., 2008). Therefore, it can be hypothesised that 
collagen binding to invertebrate SPARC does not require proteolytic activation and is of 
high affinity constitutively. To test this hypothesis, I aimed to study binding interactions 
between human and invertebrate SPARC and collagen I and IV and attempted to 
determine the crystal structure of dSPARC and cSPARC. 
 
1.6 Aims of the Project 
The broad aim of the projects outlined in this thesis was to study the interaction of the 
proteins, decorin and SPARC, with collagen.   
More specifically, the aims were as follows: 
1) The crystal structure of decorin revealed a dimeric structure in which the presumed 
collagen binding site is not accessible. Whether the dimer is functional remains 
controversial and it has been claimed that biologically active decorin is a monomer. The 
main aim of the study was to resolve the controversy about the oligomeric state of 
decorin by designing a number of decorin mutants to disrupt the crystallographic 
dimer. Size exclusion chromatography with multi-angle laser light scattering and 
analytical ultracentrifugation was used to determine the oligomeric state of decorin. A 
further aim was to identify whether decorin binds collagen as a monomer or a dimer, 
indirectly by measuring the inhibition of collagen fibrillogenesis and directly using 
solid-phase assay. 
2) The crystal structure of human SPARC (hSPARC) bound to a collagen-like triple-
helical peptide was determined in the Hohenester lab. The key collagen binding 
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residues are conserved between human and invertebrate SPARC (in this study, dSPARC 
and cSPARC). However, collagen binds to hSPARC following proteolytic cleavage of an 
inhibitory loop that is not present in invertebrate SPARC. The aim of this research was 
to investigate the role of the inhibitory loop on collagen binding by studying binding 
interactions between human and invertebrate SPARC and collagen I and IV, using solid 
phase assays and surface plasmon resonance. Another aim was to attempt to determine 
the crystal structure of dSPARC and cSPARC, which involved enzymatic deglycosylation 
or mutagenesis of the constructs to aid crystallisation. 
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and Reagents 
All chemicals used in this study were of analytical grade and all solutions were prepared 
with ultrapure deionised water. Agarose, Luria agar, calcium chloride (CaCl2), sodium 
hydrogencarbonate (NaHCO3), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), Tris(hydroxymethyl)aminomethane (Tris base), sodium dodecyl sulphate 
(SDS), polyoxyethylenesorbitan monolaurate (Tween - 20), ethylenediaminetetraacetic 
acid (EDTA), ampicillin, avidin peroxidase, K-casein from bovine milk, rat tail type I 
collagen, collagen IV from human placenta and bovine serum albumin (BSA) were 
purchased from Sigma Aldrich (Gillingham, UK). Luria Bertani broth was purchased 
from Melford (Suffolk, UK). Imidazole buffer substance was from MERCK (Nottingham, 
UK). Gibco® phosphate-buffered saline (PBS) tablets were purchased from Life 
technologies (Paisley, UK). Ammonium persulphate (APS) was obtained from Fisons 
Scientific (Loughborough, UK). Sodium chloride (NaCl), tetramethylethylenediamine 
(TEMED), Acrylamide:Bis-Acrylamide 37.5:1, ethanol and isopropanol were purchased 
from Fisher Scientific (Loughborough, UK). Quick Coomasie stain and InstantBlue™ gel 
stain were obtained from Generon (Berkshire, UK).  Protein Ladder (10-250 kDa), 
restriction enzymes and reaction buffers were purchased from New England Biolabs 
(NEB) (Ipswich, UK). HyperLadder™ I was from Bioline Reagents Ltd (London, UK). 
Platinum® Pfx Polymerase Polymerase Chain Reaction (PCR) kit was purchased from 
Invitrogen (Paisley, UK). Plasmid DNA purification kits were purchased from QIAGEN 
(Crawley, UK). Mouse anti c-myc antibody was purchased from AbD Serotec (Oxford, 
UK). Polyclonal goat anti-mouse immunoglobulins/HRP was purchased from DAKO 
(High Wycombe, UK). Goat anti-mouse decorin polyclonal antibody and rabbit anti-goat 
IgG HRP affinity purified polyclonal antibody were from R&D Systems Europe Ltd 
(Abingdon, UK). SYPRO orange dye was from Invitrogen (Paisley, UK). EZ-Link® Sulfo-
NHS-LC-Biotin was purchased from Thermo Scientific (Illinois, USA). PCR primers were 
ordered from Sigma Aldrich (Gillingham, UK) and are listed in Table 2.1. Agarose bound 
lectins were purchased from Vector Laboratories (Peterborough, UK).  
59 
 
2.1.2 Bacterial Cells and Plasmids 
Subcloning Efficiency™ DH5α™ Competent Cells were purchased from Invitrogen 
(Paisley, UK). Drosophila SPARC DNA (AJ_133736) was a gift from Takako Sasaki 
(University of Erlangen, Germany).  Plasmid cDNA containing human SPARC (hSPARC) 
DNA was provided by Erhard Hohenester (Imperial College London, UK). Bacterial 
strain transformed with C. elegans SPARC cDNA, a Bluescript plasmid isolated from a λ-
phage cDNA library, called F4-15, was kindly provided by Dr Jean Schwarzbauer 
(Princeton University, USA).  Plasmid pCMV6 containing mouse decorin cDNA was 
purchased from Origene (Maryland, USA).  
 
2.1.3 Mammalian Cells and Cell Culture Reagents 
Human embryonic kidney (HEK)293 c18 cells were purchased from American Type 
Culture Collection (Teddington, UK).  Dulbecco’s modified Eagle’s medium (D-MEM) F12 
(1:1), foetal bovine serum (FBS), penicillin/streptomycin (Pen/Strep), L-glutamine, 
trypsin-EDTA solution and Geneticin® selective antibiotic (G418 sulphate) were 
purchased from Invitrogen (Paisley, UK). Puromycin dihydrochloride was obtained 
from Sigma Aldrich (Gillingham, UK). Fugene® 6 transfection reagents were purchased 
from Roche Diagnostics (Burgess Hill, UK) and Promega Corporation (Madison, USA). 
 
2.1.4 Equipment  
A NanoDrop ND-1000 UV spectrophotometer from Labtech International (Ringmer, UK) 
was used to quantify DNA and protein concentrations. VisionWorks®LS Image 
Acquisition and Analysis Software was used to visualise DNA and protein gels. 
Mastercycler® Personal by Eppendorf (Stevenage, UK) was used for PCR cycling. 
Routine centrifugation was carried out using a ALC PK121R multispeed centrifuge 
supplied by Jencon-PLS (Bedfordshire, UK) or Eppendorf bench-top centrifuge.  Slide-A-
Lyser® dialysis cassettes and SnakeSkin™ dialysis tubing (10kDa molecular weight cut-
off) were from Thermo Scientific (Illinois, USA). Nunc tissue culture flasks (T25, T75 
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and T175) were purchased from Scientific Laboratory Supplies (Yorkshire, UK). Corning 
HYPERFlask M cell culture vessels were purchased from Fisher Scientific 
(Loughborough, UK). 5 ml HisTrap™ High performance (HP) columns were obtained 
from GE Healthcare (Buckinghamshire, UK) for use in immobilised metal affinity 
chromatography. Superdex™ 200 HR 10/30 and HiLoad™ 16/60 Superdex™ 200 prep 
grade columns from GE Healthcare (Buckinghamshire, UK) were used for gel filtration 
of proteins. An ÄKTApurifier liquid chromatography system and an ÄKTAFPLC from GE 
Healthcare were used for protein purification. Nunc Maxisorp® flat-bottom 96 well 
plates were obtained from VWR (Leicestershire, UK). A Sunrise™ microplate absorbance 
reader from Tecan Group Ltd. (Reading, UK) was used to measure absorbance in solid 
phase assays. Size exclusion chromatography - multi angle light scattering (SEC-MALS) 
was carried out using 1260 Infinity high pressure liquid chromatography (HPLC) from 
Agilent Technologies (Berkshire, UK), in-line with a light scattering detector, Wyatt Mini 
Dawn, and a refractive index detector, Optilab T-rEX.  Biacore experiments were carried 
out on a Biacore® 3000 instrument from GE Healthcare (Buckinghamshire, UK). 
Crystallisation trials were set up using a Mosquito robot from TTP Labtech. A Shimadzu 
UV-2501PC spectrophotometer was used for collagen fibrillogenesis assay. Differential 
scanning calorimetry (DSC) experiments were performed using an N-DSCIII Differential 
Scanning Calorimeter from TA Instruments (Herts, UK). Differential scanning 
fluorometry (DSF) were performed using a Stratagene Mx3005p system from Agilent 
Technologies. Analytical ultracentrifugation (AUC) experiment was performed using a 
Beckman XL-1 analytical centrifuge from Beckman Coulter (UK) Ltd (High Wycombe, 
UK).  
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2.2 Methods 
 
2.2.1 General molecular biology methods 
 
2.2.1.1 Polymerase Chain Reaction (PCR) 
PCR was performed using Platinum Pfx polymerase in 50 µl reaction mixtures. The 
reaction mixtures consisted of 5 µl of 10x amplification buffer, 3 µl of 10 mM dNTP, 5 µl 
of 10x enhancer, 3 µl of 50 mM MgSO4, 1 µl of template DNA (up between 50 ng and 200 
ng), 1 µl of each 100 µM primer, 1 µl (1.5 U) of Pfx DNA polymerase and distilled water. 
The PCR cycle was initiated by denaturation at 94°C for 1 min, followed by 29 cycles of 
denaturation at 94 °C for 30 sec, annealing at 55 °C for 45 sec and extension at 72 °C for 2 
min. The reaction was completed by a final extension at 72 °C for 6 min. The primer 
sequences are tabulated in Table 2.1.  
 
2.2.1.2 Splicing by Overlap Extension (SOE) PCR 
Overlap extension PCR (Heckman and Pease, 2007) (Figure 2.1) was used to generate 
decorin mutant cDNA constructs. Briefly, complementary oligodeoxyribonucleotide 
(oligo) primers containing the nucleotide changes and PCR was used to generate two 
mutated DNA fragments having overlapping ends. These fragments were gel purified 
and subsequently combined in a 'fusion' PCR reaction in which the overlapping, 
complementary regions containing the desired mutation anneal. 
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Figure 2.1 Splicing by overlap extension PCR for site-directed mutagenesis. The first step 
involves two independent PCR reactions using external primers (a and d) and mutagenic 
primers (b and c), yielding two intermediate products AB and CD, each containing the desired 
mutation indicated by the asterisk. Products AB and CD hybridise via their overlapping 
complementary region and form the template for the second PCR reaction which uses external 
primers a and d to make the full-length double-stranded product AD. 
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Table 2.1 Primers used for generating decorin expression plasmids. Underlined sequences GCTAGC 
and GCGGCCGC correspond to restriction sites, NheI and NotI, incorporated into the forward and 
reverse primers respectively. The coloured triplets correspond to the mutated nucleotides.  
DNA Construct Primer Sequence* (5’­3’) 
 
Dec CHis F: TCGCTAGCCCTGATATCTATGTGCCCCTACCGATG 
 
R: ATCCGCGGCCGCCTTGTAGTTTCCAAGTTGAATGGCAGAACG 
 
Decorin mutants 
external primers 
F (182bp_up):  GCGCCAGCTGATCAAGCTTCTGCCTGCC 
or 
F: TCGCTAGCCCTGATATCTATGTGCCCCTACCGATG 
 
R: ATCCGCGGCCGCCTTGTAGTTTCCAAGTTGAATGGCAGAACG 
 
Dec Q61N internal 
primers 
F: CTT CGA GTG GTG AAC TGT TCT GAT CTG GGT 
 
R: CAG ATC AGA ACA GTT CAC CAC TCG AAG ATG 
 
Dec Y130N internal 
primers 
F: TTG GAA AGG CTT AAC CTG TCT AAG AAC CAA 
 
R: GTT CTT AGA CAG GTT AAG CCT TTC CAA CTT CAC 
 
Dec YRQ-A internal 
primers 
F: TCT ATG TGC CCC GCA GCA TGC GCA TGT CAT CTT CGA GTG 
R: CAC TCG AAG ATG ACA TGC GCA TGC TGC GGG GCA CAT AGA 
Dec R121E internal 
primers 
F: CTC CAG GAA CTT GAA GTC CAT GAG AAT GAG 
R: ATT CTC ATG GAC TTC AAG TTC CTG GAG AGT TCT 
Dec E156K internal 
primers 
F: CCC AGA ACT CTC CAG AAG CTT CGT GTC CAT GAG 
R: CTC ATG GAC ACG AAG CTT CTG GAG AGT TCT GGG 
Dec K159E internal 
primers 
F: GAG AAT GAG ATC ACC GAG CTG CGG AAA TCC 
R: GGA TTT CCG CAG CTC GGT GAT CTC ATT CTC 
Dec K111S internal 
primers 
F: TTG ATC CTT GTC AAC AAC AGT ATC AGC AAA ATC AGT CCA GAG 
R: CTC TGG ACT GAT TTT GCT GAT ACT GTT GTT GAC AAG GAT CAA 
Dec RE267A internal 
primers 
F: GTT CCT CAT CTG GCT GCT CTC CAC TTG GAC AAC 
R: GTT GTC CAA GTG GAG AGC AGC CAG ATG AGG AAC 
Dec D204R internal 
primers 
F: CGC ATC TCA CGA ACC AAC ATA ACT GCG 
R: CGC AGT TAT GTT GGT TCG TGA GAT GCG 
Dec G246N internal 
primers 
F: TTG TCT AAA CTG AAT TTG AGC TTC AAC AGC ATC 
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Table 2.2 Primers used for generating SPARC expression plasmids. Underlined sequences GCTAGC 
and GCGGCCGC correspond to restriction sites, NheI and NotI, incorporated into the forward and 
reverse primers respectively. The coloured triplets correspond to the mutated nucleotides.  
 
DNA Construct 
Primer Sequence* (5’­3’) 
 
dSPARC FS-EC NHis 
F: CGGAATTCGCTAGCCGATCTGTGCGAAACGATGAGC 
R: ATCCGCGGCCGCCTAACCCAGGAGATGGGGCTG 
dSPARC FS-EC 
NHis.myc 
F: CGGAATTCGCTAGCCGATCTGTGCGAAACGATGAGC 
R: ATCCGCGGCCGCCTAACCCAGGAGATGGGGCTG 
dSPARC EC NHis 
F: CGGAATTCGCTAGCCAGGAGCTGCGAGGGCGAG 
R: ATCCGCGGCCGCCTAACCCAGGAGATGGGGCTG 
dSPARC EC NHis.myc 
F: CGGAATTCGCTAGCCAGGAGCTGCGAGGGCGAG 
R: ATCCGCGGCCGCCTAACCCAGGAGATGGGGCTG 
dSPARC FS-EC NHis 
glycosylation double 
mutant internal 
primers 
F: ACCACCACCCAGGAGACCTGG  (Mutation in FS domain) 
F: CTGGAGGCGGAGACCCAGAACTCGCGTCGCTGGTCG (Mutation in EC 
domain) 
R: CCAGGTCTCCTG GGT GGTGGT 
R: ACGCGAGTTCTGGGTCTCCGCCTCCAGCTC    
hSPARC FS-EC His.myc 
F: TTCGCTAGCC AATCCCTGCCAGAACCAC CACTGC 
R: ATCCGCGGCCGCTTAGATCACAAGATCCTTGTCGAT 
hSPARC EC His.myc 
F: TTCGCTAGCCCCCCCTTGCCTGGACTCTGAG 
R: ATCCGCGGCCGCTTAGATCACAAGATCCTTGTCGAT 
cSPARC FS-EC NHis 
F: CGGAATTCGCTAGCCCCATGCGAGGACCACCAGTGC 
R: ATCCGCGGCCGCTTAGCATCTCTCTTGGATCTC 
cSPARC EC NHis  
F: CGG AA TTCGCTAGCCGATGAGTGCACCGAAGAGCAC 
R: ATCCGCGGCCGCTTAGCATCTCTCTTGGATCTC 
cSPARC FS-EC 
NHis.myc 
F: CGGAATTCGCTAGCCCCATGCGAGGACCACCAGTGC 
R: ATCCGCGGCCGCTTAGCATCTCTCTTGGATCTC 
cSPARC EC NHis.myc 
F: CGG AA TTCGCTAGCCGATGAGTGCACCGAAGAGCAC 
R: ATCCGCGGCCGCTTAGCATCTCTCTTGGATCTC 
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2.2.1.3 Agarose Gel Electrophoresis 
1% (w/v) agarose was dissolved in 1x Tris-acetate EDTA (TAE) buffer by boiling. 
Cooled, molten agarose was supplemented with 1x SYBR® Safe DNA gel stain and 
poured into a gel chamber. DNA samples containing 1x gel loading dye (2.5% (w/v) 
Ficoll®-400, 3.3 mM Tris-HCl, pH 8.0, 11 mM EDTA, 0.017% (w/v) SDS, 0.015% (w/v) 
bromophenol blue) were loaded onto the gel and run at 100 V for 50 minutes. All 
samples were compared to 100bp or 1 kb DNA ladder and/or Hyperladder I™, 
depending on the estimated size of the products. SYBR® Safe-stained DNA was 
visualised using a DNA gel documentation system.  
 
2.2.1.4 DNA Purification by Gel Extraction 
 
The amplified PCR products were purified to remove excess primers and nucleotides. 
This was done by separating the products on 1% (w/v) agarose gels. Bands of interest 
were excised and the DNA purified using a QIAquick gel extraction kit according to the 
manufacturer’s protocol. The DNA was quantified using a Nanodrop ND-1000 
spectrophotometer. 
 
2.2.1.5 Restriction Digests 
Double digests of the amplicons and the vectors were performed using NheI/NotI at 37 
oC for 1-1.5 hours. The digestion mixtures contained DNA, NEB reaction buffer 4, 0.1 
μg/ml BSA and 10 U restriction enzymes in a 50 μl reaction volume. 1 μl of calf 
intestinal alkaline phosphatase (CIP) was added directly to the reaction mixture 
containing the cloning vector 30 minutes prior to the end of the reaction. The digested 
products were purified by gel extraction using a gel extraction kit (Qiagen) following the 
manufacturer’s protocol. 
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2.2.1.6 DNA Ligation 
The purified digestion products were ligated using a Rapid T4 DNA ligation kit (Roche) 
according to manufacturer’s protocol. 75 ng vector was mixed with a 3-fold molar 
excess of digested insert, in addition to 1x T4 DNA ligase buffer and 1 U T4 DNA ligase in 
a 10 μl reaction volume. The mixtures were incubated at 16 °C for one hour. 
 
2.2.1.7 DNA Transformation 
 
Frozen Subcloning Efficiency™ DH5α™ Competent Cells were thawed on ice and 6 μl of 
each ligation mixture was added to 50 μl cells and left on ice for 30 minutes.  The cells 
were heat-shocked at 42 oC for 45 seconds, then returned to ice for 2 minutes before 
being plated out on LB agar containing 100 µg/ml ampicillin and incubated overnight at 
37 °C.  
 
2.2.1.8 Screening for transformed DNA 
Colonies were picked and grown overnight at 37 °C in 5 ml LB broth containing 100 
µg/ml ampicillin. Plasmid DNA was extracted using Qiagen DNA Miniprep kit according 
to manufacturer’s protocol. The correct ligation products were ascertained by 
performing ‘diagnostic’ NotI/NheI double digests. Insert-containing vectors were 
subsequently sequenced (Eurofins MWG).  
 
2.2.2 Expression vectors 
 
The eukaryotic episomal expression vector pCEP-Pu, with an N-terminal His6-tag or an 
N-terminal His.myc tag or a C-terminal His6-tag, was used for expression in mammalian 
293 c18 cells (Figure 2.2). The 9.6 kb vector is based on Invitrogen’s pCEP-Sh3 vector, 
with modifications made by Rupert Timpl’s lab in München, Patrik Maurer’s lab in Köln, 
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and in our lab (Kohfeldt et al., 1997). These modifications include introduction of 
puromycin resistance gene, BM-40 secretion sequence cloned into the multiple cloning 
site and addition of fused and cleavable tags at the N- and C- termini. The vector also 
contains an EBNA-1 gene and a replication origin (oriP) site which mediate 
extrachromosomal replication and partitioning of the episome during host cell division. 
Figure 2.2 shows a vector map indicating the features of pCEP-Pu.  
The sequence-verified inserts were cloned into one of the modified pCEP-Pu vectors 
using NheI and NotI. For C-terminal tagged proteins, a vector-derived APLA sequence 
remains at the N terminus of the secreted recombinant protein following cleavage of the 
BM-40 sequence signal, and an AAAHHHHHH sequence is added at the C terminus. For 
N-terminal tagged proteins, the N-terminus of the mature protein is APLV-His6-ALA 
followed by the insert. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Vector map indicating features of pCEP-Pu. This plasmid (~ 9.6 kb) is used for 
episomal expression in HEK293-EBNA cells. It contains the BM-40 secretion signal which allows 
secretion of the protein from the cell, a multiple cloning site (MCS), cytomegalovirus promoter 
(pCMV) for transcription of recombinant genes inserted into the multiple cloning site, an EBNA-
1 gene and a replication origin (OriP) site which facilitate extrachromosomal replication of the 
plasmid during host cell division. Marker for puromycin resistance gene allows puromycin 
selection in transfected mammalian cells. 
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2.2.3 Mammalian Cell Culture 
2.2.3.1 Transfection 
Expression vectors were transfected into HEK 293-EBNA cells cultured in DMEM 
supplemented with 10% (v/v) foetal bovine serum (FBS), penicillin/streptomycin, 2 
mM L-glutamine and 25 µg/ml geneticin. Transfection was performed in T25 flasks 
using Fugene reagent according to the manufacturer’s protocol (Roche). Cells 
containing the plasmid were selected 24 hours later using 1 µg/ml puromycin. 
Transfectants were maintained under continuous selection with puromycin. All 
solutions were warmed to 37 °C prior to use. 
 
2.2.3.2 Growth and Maintenance of Cells 
Cells were grown at 37 °C in a humid atmosphere of 5 % carbon dioxide.  The adherent 
cells were passaged by decanting the growth medium, then trypsinising with 2 ml of 
trypsin:EDTA  solution for 2-3 minutes at 37 °C to detach them from the flask. Resistant 
cells, when greater than 80% confluent, were expanded progressively into T75, T175 
and finally into Corning HYPERFlasks.  
Once the cells in HYPERflasks had reached confluence, the selection medium was 
discarded; the cells were washed twice with PBS and incubated with serum-free 
medium to eliminate serum proteins from large-scale protein preparations. Serum-free 
medium containing soluble proteins (conditioned medium) was collected after one 
week. Flasks were refilled with serum-free medium and up to four exchanges were 
carried out. The media were centrifuged at 3,500 rpm for 10 minutes, filtered to remove 
cell debris and stored at 4 °C. 
 
2.2.4 Protein Purification  
 
Milligram (mg) quantities of pure and stable protein are required for structural and 
functional studies. This section describes the purification strategies used to obtain such 
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quantities of various constructs of decorin and SPARC proteins, and the bacterial 
expression and purification of PNGaseF - MBP enzyme.  
 
2.2.4.1 Immobilised Metal Ion Chromatography   
Conditioned serum-free medium (pH adjusted to 7.5) was loaded onto a 5 ml HisTrap™ 
column equilibrated with PBS (10 mM sodium phosphate pH 7.4, 2.68 mM KCl, 140 mM 
NaCl), using an ÄKTAPurifier. Proteins were eluted using 300 mM imidazole in PBS. The 
absorbance at 280 nm was monitored constantly. Selected 1 ml fractions were analysed 
by SDS-PAGE and pooled as appropriate. 
All SPARC protein samples were dialysed overnight at 4 °C against 2 L 20 mM HEPES pH 
7.5, 150 mM NaCl, 2 mM CaCl2. The protein concentration was then determined using a 
spectrophotometer. 
 
2.2.4.2 Size Exclusion Chromatography (SEC) 
SEC was carried out in order to further purify proteins. A Superdex 200 10/300 column 
or a Superdex 200 16/60 column (GE Healthcare) was equilibrated with running buffer: 
20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2 for SPARC proteins and Tris-buffered 
saline (TBS) (20 mM Tris pH 7.5, 150 mM NaCl) or PBS for decorin proteins. 530 μl or 5 
ml of each protein sample was injected into the ÄKTA system per run, depending on the 
loop used (500 μl for the smaller 10/30 column and 5 ml for the larger 16/60 column). 
Elution was monitored by UV absorbance at 280 nm. 1 or 2 ml fractions were collected. 
10 μl of each fraction were run on SDS-PAGE to identify the eluted proteins. Protein 
concentrations were quantified using a spectrophotometer at 280 nm using extinction 
coefficients calculated from the primary amino acid sequence. 
 
2.2.4.3  Bacterial Expression and Purification of PNGase F-MBP 
E. coli BL21 cells transformed with PNGase F-MBP (peptide-N-glycosidase F-maltose 
binding protein) construct (glycerol stock provided by Prof Erhard Hohenester) were 
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streaked on to an LB and Agar plate containing 100 µg/ml ampicillin and incubated 
overnight at 37 °C. A colony was picked and used to inoculate 100 ml LB culture 
containing 100 µg/ml ampicillin and grown overnight at 250 rpm at 37 °C. 50 ml of this 
starter culture was added to 1 L of LB broth and the culture incubated again at 37 °C. At 
OD600nm = 0.6, as the bacteria were in logarithmic growth phase, the culture was induced 
with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and left overnight at 30 °C in a 
shaker at 250 rpm. The next day, cells were harvested by centrifugation at 5000 g for 15 
minutes at 4 °C. The pellet was stored at -80 °C until purification.  
Frozen cell pellets were slowly thawed on ice and resuspended in 30 ml of PBS (Buffer 
A) with 1 mg/ml lysozyme, 0.1% Triton X-100 and 0.1 mM PMSF 
(phenylmethanesulphonylfluoride). The sample was incubated on ice for 10 minutes. 
The lysate was sonicated on ice for 10 cycles of alternating 30 seconds ‘on’ followed by 
30 second rest to shear the DNA. The sample was centrifuged at 30,000 g for 20 minutes 
at 4 °C to pellet the cell debris and remove unbroken cells. 1 ml of 1 mg/ml protamine 
sulphate was added to the supernatant to precipitate the DNA and the sample was 
centrifuged again at 30,000 g for 20 minutes at 4 °C. 
The cleared sample was loaded onto a 5 ml amylose resin column (NEB) washed with 
column buffer (20 mM Tris pH 7.5, 200 mM NaCl, 1 mM EDTA). The protein was eluted 
using 10 mM maltose, 20 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM EDTA. Selected 
fractions were analysed by SDS-PAGE and pooled as appropriate. 
The protein was further purified by size exclusion chromatography using a Superdex 
S200 column on an Äkta FPLC equilibrated with running buffer (40 mM Tris-HCl pH 7.5, 
100 mM NaCl, 10 mM EDTA). The volume of the protein sample was reduced to ~500 µl 
using a 10 kDa molecular weight cut-off (MWCO) Vivaspin tube and then injected into 
the ÄKTA system. Elution was monitored by UV absorbance at 280 nm. Fractions of 1 ml 
were collected. Peak fractions were pooled and concentrated to 2 mg/ml. Glycerol was 
added in a 1:1 ratio. The samples were then aliquoted, flash frozen in liquid nitrogen 
and stored at -80 °C. 
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2.2.5 Protein Methods 
2.2.5.1 SDS-PAGE  
SDS-PAGE (Laemmli, 1970) was carried out using a Hoefer™ SE-250 gel tank. Separating 
gels were either 10% (w/v) or 15% (w/v) acrylamide:bis-acrylamide, in addition to 
0.375 M Tris, pH 8.8, 0.1% (w/v) SDS, 0.04 % (w/v) APS and 0.2% (w/v) TEMED. 
Stacking gels were 4% acrylamide: bis-acrylamide plus 0.125 M Tris, pH 6.8, 0.1% (w/v) 
SDS, 0.04% APS and 0.2% (w/v) TEMED.  10 µl samples containing 1x SDS-PAGE 
loading buffer (60 mM Tris pH 6.8, 25% glycerol, 2% SDS, 0.7 M β-mercaptothanol, 
0.1% bromophenol blue) were boiled at 95 °C for 7 minutes and electrophoresed at 180 
V for 1 hour in 1x SDS-PAGE running buffer (125 mM Tris base pH 8.3, 0.96 M glycine, 
0.1% SDS). 10 μl of pre-stained broad range protein ladder (10-250 kDa) was used.  
After separation, gels were stained with either Quick Coomasie stain or InstantBlue™ gel 
stain for at least 60 minutes at room temperature with gentle shaking. This was 
followed by de-staining with deionised water overnight at room temperature. 
 
2.2.5.2 NuSep® 
NuSep® Tris-HEPES 4 ‐ 12% gels (Generon) were used for SDS‐PAGE analysis of 
protein samples. Samples containing 1 x sample buffer (60 mM Tris pH 6.8, 25% 
glycerol, 2% SDS, 0.7 M β-mercaptothanol, 0.1% bromophenol blue) were boiled at 95 
°C for 7 minutes. The gel cassettes were loaded onto the Hoefer SE-250 gel tank and 
immersed in 1 x NuSep Tris-HEPES-SDS  running buffer (100 mM Tris pH 8.0, 100 mM 
HEPES, 0.1% SDS). The boiled samples were loaded and electrophoresed at 120 V for 1 
hour. 10 μl of pre-stained broad range protein ladder (10-250 kDa) was used.  
 
2.2.5.3 Deglycosylation 
For diagnostic purposes, the N-linked glycan in SPARC proteins was removed by 
treatment with New England Biolabs (NEB) PNGase F treatment according to the 
manufacturer’s protocol. Samples were heat-denatured by adding 1 x glycoprotein 
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Denaturing buffer (0.5% SDS, 40 mM DTT) for 10 minutes at 100 °C prior to addition of 
PNGase F diluted in 1 x G7 buffer (50 mM sodium phosphate pH 7.5) and 1 x NP-40.  
For large scale deglycosylation, the protein samples were incubated with PNGaseF-MBP 
(produced as described in section 2.2.4.3) overnight at room temperature in an enzyme 
: protein ratio of 1:5.  
Drosophila SPARC fragments were treated with lectin in an attempt to remove 
remaining glycosylated forms following PNGaseF treatment. Lectin bead slurry, 
consisting of three types of lectin beads (agarose Lens culinaris agglutinin, agarose 
concanavalin A and wheat germ agglutinin) was used for this purpose. 2 ml of each type 
of beads were spun down at 800 rpm for 5 minutes and the supernatant discarded. The 
beads were then washed with double-distilled water followed by wash buffer (10 mM 
HEPES pH 7.5, 0.15 M NaCl, 0.1 mM CaCl2, 0.01 mM MnCl2) to remove sugar added to 
stabilise the lectin. The PNGaseF - treated protein sample was incubated with the slurry 
overnight on a bench-top rotator at room temperature. The supernatant from the beads 
was collected, which should contain deglycosylated protein. The lectin beads were 
loaded onto a gravity flow column. The remaining glycosylated protein bound to the 
beads were eluted using 10 ml elution buffer (10 mM HEPES pH 7.5, 0.15 M NaCl, 0.1 
mM CaCl2, 0.5 M N-acetyl-D-glucosamine, 0.2 M α-methyl mannoside, 0.2 M α-methyl 
glucoside).  
 
2.2.5.4 Crystallisation Trials 
 
Crystallisation trials were set up using various screens (see Chapter 5, tables 5 and 6). 
The protein was mixed 1:1 with well solution (100 nl + 100 nl) in 96-well sitting drop 
plates using a Mosquito robot and incubated at 20 °C.  
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2.2.6 Size Exclusion Chromatography- Multi Angle Light Scattering 
(SEC - MALS) 
400 μl of wild-type decorin and each mutant sample, at a concentration of 3 mg/ml, 
were injected and separated on a Superdex 200 10/30 column which had been pre-
equilibrated in 1 x TBS (20 mM Tris pH 7.5, 150 mM NaCl) at room temperature at a 
flow rate of 0.2 ml/min. Light scattering data were recorded on an in-line Wyatt mini-
DAWN light scattering (LS) detector which detects scattered light at three different 
angles. The light scattering detector was in series with an Optilab rEX refractive index 
detector. UV absorbance was recorded at 280 nm. A specific refractive index increment 
(dn/dc) value of 0.185 ml/g was used for protein component and 0.145 ml/g for the 
carbohydrate component of each glycoprotein (Wen et al., 1996). Each putative site for 
N-linked glycosylation was assumed to add a molecular mass of 2 kDa. The dn/dc value 
was calculated using the equation: ((0.185/100) x protein % + (0.145/100) x sugar %).  
The mass of the polypeptide fraction of the glycoproteins was determined by the three-
detector method described by (Wen et al., 1996) using an extinction coefficient of 
24961 M-1cm-1 for the decorin protein. The equation used to calculate the polypeptide 
mass for a protein, Mp, containing carbohydrates is described by Wen et. al as:  
   
    
        
 
(  )(  )
  (  ) 
 
 
Where (K2RI/KLSKUV) is an instrument calibration constant, subscript p refers to the 
polypeptide component, (LS) is the intensity of light-scattering signal, (UV) is the signal 
from the UV absorbance detector, (RI) is the refractive index signal and ε is the molar 
extinction coefficient i.e. the absorbance of 1 mg/ml glycoprotein at a 1 cm pathlength. 
All contributions from the carbohydrate are eliminated by selecting a wavelength where 
the carbohydrate does not absorb.  
The Wyatt ASTRA (version 5.3.4.20) software was used for all MW calculations. The 
laser signals were aligned, and peaks selected to determine delays to correct for the 
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difference in flow path between the UV and LS measurements. The despiking level was 
set to ‘normal’. Appropriate pre-peak baselines were selected for the UV and the three 
LS signals. The peak boundaries were defined before checking the results section of the 
software.  
 
2.2.7 Surface Plasmon Resonance (SPR)/ BIACORE 
All SPR measurements were performed on a BIACORE 3000 instrument. The 
carboxymethylated dextran surface of a CM5 chip was activated by the injection of a 
mixture of equal volumes of 0.2 M N-ethyl-N-(diethylaminopropyl)carbodiimide (EDC) 
and 0.05 M N-hydroxysuccinimide (NHS). Collagen I or collagen IV (both at 2 mg/ml in 
0.1 M acetic acid) was diluted to 100 µg/ml in 10 mM sodium citrate pH 3.2 and 
immobilised via its primary amine groups at 25 °C at a flow rate of 10 µl/min.  An 
immobilisation level of ~2000 resonance units was obtained. Unreacted NHS groups 
were deactivated and non-covalently bound proteins removed using 1 M ethanolamine 
pH 8.5.  A control flow cell, without any coupled protein, was treated identically. 
The binding assay was performed by using recombinant proteins at different 
concentrations, ranging from 0 µM to 40 µM, diluted in running buffer (10 mM HEPES 
pH 7.4, 0.15 M NaCl, 0.05% Tween-20) using a two-fold dilution series. The running 
buffer was flowed at a rate of 20 µl/min. The surface was regenerated using 10 mM 
HEPES pH 7.4, 0.15 M NaCl, followed by 0.1 M NaHCO3 pH 9.2, 2 M NaCl for 30 seconds 
each at a flow rate of 30 μl/minute.. Some interactions were measured without 
regeneration of the sensor surfaces between runs. A titration series with long injection 
phases was used for the steady-state analysis. The sensorgrams were then evaluated 
with the BIAevaluation 3.0 software. Control sensorgrams were subtracted from the 
sensorgrams obtained on immobilised collagen to account for changes in refractive 
index and nonspecific binding. The response to the running buffer was defined as the 
baseline level, and all responses were expressed relative to this baseline. 
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2.2.8 Solid Phase Assays 
 
Solid phase assays were performed in enzyme-linked immunosorbent assay (ELISA) 
format and used to test the interaction of proteins with collagen I and IV.  
5 mg of rat tail type I collagen was dissolved in 0.1 M acetic acid. 10 µg/ml of this 
collagen solution (25 µg/ml for decorin assays) diluted in 50 mM Tris pH 8.5, 100 mM 
NaCl was immobilised onto Nunc Maxisorp 96-well immunoplates by incubation 
overnight at 4 °C. Wells were washed once with 1x PBS, then blocked with 150 µl of 
0.04 mg/ml casein in 1x PBS containing 0.05% Tween-20 for two hours at room 
temperature. Proteins were diluted in incubation buffer (0.04 mg/ml κ-casein in 1x PBS 
with 0.05% Tween-20). 50 µl of proteins ranging from 0 µM to 40 µM were added to 
each well and incubated at room temperature for 3 hours. The wells were washed six 
times with 150 μl/well of incubation buffer. His.myc-tagged proteins were detected first 
by adding mouse anti-myc antibody (1:1000 dilution) for 1 hour at room temperature 
followed by sheep-anti-mouse-HRP antibody (1:1000 dilution) again for an 1 hour. 
Decorin proteins were incubated for 1 hour with 50 μl/well of goat anti-mouse decorin 
antibody (1:500 dilution in incubation buffer). After six washes with incubation buffer, 
the wells were incubated for 1 hour with 50 μl/well of horseradish peroxidase-
conjugated rabbit anti-goat IgG antibody (1:1000 dilution in incubation buffer). In 
another set of experiments, only anti-His-tag HRP conjugated antibody was used. 
Following three washes with incubation buffer and three washes with PBS (150 
μl/well), the assay was developed using 75 µl/well o-phenylenediamine 
dihydrochloride (OPD) substrate for 5 minutes and the reaction stopped using 50 
µl/well of 3 M H2SO4. Absorbance was measured at 492 nm with an ELISA microplate 
reader. 
Data were fitted using SigmaPlot to an equation for one-site saturable binding plus a 
linearly increasing background of nonspecific binding as shown in the equation below: 
                                                
         
      
 + a                                      
76 
 
Where y is the OD492 reading, x is the ligand concentration, Bmax is maximum saturable 
binding, a is the background binding of antibodies to collagen and the blocked plastic 
surface and K0.5 is the ligand concentration for half-maximal binding.  
 
2.2.9 Biotinylation  
 
Wild-type and mutant decorin and dSPARC (control) were labelled with biotin as 
follows. The samples were first dialysed against PBS, then incubated on ice with a 20-
fold molar excess of EZ-Link Sulfo-NHS-LC biotin for 2 h. Concentrated Tris/HCl buffer, 
pH 7.5, was then added to 50 mM final concentration and the samples incubated for 1 h. 
The samples were then dialysed overnight against PBS to remove excess non-reacted 
biotin and stored at 4 °C. 
 
2.2.10 Biotin - Avidin Assays 
 
Nunc Maxisorp 96-well microtitre plates were coated with 50 µl of 25 µg/ml collagen I 
in PBS, overnight at 4 °C. The wells were then washed once with PBS and blocked with 
150 µl/well of 10 mg/ml casein in 1x PBS containing 0.05% Tween-20 for two hours at 
room temperature. Proteins were serially diluted in incubation buffer (0.04 mg/ml 
casein in 1x PBS with 0.05% Tween-20). The wells were washed six times with 
incubation buffer (150 μl/well).  Different concentrations of wild-type and decorin and 
glycosylation mutants ranging from 0 µM to 10 µM were added to each well (50 μl/well) 
and incubated at room temperature for 3 hours. Following three washes with 
incubation buffer and three with PBS, biotinylated proteins were detected using 50 
μl/well avidin peroxidase (1:1000 dilution). The assay was developed using 75 µl/well 
o-phenylenediamine dihydrochloride (OPD) substrate for 5 minutes and the reaction 
stopped using 50 µl/well of 3 M H2SO4. Absorbance was measured at 492 nm with an 
ELISA microplate reader. The apparent dissociation constants were obtained by fitting 
the data with Equation 2 using SigmaPlot 12.0, 
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where y is the OD492 reading, x is the protein concentration, K0.5 is the dissociation 
constant, Bmax is the maximum of specific binding, and nx + a is a linear term to account 
for non-specific binding to collagen and the blocked plastic surface. 
 
2.2.11 Competition assays 
Biotinylated wild-type decorin (1 µM) was pre-incubated with increasing 
concentrations of non-biotinylated wild-type decorin (up to 20 µM) at room 
temperature and the mixture added to collagen I-coated plates. The assay was 
developed as described above. 
 
2.2.12 Collagen fibrillogenesis assay  
All samples were kept on ice to avoid fibril formation prior to assaying. A 1.05 mg/ml 
solution of mouse tendon collagen I isolated from tendon, treated with pepsin and 
precipitated using NaCl (provided by Prof Hans Peter Bӓchinger), in 50 mM acetic acid 
was neutralised by diluting it 33 times with 150 mM sodium phosphate, 150 mM NaCl, 
pH 7.8 and immediately placed in a plastic cuvette in a Shimadzu UV-2501PC 
spectrophotometer that was pre-warmed to 37 °C. Collagen fibril formation was 
monitored as absorbance at 400 nm at 3 minute intervals over 100 minutes. The 
inhibition assays contained wild-type and decorin mutants at a concentration of 50 
μg/ml (1.38 μM). Turbidity curves were analysed in terms of the maximum turbidity 
and the rate of turbidity change observed. 
 
 
 
 
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2.2.13 Differential Scanning Calorimetry (DSC) 
DSC experiments were performed to assess the stability of the different decorin 
mutants, using an N-DSCIII Differential Scanning Calorimeter. Decorin samples at 3 
mg/ml were dialysed against PBS. 1 ml aliquots of sample and buffer were de-gassed 
under vacuum for 15 minutes. 300 µl each of sample and buffer were loaded onto the 
sample and reference cells respectively. Following a pre-scan equilibration period of 10 
minutes, the sample was heated linearly from 5 - 20 °C at 1 °C per minute followed by 
cooling over the same temperature range. The scans were monitored and increased as 
necessary until a stable baseline was obtained.  For the actual denaturation runs, the 
temperature scan ranged from 5 - 65 °C at a heating rate of 1 °C per minute. Four 
heating scans between 5 - 65 °C were recorded for each sample. A small excess constant 
pressure of 3 atm was applied to the sample and reference cell to allow scanning to high 
temperatures without the sample boiling or forming bubbles. The temperature 
corresponding to maximum Cp was determined as the apparent melting temperature 
(Tm) i.e. the temperature at which 50% of the protein is unfolded.  
Data are quoted per mole of monomeric protein (36.6 kDa). Data analysis was 
performed by working out a conversion factor for power/heating rate to express the 
results in terms of heat capacity, Cp, having the units, kJ/ (K · mole).  
 
 
2.2.14 Differential Scanning Fluorimetry (DSF) 
DSF experiments were performed to assess the stability of WT and decorin mutants, 
using a Stratagene Mx3005P qPCR System with an excitation of 492 nm and emission of 
610 nm. Each sample was prepared in a total volume of 20 μl containing protein 
solutions at 5 μM final concentration and 1:500 SYPRO orange. The PCR plates were 
sealed with the optical foil seal. The samples were heated at a rate of 1 °C/min, from 25 
°C to 95°C, and the Tm values were calculated from the inflection points of the transition 
curves. 
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2.2.15 Analytical Ultracentrifugation (AUC) 
 
Sedimentation velocity (SV) experiment was performed in Professor Stephen Perkins’ 
lab at University College London, using a Beckman XL-1 analytical centrifuge at a rotor 
speed of 40,000 rpm and a temperature of 20 °C. Wild-type decorin was studied in a 
concentration series ranging from 0.075 mg/ml to 3.6 mg/ml. An eight-hole AnTi50 
rotor was used containing double-sector cells with 12 mm column heights. Wild-type 
decorin was extensively dialysed against PBS. The sample cells were filled with 400 µl 
decorin and the reference cells with 450 µl sample buffer (PBS).  
Wild-type decorin composition: Decorin has an absorption coefficient at 280 nm of 7.15 
cm-1 (1%, 1 cm path length). Partial specific volume ῡ for wild-type decorin was taken to 
be 0.7289 ml/g and MW of 44,310 Da, calculated using a programme called SLUV which 
calculates the v-bar and MW from the amino acid and carbohydrate composition of the 
protein. The N-linked oligosaccharides on decorin were assumed to be bi-antennary, 
consisting of a core of GlcNAc2Man3 and two NeuNAc.Gal.GlcNAc antennae.  
Data analysis: The SV data were analysed with SEDFIT software (Version 14.0) using the 
continuous c(s) analysis method to determine the sedimentation coefficients s20,w (s20,w 
refers to sedimentation coefficient corrected for water). The buffer density and viscosity 
values were taken to be the theoretical values calculated by SEDNTERP - in this case, for 
PBS (10 mM Na2PO4, 140mM NaCl, 2.68mM KCl), 1.00543 and 0.01020 respectively. 
SEDFIT fits the sedimentation boundaries using the Lamm equation (Schuck, 2000) 
which assumes that all species in solution have the same frictional ratio, f/f0, in each fit. 
The final c(s) distribution plot used a fixed resolution of 200 sedimentation coefficients 
between 0.5 and 15 S. All size distributions were determined with a confidence level of 
p = 0.95. Each fit was optimised by floating f/f0, baseline and meniscus and keeping the 
partial specific volume, solvent density and the cell volume fixed until the lowest root-
mean-square deviation (rmsd) was found and the fit looked good on visual inspection. 
The c(s) integration function (area under the curve) was used to find the percentage of 
different species in the total loading concentration.  
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Theoretical sedimentation coefficients s20,w for decorin monomer and dimer were 
calculated using the HYDROPRO programme (Garcia De La Torre et al., 2000a). This 
programme uses the atomic coordinates of the protein to calculate s20,w by converting 
the protein to a hollow shell model consisting of spheres only. Mouse decorin monomer 
and dimer were modelled based on the crystal structure of bovine decorin (PDB code 
1xku) with bi-antennary carbohydrates added perpendicular to the protein domain at 
all four of the predicted glycosylation sites. The hydration shell was represented using 
the default atomic-element radius (AER) value of 0.31 nm for all atoms.  
 
Estimation of Kd for protein in monomer-dimer equilibrium: 
An equation that relates the dimer fraction to the protein concentration was derived as 
described by Benfield et al. (2011) and modified as follows: 
For a system in monomer-dimer equilibrium, 
M + M ↔ D               Eq .(1) 
where M and D are monomers and dimers respectively. The equilibrium dissociation 
constant Kd is defined by: 
    
    
   
                Eq. (2) 
 
where [M] and [D] represent molar concentrations (mol/L) of monomer and dimer 
respectively. The total protein concentration [M]T in equivalent monomers is: 
[M]T = [M] + 2[D]      Eq. (3) 
This can be re-arranged as: 
                
         
 
         Eq. (4) 
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Substituting (4) into (2): 
    
     
         
     Eq. (5) 
Solving Eq. (5) For [M] 
     
    √  
          
 
         Eq. (6) 
                                                        
                                                                      
   
    
 · 100 
 
                                                                         
    
    
 · 100 
It then follows that, 
         
   
    
  
√  
             
     
             Eq. (7) 
Hence, 
        (  
√  
             
     
)                   Eq. (8) 
 
Plotting % dimer against [M]T gives us the Kd which is the only fittable parameter in the 
above equation.  
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Chapter 3: Results  
Analysis of decorin dimerisation 
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3. Results 
 
The crystal structure of decorin revealed a seemingly tight dimeric structure in which 
the concave faces of two monomers form the dimer interface, thus making the 
presumed collagen binding site inaccessible. The physiological relevance of the decorin 
dimer remains controversial and it has been claimed that biologically active decorin is a 
monomer.  
The main aim of the study was to resolve the controversy about the oligomeric state of 
decorin by designing a number of decorin mutants to disrupt the crystallographic 
dimer. I used size exclusion chromatography with multi-angle laser light scattering and 
analytical ultracentrifugation was used to determine the oligomeric states of wild-type 
and mutant decorin. The stabilities of wild-type and mutant decorin were quantified by 
differential scanning calorimetry and differential scanning fluorimetry. A further aim 
was to identify whether decorin binds collagen as a monomer or a dimer, directly using 
solid-phase assay and indirectly by measuring the inhibition of collagen fibrillogenesis. 
 
 
3.1 Mouse decorin construct design 
 
The amino acid identity of decorin across species is about 80% (Figure 3.1). A wild-
type (WT) mouse decorin expression construct (referred to as decorin) corresponding 
to the ordered residues in the crystal structure of bovine decorin core protein was 
created. This construct consists of residues 45-354 of the protein (UniProt P28654, 
residue numbering scheme includes the signal peptide). A His6-tag was added at the C-
terminus. Since the C-terminal cap is not involved in the dimer interface, the tag is not 
expected to affect dimerisation. 
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Figure 3.1 Amino acid sequence alignment of bovine, mouse and human decorin. 
Conserved residues are shaded in grey. The engineered glycosylation sites are shaded pink. 
Putative N-glycosylation sites are in pink. Various other independent mutations are coloured 
cyan. Putative collagen binding residues (Kalamajski et al., 2007, Kresse et al., 1997) are shaded 
yellow. Cysteines are in red. The residue numbering above the alignment corresponds to that of 
bovine decorin. Sequences from the N-terminus to LRR12 are shown. The LRR consensus 
sequences (L..L.L..N.L) are indicated below the alignment.  
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3.2 Purification of wild-type decorin 
The WT decorin construct was used for the episomal transfection of HEK293 cells since 
the post-translational modifications produced by these cells are similar to those of 
native mammalian glycoproteins. WT decorin protein was purified to homogeneity from 
serum-free medium by nickel affinity chromatography, followed by SEC (Figure 3.2A). 
The yield from 2 L of medium was 15.5 mg of protein. The SEC fractions were analysed 
by SDS-PAGE (Figure 3.2B). All purified decorin gave two bands on reducing SDS-PAGE 
- the lower band corresponding to glycosylated decorin at ~45 kDa (the predicted 
molecular mass from the amino acid sequence, 36.2 kD). Due to the presence of N-
linked glycosylation sites in decorin, the purified proteins migrate as diffuse bands at 
higher molecular mass on SDS-PAGE. The band at ~ 80 kDa, is unlikely to be a 
disulphide-linked dimer as the gel has been run under reducing conditions. It is possibly 
a gel artefact since the protein elutes as a single species in SEC and it is not seen on all 
gels (e.g. Figure 3.19).  
 
 
Figure 3.2 Purification of WT decorin. A. The elution profile of purified WT Dec CHis on a 
Superdex S200 16/60 column is shown. The arrows show the peak elution volumes of 
molecular mass standards in kDa. Protein samples were eluted in TBS (20 mM Tris pH 7.5, 
150 mM NaCl). B. Reducing SDS-PAGE analysis of Dec CHis purification (Coomassie Blue stain). 
Peak fractions correspond to the SEC peak in A. The positions of selected molecular mass 
markers are shown on the left. 
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3.3 Purification of engineered glycosylation mutants 
In order to design mouse decorin constructs that are incompatible with the dimer 
structure presented by Scott et. al (2004), I designed a number of mutants including two 
which had glycosylation sites engineered into the dimer interface (Figure 3.1). Glu61 
(Gln37 in bovine decorin) in the N-terminal cap (Q61N mutant) and Tyr130 (Tyr106 in 
bovine decorin) in LRR4 (Y130N mutant) were mutated to Asn, which created 
consensus sites for glycosylation at these locations. Based on the NetNGlyc 1.0 server 
(http://www.cbs.dtu.dk/services/NetNGlyc/), the asparagines at positions 61 and 130 
have predicted glycosylation potentials of 0.61 and 0.72 respectively (threshold = 0.5), 
suggesting that these engineered glycosylation sites have a high probability of being 
modified. 
These mutants were secreted from HEK293 cells as efficiently as wild-type decorin, 
indicating that the proteins were folded correctly. The yields from 2 L of medium were 
33.4 mg of Q61N CHis and 23.5 mg of Y130N CHis. The SEC profiles of the two mutants 
overlaid with that of wild-type decorin are shown in Figure 3.3. The two mutants with 
engineered glycosylation sites elute later compared with the wild-type protein, 
suggesting that they are smaller in size, i.e. possibly monomeric in solution. The 
presence of extra peaks in the Y130N mutant SEC profile suggests protein aggregation. 
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Figure 3.3 SEC analysis of decorin glycosylation mutants. The elution profiles of purified WT 
Dec CHis, Q61N and Y130N mutants on a Superdex S200 16/60 column are shown. The arrows 
show the peak elution volumes of molecular weight standards in kDa. Protein samples were 
eluted in TBS (20 mM Tris pH 7.5, 150 mM NaCl).  
 
SDS-PAGE analysis of wild-type decorin under reducing conditions shows a band at ~ 
45 kDa, consistent with a calculated molecular mass, 36.2 kDa plus four N-linked 
glycosylation sites in the mouse decorin sequence (Figure 3.4). The two glycosylation 
mutants (Q61N and Y130N) appear fuzzier and migrate at a higher molecular mass, 
most likely due to the addition of the extra glycan.  The shift in molecular mass of the 
Y130N is less clear, either due to the absence of an extra glycan or because the glycan is 
not detectable by SDS-PAGE. Since I already had one mutant with a clearly visible extra 
glycan (Q61N mutant), I did not further investigate the glycosylation profile of the 
Y130N mutant. Removal of the N-linked glycans by PNGase F digestion following 
denaturation of the samples generated identical sharp bands of lower molecular weight 
(~ 30 kDa) corresponding to the core deglycosylated proteins (Figure 3.4).   
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Figure 3.4 SDS-PAGE of wild-type decorin and glycosylation site mutants under reducing 
conditions. The purified proteins (WT Dec CHis, Q61N and Y130N mutants) were left 
undigested or treated with PNGase F following denaturation and then analysed by SDS-PAGE. 
The positions of selected molecular weight markers are indicated on the left.  
 
3.4 Purification of other mutants 
Two other constructs were made to introduce mutations into the decorin dimer 
interface: a charge reversal mutation, R151E in LRR5 (Arg127 in bovine decorin), which 
reverses a charge in the extensive hydrogen-bonding network at the dimer interface; 
and a triple mutation in the N-terminal cap, Y51A/R52A/Q54A (Phe27, Arg28 and 
Gln30 in bovine decorin), which removes three side-chains involved in the dimer 
interface. As controls, I designed two mutants on the outer surface of decorin (E156K 
and K159E) which should leave the dimer interface unaffected. All mutants were highly 
expressed and the yields following affinity purification and SEC from 2 L of medium 
were as follows: 11.8 mg of R151E, 5.5 mg of Y51A/R52A/Q54A, 11.9 mg of E156K and 
15.1 mg of K159E (Figure 3.5).  
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Figure 3.5 SDS-PAGE of mouse decorin mutants under reducing conditions. The purified 
proteins (R151E, Y51A/R52A/Q54A, E156K and K159E mutants) were analysed by SDS-PAGE. 
The positions of selected molecular weight markers are indicated on the left.  
 
 
Figure 3.6 shows the positions of the engineered mutations in mouse decorin mapped 
onto the crystal structure of bovine decorin.  
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Figure 3.6 Positions of the engineered mutations in mouse decorin mapped onto the 
crystal structure of bovine decorin. The independently mutated residues on the dimer 
interface are each colour-coded and the control mutants located outside the dimer interface 
(E156K and K159E) are coloured orange. The N- and C- termini are labelled on one subunit.  
Drawn from PDB entry 1XKU (Scott et al., 2004).  
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3.5 Oligomeric states of wild-type and mutant decorin 
Size exclusion chromatography with multi-angle laser light scattering (SEC-MALS) was 
used to determine oligomeric states of wild-type mouse decorin and its dimer interface 
mutants.  This technique allows the determination of absolute molecular masses of 
proteins in a reference-free manner. In conventional SEC, the elution position is affected 
by the shape (hydrodynamic radius) of the protein. So if the protein is elongated it will 
elute earlier from the column, hence appearing larger than its true molecular weight or 
if it is ‘sticky’ i.e. it interacts with the column matrix, it will elute later.  However, 
molecular masses determined by light scattering are independent of the shape of the 
protein and the elution volume. Another advantage of SEC - MALS is that in the case of 
glycoproteins, it allows the de-convolution of the effect of the carbohydrates from that 
of the core protein (Wen et al., 1996).  
Wild-type mouse decorin injected at a concentration of 3 mg/ml (83 μM) eluted as an 
asymmetric peak with a pronounced tail (Figure. 3.7). The molecular mass of the 
polypeptide fraction of the protein was determined to be 64.4 kDa (Table 3.1). This 
value is much closer to the calculated mass of a dimer (72.4 kDa) than that of a 
monomer (36.2 kDa). The average molecular mass of the dimer is slightly lower than 
expected because there is some dissociation into monomers, giving rise to an 
asymmetric peak. The molecular mass of the glycoconjugate (i.e. protein plus 
carbohydrate modifications) was determined to be 83.5 kDa, closely matching the 
reported mass of 84.6 kDa for dimeric bovine decorin core glycoprotein (Scott et al., 
2003).  
As expected, the control mutants, E156K AND K159E, of mouse decorin were dimeric 
with molecular weights of 65 and 60 kDa respectively for the core proteins without 
modifications (Figure 3.7, Table 3.1). The Y51A/R52A/Q54A and R151E mutants were 
also dimeric, indicating that fairly dramatic amino acid substitutions do not disrupt the 
dimer. For some of the samples, Y51A/R52A/Q54A mutant in particular, peak 
broadening was observed due to polydispersity, resulting in the molecular masses not 
being constant across the peaks. The elution profiles of Q61N and Y130N mutants 
indicate that these are pure monomers as symmetric peaks were detected by SEC-MALS, 
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with molecular masses consistent with those calculated from their primary sequences 
(Fig. 3.7, Table 3.1). It can be inferred that the addition of the extra glycan in the Q61N 
mutant resulted in the disruption of the decorin dimer. The same cannot be inferred 
categorically for the Y130 mutant, since the additional glycan modification is not 
evident in SDS-PAGE (Figure 3.4). However, our aim was only to obtain monomeric 
decorin mutants, hence we did not investigate the modifications in the Y130N mutant 
further. Thus, we were able to disrupt the decorin dimer by engineering glycosylation 
sites into the dimer interface.  
 
 
 
 
Table 3.1 Molecular masses of decorin and its mutants as determined by SEC-MALS. The 
relative errors of the experimentally determined masses are <5%. 
Protein(s) 
Calculated 
molecular 
mass (kDa) 
N-linked 
glycosylation 
sites 
Peak 
elution 
volume 
(ml) 
Experimental 
mass of 
glycoprotein 
(kDa)a 
Experimental 
mass of 
polypeptide 
fraction (kDa)b 
WT 36.2 4 14.5 83.5 64.4 
Y51A/R52A/Q54A 36.0 4 14.1 85.3 65.3 
R151E 36.2 4 14.1 88.4 68.4 
E156K 36.2 4 14.5 79.7 65.0 
K159E 36.2 4 14.4 78.9 60.3 
Q61N 36.2 5 15.5 52.1 37.6 
Y130N 36.2 5 15.1 51.5 36.7 
aDerived from the refractive index and light scattering signals. 
bDerived from the absorbance, refractive index and light scattering signals (Wen et al., 1996). 
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Figure 3.7 SEC-MALS chromatograms of wild-type and mutant decorin. Proteins were 
injected at 3 mg/ml (83 µM) onto a Superdex S200 column. Differential refractive index (ΔRI) is 
a measure of protein concentration (solid lines; left y- axis). Molecular masses (dashed lines) of 
the polypeptide fractions are plotted across the peaks. The theoretical molecular mass of 
decorin core protein (including purification tag) is 36.2 kDa. 
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3.6 Study of monomer-dimer equilibrium 
The initial SEC-MALS data gave the first indication that wild-type decorin exists in a 
monomer-dimer equilibrium in solution. To investigate the monomer-dimer 
equilibrium quantitatively, we used sedimentation velocity analytical 
ultracentrifugation (AUC). AUC is a powerful technique to quantitatively study the 
interaction of proteins in solution. In a sedimentation velocity (SV) experiment, the 
rates of movement of samples are observed as they sediment at very high rotor speed 
due to differences in density, mass and shape. Two optical systems are used to monitor 
sedimentation: absorbance at 280 nm and interference optics, as a function of radial 
distance. The sedimentation coefficient, S20,w, of the protein refers to the rate at which 
the sedimentation boundary moves. It gives information about both the mass and the 
shape of the protein.  The units of S20,w are in Svedbergs (S) where 1 S = 10−13 seconds. 
Sedimentation velocity data were collected at seven concentrations of wild-type 
decorin, ranging from 0.028 to 3.4 mg/ml (0.77 to 94 μM) in PBS, at a rotor speed of 
40,000rpm. SDS-PAGE before and after the AUC run revealed no aggregation (Figure 
3.8).  
 
 
 
 
 
 
 
 
Figure 3.8 SDS-PAGE of wild-type decorin before and after the AUC run. Analysis by SDS-
PAGE prior to and following the AUC runs shows no apparent formation of aggregates. The 
positions of selected molecular weight markers are shown on the left.  
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HYDROPRO (Garcia de la Torre et al., 2000b) was used to calculate the theoretical S20,w, 
based on an atomic shell model of bovine decorin with appropriate bi-antennary 
oligosaccharide additions, which yielded S20,w values of 3.0 S and 4.7 S for monomeric 
and dimeric mouse decorin respectively. SEDFIT (Brown and Schuck, 2006) was used to 
perform continuous size distribution c(s) analysis of the interference optics data 
(Figure 3.9). Two distinct peaks were observed, one at 3.6 S and one at 4.7-5.3 S, which 
were interpreted to be monomer and dimer respectively (Figure 3.10). The agreement 
between the calculated and experimental S20,w values confirms the existence of mouse 
decorin in these oligomeric states. The relative proportion of these species varied with 
protein concentration. At 0.028 mg/ml (0.77 µM), the distribution shows predominantly 
monomer and a small amount of dimer. The ratio is reversed at 3.4 mg/ml (94 µM), 
where mostly dimer is present (Figure 3.10). The dissociation constant Kd for the 
decorin dimer was calculated to be 1.37 ± 0.30 µM (Figure 3.11), indicating that at 
submicromolar concentrations, decorin is predominantly monomeric. 
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Figure 3.9 Sedimentation velocity analytical ultracentrifugation of WT decorin. 
Representative boundary fits of fringes collected by interference measurements, showing every 
third scan (from 0.43 to 3.4 mg/ml) and every fifth scan at the 3 lowest concentrations (upper 
panel) for reason of clarity. Scan boundaries are in black and their fits in red. Experiments were 
performed at 20 °C with WT decorin in PBS. Scans were fitted to the Lamm equation using 
SEDFIT. 
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Figure 3.10 Continuous size distributions at seven different concentrations. The peaks for 
monomer (m) and dimer (d) are indicated.  At 0.028 mg/ml, the peaks in the c(s) distributions 
show predominantly monomer and a small amount of dimer. The ratio is reversed at 3.4 mg/ml, 
where mostly dimer is present. Experiments were performed at 20 °C with WT decorin in PBS.  
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Figure 3.11 Determination of the dimer dissociation constant for WT decorin. Fraction 
dimer plotted as a function of protein concentration. The relative amounts of monomer and 
dimer were determined from integration of the peaks in the c(s) distribution. The data were 
fitted to a model of monomer-dimer equilibrium (Eq. 8 in section 2.2.15). 
 
Similar AUC experiments were carried out with the Y51A/R52A/Q54A and R151E 
mutants to determine their dissociation constants. SDS-PAGE before and after the AUC 
runs revealed no aggregation (Figure 3.12). Continuous size distribution c(s) analysis 
of selected interference optics data of the mutants are shown (Figure 3.13). 
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Figure 3.12 SDS-PAGE of mouse decorin mutants (R151E and Y51A/R52A/Q54A) before 
and after the AUC run. Analysis by SDS-PAGE prior to and following the AUC runs shows no 
apparent formation of aggregates. The positions of selected molecular weight markers are 
shown on the left.  
 
 
 
Figure 3.13 Continuous size distributions at three different concentrations of (A) 
Y51A/R52A/Q54A and (B) R151E mutants. The peaks for monomer (m) and dimer (d) are 
indicated.  Experiments were performed at 20 °C with decorin mutants in PBS.  
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The dissociation constant of the Y51A/R52A/Q54A mutant was derived to be 2.3 ± 0.8 
µM (Figure 3.14A) and that of R151E was 0.47 ± 0.09 µM (Figure 3.14B), i.e. both 
were found to be similar to that of WT decorin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Determination of the dimer dissociation constants for decorin mutants. A) 
Y51A/R52A/Q54A and B) R151E. Fraction dimer plotted as a function of protein concentration. 
The relative amounts of monomer and dimer were determined from integration of the peaks in 
the c(s) distribution. The data were fitted to a model of monomer-dimer equilibrium (Eq. 8 in 
section 2.2.15).  
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3.7 Thermal stability of WT and mutant decorin 
 
So far I have shown that WT decorin and dimeric mutants, R151E and 
Y51A/R52A/Q54A, exist in concentration-dependent monomer-dimer equilibria with 
comparable dimer dissociation constants, and that stable monomeric mutants (Q61N 
and Y130N) can be obtained. I then sought to analyse the thermal stabilities of wild-type 
decorin and the monomeric Q61N mutant using differential scanning calorimetry (DSC). 
DSC is a thermal analysis technique that can be used to study how the heat capacity of a 
protein (Cp) changes with temperature. A DSC instrument measures the amount of heat 
absorbed or released by a sample if heated or cooled. Proteins unfold at a characteristic 
temperature as the heating progresses, giving rise to an endothermic peak. 
WT decorin denatures at a melting temperature of 50 °C and the Q61N mutant protein 
at 52 °C at pH 7.4 (Figure 3.15). This compares with the reported Tm of 46 °C for bovine 
decorin (Scott et al., 2006). The denaturation was not completely reversible as the 
signal following the second up-scan was roughly 10% that of the first. This is in 
contradiction to reports by Scott et al. (2006) that heat denaturation of decorin is 
completely reversible but is in agreement with the findings of Krishnan et al. (1999) 
that recombinant decorin does not recover after heat denaturation up to 60 °C.  
The protein samples showed signs of precipitation when taken out of the DSC cell. Due 
to the irreversibility of the thermal denaturation process, enthalpies could not be 
calculated.  
These results show that engineered monomeric mouse decorin is as stable as wild-type 
decorin. 
 
  
 
 
102 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Thermal denaturation studies of WT and monomeric decorin by DSC. 
Differential scanning calorimetry unfolding curves of WT (black line) and monomeric (red line) 
decorin as a function of temperature at pH 7.4. Proteins were at a concentration of 3 mg/ml in 
PBS. The melting temperatures are 50 °C for WT decorin and 52 °C for the Q61N mutant. 
 
We also tested the thermal stabilities of the remaining mutants using differential 
scanning fluorimetry (DSF). DSF is a rapid technique for the assessment of protein 
stability. It monitors thermal unfolding of proteins in the presence of a dye that 
fluoresces in non-polar environments, such as the hydrophobic sites on unfolded 
proteins (Niesen et al., 2007). It is superior to other thermal scanning methods such as 
DSC in being relatively high-throughput and requiring small amounts of protein. 
The melting curves for WT decorin and mutants indicate that they unfold within a 
narrow temperature range of 49 – 51 °C (Figure 3.16). The monomeric mutants (Q61N 
and Y130N) were slightly more stable than the wild-type protein. 
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Figure 3.16 Thermal denaturation studies of WT and monomeric decorin by DSF. 
Differential scanning fluorimetry denaturation curves are shown for WT and mutant decorin as 
a function of temperature. Proteins were at a concentration of 0.181 mg/ml in PBS. The melting 
temperatures derived from the inflection points of the curves are: 49 °C for R151E, 50 °C for 
WT, Y51A/R52A/Q54A, and 51 °C for the Q61N and Y130 mutants. Shown is a representative of 
two independent experiments performed in triplicate.  
 
 
3.8 Collagen binding by WT and mutant decorin 
3.8.1 Collagen - decorin binding assays 
The ability of WT and mutant decorin to bind collagen was tested in a solid phase 
binding assay previously described by Tenni et al. (2002). Immobilised collagen I was 
incubated with serial dilutions of biotinylated mouse decorin proteins. Bound decorin 
was detected with avidin coupled to peroxidase from horseradish. As a positive control, 
I tested the interaction of biotinylated Drosophila SPARC with collagen I, which showed 
saturable binding (Figure 3.17A). Wild-type decorin and the monomeric Q61N and 
Y130N mutants bound collagen in a very similar concentration-dependent manner, 
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indicating that the mutations might not have an effect on collagen binding (Figure 
3.17B). There was, however, significant binding of decorin to plates not coated with 
collagen (Figure 3.17B, open circle) despite the presence of high concentrations of 
casein in the blocking and incubation buffers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Binding of dSPARC, WT and monomeric decorin to collagen I. A. Collagen 
binding by dSPARC FS-EC His-myc as a positive control. B. Collagen binding by WT and mutant 
decorin (Q61N and Y130N). Collagen I was immobilised onto plastic and increasing amounts of 
biotinylated decorin added. The binding was detected using avidin peroxidise from horseradish. 
Data shown are representative of multiple independent experiments. Data were fitted by a 
single-site saturation model with a linearly increasing nonspecific background. 
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Since the additional glycan modifications at positions 61 and 130 did not inhibit 
collagen binding, we inferred that the engineered single mutations were not enough to 
affect binding of decorin to collagen. However, we were still keen to know which 
residues in the decorin dimer interface partake in its interaction with collagen. Based on 
the bovine decorin crystal structure, we selected amino acid residues located on the 
concave face and produced five mutants built onto the Q61N mutant that we expected 
to have an effect on collagen binding (Figure 3.18):  
1) Q61N/K111S: a mutation which introduces another consensus site for N-linked 
glycosylation with a glycosylation potential of 0.59  
2) Q61N/R267A/E268A: a double alanine substitution that removes two side chains 
that are involved in the interface  
3) Q61N/D204R: a charge reversal mutation in LRR7 - the Asp residue has been 
previously shown to be important in collagen binding (Kalamajski et al., 2007) 
4) Q61N/G246N: a mutation which introduces another consensus site for N-linked 
glycosylation with a glycosylation potential of 0.54  
5) Q61N/G246R: a Gly to Arg substitution to introduce a charged residue to plug a ‘hole’ 
in the interface. 
We hoped that at least one of these mutants would have a profound impact on collagen 
binding so we identity the collagen binding site in decorin.  
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Figure 3.18 Surface representation of bovine decorin crystal with location of mutations 
highlighted. Orange indicates conserved region based on the sequence conservation of decorin 
from various organisms (cow, mouse, human, rabbit, pig, dog, horse, chick, zebrafish and 
xenopus). The region that is not conserved is in grey. The location of the Q61N mutation is 
shown in magenta. The five independent mutations built onto the Q61N mutant are coloured 
green. The residue numbers correspond to those in mouse decorin. Two out of three naturally 
occurring N-glycosylation sites are shown in red. 
 
All five mutants were highly expressed from episomally transfected HEK293 cells and 
purified to homogeneity by nickel affinity chromatography from serum-free medium, 
followed by SEC. The purified samples were analysed by SDS-PAGE (Figure 3.19).  
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Figure 3.19 Reducing SDS-PAGE analysis of WT decorin and monomeric decorin mutants 
(Coomassie Blue stain). The mutants have higher electrophoretic mobility according to their 
glycosylation status. The glycosylated mutant Q61N runs at higher molecular mass compared to 
the WT protein. Q61N/K111S and Q61N/G246N have additional glycosylation sites introduced 
and hence appear slightly bigger than Q61N mutant. The positions of selected molecular weight 
markers are indicated on the left. 
 
We tested the interaction of these mutants (Q61N/K111S, Q61N/R267A/E268A, 
Q61N/D204R, Q61N/G246N and Q61N/G246R) with collagen I using a solid phase 
assay with biotinylated decorin proteins (Figure 3.20). Surprisingly, all five monomeric 
mutants bound collagen in a similar manner. However, the unacceptably high levels of 
non-specific binding despite using high concentrations of casein (1%) in the blocking 
and incubation buffers, made us suspicious of the validity of the results of this assay.  
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Figure 3.20 Collagen binding by WT decorin and monomeric mutants. Solid-phase binding 
assay was carried out with increasing amounts of biotinylated WT decorin and four double 
mutants (K111S, D204R, G246N, G246R) on immobilised rat tail collagen I. Data shown are 
representative of at least three independent experiments. 
 
Minimal biotinylation using only 2-fold molar excess biotin was tried to reduce the 
amount of non-specific binding but this did not show saturable binding (Figure 3.21). 
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Figure 3.21 Collagen binding by Q61N and other monomeric mutants. Solid-phase binding 
assay was carried out with increasing amounts of minimally biotinylated Q61N and five double 
mutants (Q61N/K111S, Q61N/R267A/E268A, Q61N/D204R, Q61N/G246N, Q61N/G246R) 
added to immobilised rat tail collagen I.  
 
3.8.2 Collagen - decorin competition assay 
My results so far showed that the engineered glycans (Q61N and Y130N) and also the 
double mutations failed to obstruct collagen binding in a solid phase assay using 
biotinylated decorin proteins. However, I was wary of the high levels of non-specific 
binding and decided to check the validity of my biotin-avidin assay. The specificity of 
decorin - collagen I interaction was tested in a competition binding assay, in which 
increasing concentrations of non-biotinylated WT decorin (up to 20 µM) compete with 
biotinylated WT decorin (1 µM) for binding to collagen. This experiment suggests that at 
least ~50% of the binding of biotinylated decorin was non-specific as it could not be 
effectively competed with 20-fold excess of unlabelled decorin (Figure 3.22). 
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Figure 3.22 Decorin - collagen I competitive binding assay. Solid-phase binding assay with 
recombinant biotinylated decorin and increasing concentrations of non-biotinylated decorin, 
added for three hours at room temperature to 96 wells coated with collagen at 25 μg/ml. The 
addition of a 20-fold excess of non-biotinylated wild-type decorin only partially inhibits the 
interaction between biotinylated wild-type decorin and collagen I.   
 
Since I could not be confident about the results of my biotin-avidin solid phase assay, I 
decided to measure decorin binding using an anti-mouse decorin primary antibody. 
By carrying out a titration experiment with various dilutions of the antibodies, I 
established that the optimum antibody concentrations for use in my solid phase assay 
i.e. the concentration(s) which give the best colorimetric reading with minimum 
background, were those quoted by the manufacturers (data not shown).  
I also confirmed that the mutations are not within the epitopes of the anti-decorin 
antibody (Figure 3.23).   The primary antibody exhibits equal or better binding to all 
decorin proteins, except Q61N/K111S and Q61N/D204R.  
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Figure 3.23 Anti-mouse decorin antibody binding to WT and mutant mouse decorin.  
Solid-phase binding assay was carried out with 96-well plates coated with decorin proteins. 
Data are expressed as the average of duplicate data points.  
 
I proceeded to carry out solid phase assays with WT, Q61N, Y130N and R151E mutants. 
WT decorin showed dose-dependent, saturable binding to collagen with an apparent 
dissociation constant of K0.5 = 0.31 ± 0.14 μM (Figure 3.24). The K0.5 value represents 
the mean ± SEM from three independent experiments. This is consistent with previous 
observations by Kalamajski et al. (2007) and Tenni et al. (2002). In contrast to the wild-
type protein, the Q61N, Y130N and R151E mutants showed greatly reduced binding 
affinities but were not completely inactive.  These results show that the concave face of 
decorin is involved in collagen binding. 
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Figure 3.24 Binding of WT and mutant mouse decorin to immobilised collagen.  Solid-
phase binding assay was carried out with increasing amounts of WT or mutant decorin added to 
96-well plates coated with rat tail collagen I. Bound decorin was detected by anti-mouse decorin 
antibody followed by HRP-conjugated rabbit anti-goat IgG antibody, and measured as 
absorbance at 492 nm. Shown is a representative of three independent experiments, each 
performed in duplicate. The curves were generated by non-linear least squares fitting of the 
data by an equation describing single-site binding with linear background. 
 
However, the strong binding seen in this set of experiments did not prove to be very 
reproducible when repeated with a different batch of proteins, regardless of the amount 
of blocking agent used (up to 10 mg/ml casein) and/or the use of different antibodies 
(anti-mouse decorin antibody, anti-His-tag antibody). The data obtained using anti-His-
tag antibody for detection are shown in Figure 3.25. I also included the 
Y51A/R52A/Q54A mutant in this assay.  
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Figure 3.25 Collagen binding by WT and mutant mouse decorin.  Solid-phase binding assay 
was carried out with increasing amounts of WT or mutant decorin added to 96-well plates 
coated with rat tail collagen I. Bound decorin was detected by anti-His-tag HRP-conjugated 
antibody and measured as absorbance at 492 nm. Shown is a representative of three 
independent experiments, each performed in duplicate. The curves were generated by non-
linear least squares fitting of the data by an equation describing single-site binding with linear 
background. 
 
Even though I am not confident about reporting K0.5 values for these interactions as they 
varied from experiment to experiment, I consistently observe stronger collagen binding 
by wild-type decorin and the Y51A/R52A/Q54A mutant than any of the single point 
mutants (Figure 3.25).  
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3.8.3 Collagen fibrillogenesis assay 
 
Since the results of the solid phase assays were not very robust, I decided to carry out a 
collagen fibrillogenesis assay which is the classic assay for testing decorin function.   
 
Wild-type decorin retarded fibrillogenesis of type I collagen as has been reported 
previously (Douglas et al., 2006, Zhang et al., 2009, Raspanti et al., 2007, Kalamajski et 
al., 2007). The Y51A/R52A/Q54A mutant delayed fibrillogenesis similar to the WT 
protein. The mutants Q61N, Y130N and R151E did not. This assay was repeated six 
times using different batches of collagen with similar results (Figure 3.26). These 
findings indicate that mutations in the decorin dimer interface interfere with collagen 
binding. 
 
 
 
 
Figure 3.26 Effect of decorin on collagen fibrillogenesis. Mouse type I collagen (32 μg/ml) 
was incubated at 37 °C and pH 7.8. Fibril formation was monitored by turbidity readings at 400 
nm at 0.5 minute intervals. WT and mutant mouse decorin proteins were added at a 
concentration of 50 μg/ml. A and B show representative experiments using two different 
batches of collagen. For each data set, data shown are representative of three independent 
experiments  
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Thus the combined results of the solid phase and fibrillogenesis assays indicate that the 
concave face of decorin (residues 61, 130 and 151 in particular) is involved in collagen 
binding. 
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Chapter 4: Discussion  
Analysis of decorin dimerisation 
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4. Discussion 
 
SLRPs such as decorin and biglycan are known to bind various types of collagens, 
thereby regulating the assembly of fibrils in skin, tendons, and cornea (Kalamajski and 
Oldberg, 2010, Chen and Birk, 2013). The biological significance of these interactions in 
vivo can be deduced from the phenotype of decorin-deficient mice. Mice lacking decorin 
are characterised by fragile skin, and their collagen fibrils have irregular diameters due 
to uncontrolled lateral fusion of fibrils (Danielson et al., 1997). Molecular modelling 
studies of the interactions between decorin core protein and type I collagen fibrils have 
suggested that the concave face of decorin may bind to one or more triple helices 
(Weber et al., 1996, Orgel et al., 2009). Consistent with this notion, the concave face is 
the most conserved region (Scott et al., 2004). However, the crystal structures of 
decorin and biglycan revealed that the concave face is involved in forming a tight dimer, 
making it potentially unavailable for ligand binding (Scott et al., 2004, Scott et al., 2006). 
Hence, there has been controversy about the oligomeric status of decorin (Goldoni et al., 
2004) and how it binds collagen was unclear. In this thesis, I have attempted to resolve 
this controversy by defining the oligomeric state of decorin and studying its interactions 
with collagen. 
The key findings from my thesis are: 
1) Wild-type decorin exists in a monomer-dimer equilibrium with a dimer dissociation 
constant of 1.37 ± 0.30 µM. 
2) Engineering glycosylation sites into the dimer interface abolished dimerisation; other 
interface mutants remained dimeric. 
3) Both wild-type and mutant decorin are equally stable in thermal denaturation 
studies. 
4) Mutants in the dimer interface abolished collagen binding, regardless of the 
oligomeric status of the mutants. 
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Goldoni et al. (2004) provided some lines of evidence to suggest that decorin is 
monomeric in solution and that the oligomerisation of decorin observed by Scott et al. 
(2004) is a result of extensive dialysis of the samples against water followed by freeze-
drying, leading to non-specific association. However, each of the techniques used by 
Goldoni et al. to determine the oligomeric state of decorin had their disadvantages. 
Unlike Scott et al. (2004), they used recombinant decorin under non-denaturing 
conditions. Conventional SEC was used to show that decorin behaved as a monomer 
since it nearly coelutes with BSA (MW ~ 66 kDa). But SEC is not as suitable as SEC-
MALS in determining molecular masses due to reasons discussed in chapter 3. Chemical 
crosslinking was used to show that very high concentrations of cross-linking agents are 
required for preferential dimer formation in decorin, compared with other dimeric 
proteins such as the EGFR. But crosslinking depends more on the availability of lysine 
residues than the concentration of cross-linking agents, and only two of the fifty-four 
lysines available on decorin are close enough to be crosslinked for dimer formation 
(Scott et al., 2006).  The third line of evidence was from mass-spectrometry (MALDI-MS) 
data which gave a mass of ~ 44 kDa for the decorin core protein, but this technique is 
performed in vacuo, not in solution. In addition, Goldoni et al. did not provide any 
indication of the stability of their decorin preparation. Hence, the controversy still 
prevailed and a comprehensive study using robust biophysical techniques to determine 
the oligomeric status of decorin was missing.  
I attempted to analyse the role of the concave face of decorin by mutating solvent-
exposed residues in the LRRs. Since the LRR fold is very resilient to non-conservative 
replacements of residues (Howitt et al., 2004), dramatic amino acid substitutions were 
chosen, including the introduction of two new glycosylation sites. Wild-type decorin and 
interface mutants were expressed in mammalian cells to ensure appropriate post-
translational modifications. Previous studies have reported that removal of N-linked 
oligosaccharides leads to aggregation and reduced solubility of decorin core protein 
(Scott and Dodd, 1990). All proteins were highly expressed and soluble, indicating 
correct folding. The yield of Y51A/R52A/Q54A was relatively poor compared to WT and 
other mutants and this could be due to the triple mutation being more dramatic 
compared with point mutations.  
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The oligomeric states of WT and mutant decorin at 3 mg/ml (83 µM) were determined 
using SEC-MALS, which allows continuous monitoring of light scattering and refractive 
index as the samples elute from a gel filtration column. These experiments suggested 
that WT decorin exists in a monomer-dimer equilibrium. The elution profiles of 
Y51A/R52A/Q54A and R151E mutants, and the negative control mutants located 
outside the interface, E156K and K159E, all resembled that of WT decorin i.e. they were 
dimeric. However, the mutants with engineered glycosylation sites are purely 
monomeric (MW~ 36.2 kDa), even at such high concentrations, indicating that the 
decorin dimer had been disrupted.  
I investigated the monomer-dimer equilibrium quantitatively using analytical 
ultracentrifugation and determined a dimer dissociation constant of 1.37 ± 0.30 µM for 
WT decorin. This is similar to the dimer dissociation constant of 4.5 µM obtained for 
biglycan (calculated from a free energy of association of -7.3 kcal/mol), which has been 
shown to dimerise reversibly in solution (Liu et al., 1994). Two distinct peaks in the c(s) 
distribution (corresponding to monomers and dimers) can be seen in sedimentation 
velocity studies, indicating that the rate of interconversion of species is slow on the 
time-scale of sedimentation. This is in contrast to the SEC-MALS experiment where a 
dimeric peak with a pronounced tail and a slightly lower than expected molecular mass 
is observed, suggesting a more rapidly equilibrating system. The two results are not 
necessarily inconsistent and are likely due to differences in the two methods. In SEC, the 
resolution of the technique may not be high enough for the two peaks to be separated 
chromatographically. In AUC, the dimer sediments faster than the monomer and is 
therefore, always in the presence of the monomer. The longer running time of this 
technique (~15 hours) means that both monomers and dimers sediment, giving rise to 
two peaks in the c(s) distribution.  
Sedimentation velocity studies on the dimeric R151E and Y51A/R52A/Q54A mutants 
yielded dimer dissociation constants similar to that of WT decorin.  Thus, at high 
concentrations typically used in solution scattering (Scott et al., 2006, Scott et al., 2003) 
and crystallisation experiments (Scott et al., 2004, Scott et al., 2006), decorin and 
biglycan are dimeric. At likely physiological concentrations, dimers will dissociate into 
monomers. 
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All forces that stabilise the native structures of proteins are sensitive to changes in 
temperature. Hence, the susceptibility of proteins to thermal denaturation is an 
indicator of their stabilities (Sola and Griebenow, 2009). The stabilities of WT and 
mutant decorin were assessed by DSC and DSF. All mutants showed similar 
denaturation profiles and unfolded within a narrow temperature range of 49 – 51 °C. 
Thus, the mutations did not have an adverse effect on the structure and stability of the 
decorin core. Engineered monomeric mouse decorin was found to be marginally more 
stable than wild-type decorin. This is not unexpected since the stabilising effect of 
glycans is well-known and glycoengineering is regularly used by the pharmaceutical 
industry to improve the stability of protein pharmaceuticals (Sola and Griebenow, 
2009). Stability can be increased in two different ways: a) lowering the energy level of 
the native folded state, and b) increasing the energy level of the unfolded state. 
Experiments by Kwon et al. to study the effects of glycosylation on the unfolding and 
refolding rates of human alpha 1-antitrypsin showed that glycosylation slows down the 
unfolding process without affecting the refolding rates significantly (Kwon and Yu, 
1997). It was proposed that the increase in thermodynamic stability caused by 
glycosylation could be due to stabilisation of the native state and not due to 
destabilisation of the unfolded state (Sola and Griebenow, 2009). Each glycan unit 
attached to the protein surface provides ~ 1-2 kcal/mol of thermodynamic stabilisation 
(Sola et al., 2007).  Conversely, another study using Kazal-type serine protease 
inhibitors hypothesised that carbohydrates sterically restrict peptide backbone 
mobility, thus destabilising the unfolded state by reducing the entropy of unfolding 
(DeKoster and Robertson, 1997). Our results contradict the conclusion of Scott et al. 
that monomeric decorin cannot be stable in solution (Scott et al., 2003). Unfolding 
experiments with decorin and biglycan revealed transitions from folded (dimer) to 
unfolded (monomer) (Scott et al., 2003, Scott et al., 2006). This has been taken as 
evidence that dimerisation is required for stabilisation of decorin and biglycan, but I 
have managed to obtain monomeric decorin by engineering glycosylation sites into the 
dimer interface (Q61N and Y130N). Scott et al. also showed that the denaturation of 
decorin was completely reversible, in contrast to our findings and those of Krishnan et 
al. (1999). Scott et al. attributed this to the lack of disulphides due to the vaccinia 
virus/T7 bacteriophage expression system used by Krishnan et al. (1999).  I have used a 
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mammalian expression system to produce recombinant decorin, so it is unlikely that the 
inability of decorin to refold following heat denaturation is due to the absence of 
disulphides.  
LRR proteins such as internalinA (Schubert et al., 2002), the Nogo receptor (He et al., 
2003) and domain 3 of Slit (Howitt et al., 2004) exist as stable monomers. In contrast, 
many crystal structures of LRR proteins reveal putative dimerisation interfaces. 
Proteins such as AMIGO-1 (Kajander et al., 2011) and LRR domain 4 of Slit2 (Seiradake 
et al., 2009) dimerise similarly to decorin and do not dissociate into monomers. 
Mutations in the dimer interface of AMIGO-1 affect folding and stability (Kajander et al., 
2011). Some LRR proteins such as the ectodomain of the human Toll-like receptor 3 
have glycosylation sites on both the convex and concave faces and one of the two major 
side faces, leaving only one of the side faces for ligand binding or formation of 
homodimer (Choe et al., 2005). The TLR3 ectodomain is monomeric in solution but the 
full-length transmembrane protein may be able to form stable or transient dimers. 
However, for most of the crystallographic dimers of LRR proteins elucidated so far, 
there is no biophysical and/or functional evidence to suggest that these dimers are 
stable in solution and not a consequence of associations formed in the crystal lattice 
(Bella et al., 2008). In addition, the functional relevance of oligomerisation is not clear. 
For example, the crystal structure of Yersinia pestis cytotoxin, YopM, an LRR protein, 
revealed a tetramer wherein the four monomers bury a large amount of the 
hydrophobic surfaces. However, SEC-MALS shows that the protein is monomeric, with 
or without the presence of calcium and cross-linking studies show oligomerisation only 
in the presence of calcium. In addition, the biological significance of oligomerisation is 
unclear, hence it is assumed that tetramerisation is an artefact resulting from the high 
concentration of calcium in crystallisation solutions (Evdokimov et al., 2001). Thus, in 
the absence of further evidence, it should be assumed that at physiological 
concentrations, the quaternary structures of these proteins are predominantly 
monomeric.  
The total buried surface area between LRR-domain dimer interfaces or between LRR 
domains and their ligands, are often taken as indicators of affinity of interactions i.e. in 
principle, large buried surfaces suggest tight complexes. For LRR – ligand complexes, 
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the total buried surfaces are typically in the 2500-3400 Å2 range (i.e. the size of the 
interface is half of this value) (Bella et al., 2008). For ribonuclease inhibitor bound to 
one of its ligands, angiogenin, such high contact surfaces (2680 Å2) are associated with 
equilibrium dissociation constants in the femtomolar range (Papageorgiou et al., 1997). 
For the decorin crystallographic dimer, a similar contact area of 2300 Å2 has been used 
to explain the observed tight interaction between the two monomers (Scott et al., 2004). 
The crystal structure revealed a banana-shaped molecule that maximise the surface 
area, unlike the more rounded, horseshoe-shaped ribonuclease inhibitor. However, 
there are instances when the total buried surface does not relate to the binding affinity. 
Interaction between internalinA and its ligand, human E-cadherin1 domain, buries a 
total area of 2400 Å2 but the affinity of the interaction is remarkably weak, in the 
micromolar range (~ 50 µM) (Schubert et al., 2002).  Thus, the total contact area alone 
is not a reliable indicator of the strength of interactions between the LRR domain and its 
ligands, and specific interactions need to be taken into account, together with other 
evidence from biophysical studies. In the case of decorin, molecular interactions at the 
decorin dimer interface are made up of a few hydrophobic and aromatic residues which 
are sandwiched, and hydrogen bonds or salt bridges. The latter are intrinsically weak in 
an aqueous environment as polar/charged residues buried in the interface form weak 
hydrogen bonds with protein atoms, rather than strong hydrogen bonding to the 
solvent (Xu et al., 1997). The geometries of polar and charged residues are also 
important in determining their quality since owing to constraints imposed by bond 
lengths and bond angles, the geometries of hydrogen bonds are unlikely to be optimised 
across protein interfaces (Xu et al., 1997). I determined the shape complementarity 
between the two decorin monomers using a shape correlation statistic, Sc, which 
depends both on the relative shapes of the surfaces with respect to each other and on 
the extent to which the interaction brings individual elements of the opposing surfaces 
into proximity (Lawrence and Colman, 1993). Interfaces with perfect fits have an Sc 
value of one, whereas uncorrelated interfaces have Sc values nearing zero. An Sc value of 
0.73 was obtained for the decorin dimer which falls within the typical range of 0.70 to 
0.76 found for oligomeric proteins, indicating good shape complementarity. This value 
is a measure of the ‘global’ shape correlation but does not account for areas such as 
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solvent-filled pockets seen in the concave face of decorin, which have poorer shape 
correlation.  
To summarise, here, I have provided compelling biophysical evidence that in the case 
with decorin, dimerisation is weak and reversible.  
The decorin protein core binds collagen while the GAGs extend outward into the inter-
fibril space. In vitro fibrillogenesis assays and solid phase assays indicate the 
involvement of the core protein in collagen binding, independent of the GAG chains 
(Rada et al., 1993, Kalamajski et al., 2007, Vogel et al., 1987). The GAG chain on decorin 
has no detectable effect of decorin structure and conformational stability when 
examined by circular dichroism spectroscopy (Krishnan et al., 1999).  GAGs bound to 
decorin act like bridges and transfer forces between contiguous collagen ﬁbrils, thus 
providing mechanical integrity to tissues (Redaelli et al., 2003). The concave face of 
decorin, LRR6 and LRR7 in particular, has been implicated in collagen binding 
(Kalamajski et al., 2007, Kresse et al., 1997). The convex face of decorin is made of 
residues with a higher degree of evolutionary sequence variability than the concave 
face. In addition, the presence of endogenous N-oligosaccharides on one of the side faces 
of the dimer indicates that this side is not involved in decorin-collagen interactions. 
McEwan et al. have suggested hypothetical ligand-binding scenarios for dimeric decorin 
including a) dimeric decorin binding collagen with a 2:2 stoichiometry, and b) the dimer 
dissociating to interact with collagen as monomers (McEwan et al., 2006).  
In order to characterise decorin binding to collagen type I, I carried out solid phase 
binding assays with immobilised collagen I. This technique proved to be less robust 
than expected due to high levels of non-specific binding and issues with reproducibility 
using different batches of proteins. Solid phase decorin-collagen binding data in the 
literature also show weak and noisy signals and high levels of non-specific binding 
(Kalamajski et al., 2007, Kresse et al., 1997). Tenni et al. (2002) have performed solid 
phase assays to test the interaction of biotinylated decorin with methylated type I 
collagen peptide fragments but I have not been able to reproduce this using biotinylated 
decorin and immobilised rat tail collagen I. The problem is likely to be in the nature of 
decorin rather than the assay format itself since I encountered no such issues when 
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performing the same assay with other proteins such as SPARC (chapter 4 of this thesis). 
Even though I am not confident in quoting K0.5 values for the interactions, the behaviour 
of the mutants was consistent i.e. WT decorin and Y51A/R52A/Q54A mutant bind 
collagen more strongly than any of the dimer-interface single mutants (Q61N, Y130N 
and R151E). The minimal binding observed with the single mutants is likely to be non-
specific.  
The collagen fibrillogenesis assay, on the other hand, is very robust and was 
reproducible with different batches of decorin and collagen. Collagen incubated at 37 °C 
in buffers with a neutral pH assembles into insoluble fibrils; the kinetics of this process 
can be monitored by turbidimetry (Vogel et al., 1984). Collagen fibrillogenesis is a multi-
step process which begins with the assembly of collagen to form fibril intermediates. 
These immature preformed intermediates undergo linear and lateral growth to form 
mature fibrils.  Genetic studies of fibrillogenesis in the cornea of decorin- and biglycan- 
deficient mice have shown that these SLRPs, positioned on fibrils in an orthogonal 
array, do not affect the initial formation of fibril intermediates but regulate linear 
growth and lateral association (Zhang et al., 2009).  
Several studies have used turbidity assays to examine the effects of decorin on collagen 
ﬁbrillogenesis (Vogel et al., 1984, Uldbjerg and Danielsen, 1988, Kalamajski et al., 2007). 
The lag phase of the turbidity curve is mainly characterised by longitudinal growth; the 
collagen appears as thin filaments. The increase in turbidity is due to lateral association 
of these fibrils (Hedbom and Heinegard, 1989). Mutations in the dimer interface 
abolished the ability of decorin to inhibit fibrillogenesis by hindering lateral growth of 
fibrils. In contrast, a triple mutant (Y51A/R52A/Q54A), with mutations in the N-
terminal cap region, significantly inhibited fibrillogenesis although not as efficiently as 
WT decorin. Previous studies have reported the importance of LRR6 (Kresse et al., 
1997) and LRR7 (Kalamajski et al., 2007) in collagen binding. Hence, a large part of the 
concave face of decorin seems to be involved in collagen binding. This view is supported 
by molecular modelling studies using the experimentally derived structure of fibrillar 
type I collagen (Orgel et al., 2006, Perumal et al., 2008) which shows that monomeric 
decorin shows the most appropriate shape complementarity with collagen and can 
interact with up to six triple helices on the fibril surface (Orgel et al., 2009). Rather than 
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any small collection of amino acid interactions being specifically responsible for the 
decorin-collagen association, there seems to be an array of potential hydrogen bonds 
and electrostatic interactions (Orgel et al., 2009). 
Another interpretation of my findings would be that collagen binding requires an intact 
decorin dimer and that the monomeric mutants, Q61N and Y130N, are inactive due to 
disruption of the dimer. In that case, the dimeric R151E mutant should have been active 
as well but this is not the case. At the concentrations used in the fibrillogenesis assay, 
WT and R151E mutant are 50% and 34% monomer respectively, calculated from their 
dissociation constants determined by AUC. Such a small difference cannot explain the 
complete loss of binding by the R151E mutant. Hence, our model that the concave face 
of decorin mediates collagen binding by dissociation of dimer to monomers, still stands. 
To summarise, I have shown that decorin dimerisation is reversible and that the 
concave face of decorin is alternately involved in dimerisation and collagen binding 
(Table 4.1). 
 
Table 4.1 Summary of results obtained with mouse decorin and its mutants. 
Protein 
Location of 
mutated 
residue(s) 
Oligomeric statea 
Collagen 
bindingb 
WT 
 
Monomer-dimer 
equilibrium 
Yes 
Y51A/R52A/Q54
A 
N-terminal cap 
Monomer-dimer 
equilibrium 
Yes 
Q61N LRR1 Monomer No 
Y130N LRR4 Monomer No 
R151E 
LRR5 
Monomer-dimer 
equilibrium 
No 
aDetermined by SEC-MALS and AUC 
bDetermined by collagen fibrillogenesis and solid-phase binding assays 
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Future work 
The work outlined in this thesis has made significant progress in resolving the 
controversy about the oligomeric status of decorin and how this affects collagen 
binding. Identification of a stable monomeric mutant that retains the ability to bind 
collagen would be definitive proof of our model but this may be difficult to obtain since 
the dimer interface is the same region that is involved in collagen binding. It would be 
useful to identify collagen peptides that bind decorin since these can be used to carry 
out solution scattering and/or co-crystallisation experiments to show that the decorin 
monomer mediates collagen binding. Residues in the core region of decorin and other 
class I SLRPs such as biglycan and asporin have high sequence identity so it would be 
interesting to study how these proteins interact with collagen as well.  
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Chapter 5: Results  
Structural and functional studies of 
invertebrate SPARC binding to 
collagen 
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5. Results 
The crystal structure of human SPARC (hSPARC) bound to a collagen-like triple-helical 
peptide was determined in the Hohenester lab (Hohenester et al., 2008). The key 
collagen binding residues are conserved between human and invertebrate SPARC 
(Drosophila and C. elegans). However, collagen binds to hSPARC following proteolytic 
cleavage of an inhibitory loop that is not present in invertebrate SPARC (Sasaki et al., 
1997). The aim of this study was to determine the crystal structures of dSPARC and 
cSPARC. This involved enzymatic deglycosylation or mutagenesis of the constructs to 
aid crystallisation. A further aim was to investigate the role of the inhibitory loop on 
collagen binding by studying binding interactions between human and invertebrate 
SPARC and collagen I and IV, using solid phase assays and surface plasmon resonance.  
 
5.1 Purification of SPARC proteins 
5.1.1 Purification of SPARC His.myc tagged constructs 
SPARC FS-EC and EC constructs, containing N-terminal His-myc tags, were produced in 
episomally transfected HEK293 cells. These constructs were generated for use in 
biochemical assays such as ELISA and BIAcore. All 6 constructs (from hSPARC, dSPARC, 
cSPARC) were purified to homogeneity by nickel affinity chromatography from serum-
free medium, followed by dialysis against appropriate Ca2+- containing buffer. The 
yields for SPARC His-myc proteins from 1.5 L of medium are tabulated in Table 5.1. The 
purified samples were analysed by SDS-PAGE (Figure 5.1). Due to the presence of N-
linked glycosylation sites in SPARC (Table 5.1), the purified proteins migrate as diffuse 
bands at higher molecular mass on SDS-PAGE (Figure 5.1).  
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Table 5.1 Molecular masses of SPARC proteins, number of N-linked glycosylation sites and 
yields from 1.5 L of serum-free medium 
Protein(s) Residues 
Calculated 
molecular 
mass  (kDa) 
N-linked 
glycosylation sites 
Yield per 1.5 L of 
serum-free 
medium (mg) 
dSPARC FS-EC NHis-
myc 
83 - 304 31.3 2 19.5 
dSPARC EC NHis-myc 169 - 304 21.6 1 15.8 
hSPARC FS-EC NHis-
myc 
70 - 303 32.7 2 18.4 
hSPARC EC NHis-myc 153 - 303 23.4 1 13.3 
cSPARC FS-EC NHis-
myc 
52 - 264 30.1 2 10.9 
cSPARC EC NHis-myc 139 - 264 20.3 1 9.4 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Purification of SPARC proteins. A. SDS-PAGE analysis of purified dSPARC & 
hSPARC NHis-myc tagged constructs EC. B. SDS-PAGE analysis of cSPARC NHis-myc tagged 
constructs. Protein samples were dialysed against 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM 
CaCl2. The positions of selected molecular mass markers are shown on the left. 
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5.2 Expression and Purification of PNGase F-MBP 
Peptide-N-glycosidase F (PNGase F) is an enzyme that cleaves between the innermost 
GlcNAc and asparagine residues of N-linked glycan modifications. Purified active 
PNGase F-MBP protein was required in order to deglycosylate SPARC constructs for 
crystallisation trials. The PNGase F-MBP protein was expressed in E. coli BL21 cells. 
Purification was performed by affinity chromatography on an amylose resin column and 
the purified protein was eluted in 10 mM maltose, 20 mM Tris-HCl pH 7.5, 200 mM 
NaCl, 1 mM EDTA (Figure 5.2) and gel filtered in 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 5 
mM Na2EDTA. A 1 L culture yielded 13 mg of protein.  
 
 
Figure 5.2 SDS-PAGE analysis of PNGaseF-MBP IMAC purification. SDS PAGE analysis 
shows: Son, whole cell lysate after sonication; SnP, supernatant after centrifugation with 
protamine sulphate; new, purified PNGase F-MBP eluted in 10 mM maltose, 20 mM Tris-HCl pH 
7.5, 200 mM NaCl, 1 mM EDTA; old,  PNGase F-MBP sample from previous stock. The band at 80 
kDa corresponds to the intact fusion enzyme. The lower band(s) most likely corresponds to a 
cleaved product containing the MBP tag. The positions of selected molecular mass markers are 
shown on the right.  
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5.3 Purification of SPARC His tagged constructs and crystallisation 
trials 
5.3.1 Purification of dSPARC EC constructs for crystallisation trials 
A dSPARC EC domain construct containing an N-terminal His-tag was produced in 
episomally transfected HEK293 cells and purified by nickel affinity chromatography 
from serum-free medium.  
The EC NHis construct was deglycosylated using PNGase F. Figure 4.3A shows the SDS-
PAGE gel of the deglycosylated form along with the undigested protein. The 
deglycosylated protein band migrated at its predicted molecular mass of ~19 kDa. SEC 
was carried out in order to further purify the samples for crystallisation trials. The SEC 
elution profile for SPARC EC NHis is shown in Figure 5.3B. A small shoulder in the 
eluted peak (at 14.9 ml) suggests that the protein can form higher oligomers in solution. 
When analysed by SDS-PAGE all the fractions have the same band pattern suggesting 
that the association may be non-covalent (data not shown). The protein was 
concentrated to 10.3 mg/ml and 17.8 mg/ml and crystallisation screens were set up and 
kept at 21°C.  These trials failed to yield crystals (Table 5.2).  
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Figure 5.3 Deglycosylation of dSPARC EC NHis and its purification by SEC. A. Reducing SDS-
PAGE analysis showing removal of N-linked glycans from SPARC EC-NHis. The band 
corresponding to a possible SPARC EC-NHis dimer disappears upon prolonged boiling of the 
protein sample. The positions of selected molecular mass markers are shown on the left.  B. The 
elution profile of purified SPARC EC-NHis on a Superdex S200 column is shown. Protein samples 
were eluted in 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2. The arrows show the peak 
elution volumes of molecular mass standards in kDa. 
 
5.3.2 Purification of dSPARC FS-EC constructs for crystallisation trials 
A dSPARC construct containing the FS-EC domain with an N-terminal His tag was 
produced in episomally transfected HEK293 cells and purified by nickel affinity 
chromatography from serum-free medium. The yield from 1.5 L of cell culture medium 
was 32.4 mg of protein. 
 
5.3.2.1 Analytical deglycosylation of dSPARC FS-EC NHis 
Enzymatic methods of deglycosylation are required to remove heterogeneity in 
glycoproteins for subsequent structural analysis. A small-scale deglycosylation 
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experiment was carried out using PNGaseF-MBP to test out various conditions to find 
the gentlest method of removing N-linked glycans, without denaturing the protein.  A 
1:25 enzyme : substrate ratio seems to partially deglycosylate the sample, producing an 
intermediate product in addition to the deglycosylated protein (Figure 5.4). Using 1:5 
enzyme : protein molar ratio resulted in a high level of deglycosylation. Since the 
reactions seem to be independent of incubation temperature, subsequent large-scale 
deglycosylation experiments were performed overnight at room temperature using a 
1:5 enzyme : protein molar ratio.  
 
 
Figure 5.4 SDS-PAGE analysis showing degree of deglycosylation of N-linked glycans from 
dSPARC FS-EC NHis. The deglycosylation efficiency was determined by having two different 
enzyme to protein molar ratios (1 : 5 and 1 : 25) at two different temperatures (4 °C and 35 °C). 
Molecular weight of dSPARC FS-EC NHis, based on amino acid composition, is 27 kDa. The 
positions of selected molecular mass markers are indicated on the left.   
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The FS-EC NHis construct was deglycosylated using PNGase F-MBP. Another round of 
affinity chromatography was performed to remove the enzyme. The protein was then 
further purified by SEC (Figure 5.5A). The elution profile shows the presence of mixed 
species in solution – presumed monomeric and dimeric.  SDS-PAGE analysis following 
deglycosylation shows that the glycans were not removed completely by PNGase F-MBP 
treatment as two bands are still present – one above 30 kDa (the deglycosylated protein 
is 29 kDa) (Figure 5.5B). The sample was concentrated to 11.4 mg/ml                                                                                                                                                                                                                                                                                                                                                                    
and crystallisation screens were set up and kept at 21 °C.  This trial failed to yield 
crystals most likely due to the presence of mixed species of different oligomeric states 
and also due to partial deglycosylation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Purification and deglycosylation of dSPARC FS-EC NHis A. The elution profile of 
purified dSPARC FS-EC NHis on a Superdex S200 column is shown. Protein samples were eluted 
in 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2. The profile shows presence of two different 
oligomeric states. The peak region below the black line corresponds to the pooled fractions in B. 
The arrows show the peak elution volumes of molecular mass standards in kDa. B. SDS-PAGE 
analysis of dSPARC FS-EC NHis deglycosylation. The gel shows that the protein has not been 
deglycosylated completely by PNGase F treatment as there are two bands present (shown by 
arrows). The positions of selected molecular mass markers are shown on the left.   
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5.3.2.2 Lectin treatment 
Since enzymatic treatment did not result in complete deglycosylation of dSPARC 
constructs, the next approach was to treat the sample with lectins, carbohydrate-
binding proteins, following PNGaseF-MBP digestion, to remove any residual 
glycosylated proteins. It was not possible to obtain fully deglycosylated protein using 
this method, as shown by the presence of two bands, one above 30 kDa (Figure 5.6).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 SDS-PAGE analysis showing degree of deglycosylation of N-linked glycans from 
dSPARC FSEC-NHis. The presence of two bands (shown by arrows), including one above 30 
kDa, indicates that treatment with lectin did not remove all glycosylated species. The positions 
of selected molecular mass markers are shown on the left.   
 
5.3.2.3 dSPARC glycosylation site mutant 
A dSPARC double mutant, with mutations in the 2 putative glycosylation sites (N126 
and N214 to Q), was generated in the hope that removing carbohydrates might facilitate 
crystallisation. The yield was ~12 mg from 2 L of cell culture medium. Crystallisation 
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trials were set up at 10.2 mg/ml and at 19.4 mg/ml and no crystals were formed under 
these conditions (Table 5.2). 
5.3.3 Purification of cSPARC proteins for crystallisation trials 
At this point, attempts were made to crystallise SPARC from an alternative invertebrate 
species, namely C. elegans, in its native state. cSPARC FS-EC (residues 52-264) and EC 
(residues 139-264) constructs, containing N-terminal His-tags, were produced in 
episomally transfected HEK293 cells.  
The yield from 2 L of cell culture medium was 3.7 mg of cSPARC EC NHis protein. Figure 
5.7A shows the SEC profile of this protein. The first peak is within the void volume of 
the column. The second peak (starred) could be a dimer. The major peak, eluting at ~12 
ml, contains monomeric SPARC EC NHis (~ 16 kDa). The two bands on SDS-PAGE 
(Figure 5.7B) correspond to different glycoforms of the protein. 
 
 
 
 
Figure 5.7 Purification of cSPARC EC NHis A. The elution profile of purified cSPARC EC NHis 
on a Superdex S75 column is shown. Protein samples were eluted in 20 mM HEPES pH 7.5, 150 
mM NaCl, 2 mM CaCl2. The profile shows presence of cSPARC EC NHis monomer and a tiny 
proportion of dimer. The peak region below the black line corresponds to the pooled fractions 
in B. The arrows show the peak elution volumes of molecular mass standards in kDa.  B. SDS-
PAGE analysis of cSPARC EC NHis purification. The lane marked with an asterisk and the 
underlined fractions refer to the corresponding SEC peak(s). The positions of selected molecular 
mass markers are shown on the left.   
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For cSPARC FS-EC NHis protein, the yield from 2 L of cell culture medium was 13.4 mg. 
Figure 5.8A shows the SEC profile. The first peak is within the void volume of the 
column. The second peak (starred) could be a dimer. The major peak, eluting at ~10.8 
ml, contains monomeric cSPARC FS-EC NHis (~ 26 kDa).  
 
 
 
 
Figure 5.8 Purification of cSPARC FS-EC NHis. A. The elution profile of purified cSPARC FS-EC 
NHis on a Superdex S75 column is shown. Protein samples were eluted in 20 mM HEPES pH 7.5, 
150 mM NaCl, 2 mM CaCl2. The profile shows presence of cSPARC FS-EC NHis monomer and a 
small proportion of dimer. The peak region below the black line corresponds to the pooled 
fractions in B. The arrows show the peak elution volumes of molecular mass standards in kDa. 
B. SDS-PAGE analysis of cSPARC FS-EC NHis purification. The lane marked with an asterisk and 
the underlined fractions refer to the corresponding SEC peak(s). The positions of known 
molecular mass markers are shown on the left. 
 
Crystallisation trials were set up with cSPARC EC NHis at 7.9 mg/ml and cSPARC FS-EC 
NHis at 18.9 mg/ml. Both proteins failed to crystallise in their fully glycosylated states 
(Table 5.2).  
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Table 5.2 Summary of crystallisation trials. Concentrated proteins were screened against 
various pre-filled 96-well plate screens. ‘x’ indicates the screen has been used to set up 
trials. A list of the composition of the crystallisation screens can be found at 
http://www3.imperial.ac.uk/xraycrystallography/crystn/xtalscreens. Refer to table 5.3 for 
the names of the screens and their manufacturers. 
Construct 
Concentration 
in mg/ml 
Plate ID/Screen 
ICL1 ICL2 ICL3 ICL4 ICL5 ICL6 ICL7 ICL8 ICL9 ICL10 ICL11 ICL12 ICL13 ICL14 
dSPARC 
EC NHis 
10.3/17.8 x/x x/x x/x x/x  /x x/x x/x  x/x   /x /x 
dSPARC 
FS-EC 
NHis, 
deglyc 
11.4 x x x x   x x  x   x  
dSPARC 
FS-EC 
NHis glyc 
mut 
10.2/19.4 x/x x/x x/x x/x x/x  x/x x/x    /x /x  
cSPARC 
FS-EC 
NHis 
18.9 x x x x x  x x   x x x  
cSPARC 
EC NHis 
7.9  x x    x x    x   
 
Table 5.3 Summary of crystallisation trials (continued). List of pre-filled 96-well plate 
screens and their manufacturers.  
Plate ID Screen Company 
ICL1 Crystal Screen 1 and 2 Hampton Research 
ICL2 Wizard 1 and 2 Emerald Biosystems 
ICL3 PEG/ion and Natrix Hampton Research 
ICL4 Index Hampton Research 
ICL5 SaltRx Hampton Research 
ICL6 Memstart/Memsys Molecular Dimensions 
ICL7 PACT Premier Molecular Dimensions 
ICL8 JCSG+ Molecular Dimensions 
ICL9 MemGold Molecular Dimensions 
ICL10 PEG/Ion 2 and Wizard 3 
Hampton Research/Emerald 
Biosystems 
ICL11 JBScreen Cryo Jena Biosciences 
ICL12 Proplex Molecular Dimensions 
ICL13 Morpheus Molecular Dimensions 
ICL14 PGAScreen Molecular Dimensions 
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5.4 Collagen binding analyses of SPARC proteins by ELISA and SPR 
5.4.1 Solid phase binding assays (ELISA) 
Solid phase enzyme-linked immunosorbent assay (ELISA) have been used previously to 
test binding of nematode SPARC to collagens I and IV (Maurer et al., 1997). I carried out 
similar assays to measure the binding of soluble vertebrate and invertebrate SPARC 
proteins to immobilised collagens I and IV. These proteins were N-terminally tagged 
with a His6 tag and a myc epitope (Section 5.1.1). The EC constructs did not show any 
appreciable interactions in this assay format (data not shown). 
Drosophila SPARC FS-EC showed high affinity, dose-dependent binding to immobilised 
rat tail collagen I with a half-maximal binding (K0.5) of 0.8 ± 0.2 µM (Figure 5.9, Table 
5.4). The K0.5 value represents the mean ± SEM from four independent experiments. 
Human SPARC FS-EC showed comparatively lower collagen binding (K0.5 = 7.1 ± 1.4 
µM). cSPARC exhibited very little binding to collagen I (Figure 5.9, Table 5.4), with K0.5 
about an order of magnitude higher than previously reported by Maurer et al. (1997). 
Binding of the SPARC proteins to the blocking protein, κ-casein, was negligible (Figure 
5.9).  
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Figure 5.9 Solid phase binding assays with recombinant dSPARC, hSPARC, cSPARC and 
collagen I. Recombinant SPARC FS-EC proteins were added for 3 h at room temperature to 96-
well plates coated with collagen I at 10 µg/ml. Shown is a representative of at least two 
independent experiments. The curves were generated by non-linear least squares fitting of the 
data by an equation describing single-site binding. Blank: binding of cSPARC to non collagen -
coated wells.  
 
 
Table 5.4 Apparent dissociation constants (mean ± standard error) of SPARC FS-EC NHis-
myc proteins binding to immobilised type I collagen (n = 2- 4 independent experiments). 
Protein K0.5 (µM)a 
dSPARC 0.8 ± 0.2 
hSPARC 7.1 ± 1.4  
cSPARC 20, 35 
aConcentration of SPARC proteins at 50% of saturable binding 
 
141 
 
In solid phase assays with immobilised collagen IV, human SPARC FS-EC showed high 
affinity, dose-dependent binding with a half-maximal binding (K0.5) of 2.6 ± 0.3 µM 
(Figure 5.10, Table 5.8). This is in agreement with previously reported values of 2 µM 
(Sasaki et al., 1997). Drosophila SPARC FS-EC showed comparatively lower collagen 
binding (K0.5 = 12.9 ± 2.6 µM). cSPARC FS-EC exhibited very little binding to collagen IV 
(Figure 5.10, Table 5.5), with K0.5 about an 10-20 fold higher than previously reported 
by Maurer et al. (1997).  
 
 
 
 
 
 
 
 
 
Figure 5.10 Solid phase binding assays with recombinant dSPARC, hSPARC, cSPARC and 
collagen IV. Recombinant SPARC FS-EC proteins were added for 3 h at room temperature to 96-
well plates coated with collagen IV at 10 µg/ml. Shown is a representative of at least two 
independent experiments. The curves were generated by non-linear least squares fitting of the 
data by an equation describing single-site binding. Blank: binding of cSPARC to non collagen- 
coated wells.  
Table 5.5 Apparent dissociation constants (mean ± standard error) of SPARC FS-EC NHis-
myc proteins binding to immobilised type IV collagen (n = 2- 4 independent experiments). 
Protein K0.5 (µM)a 
dSPARC 12.9 ± 2.6 
hSPARC 2.6 ± 0.3 
cSPARC 46, 29 
aConcentration of SPARC proteins at 50% of saturable binding 
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5.4.2 SPR studies 
Solid phase assays are not very reliable for low affinity interactions with fast off-rates, 
due to the numerous wash steps involved. In our hands, such experiments with SPARC 
constructs containing only the EC domain did not show much binding above 
background levels, most likely due to very weak binding. Therefore, I carried out 
surface plasmon resonance (SPR)/ Biacore assays to measure dissociation constants 
between SPARC proteins and human collagen I.  
BIACORE is a label free method used to study macromolecular interactions in real time. 
It exploits the phenomenon of SPR which occurs when polarised light undergoes total 
internal reflection by striking a gold-coated glass prism. One binding partner (ligand) is 
immobilised on a chip surface while the other (analyte) is flowed across the surface. As 
the analyte binds to the ligand, an increase in the refractive index occurs due to the 
accumulation of protein on the chip surface. This change is measured and the result is 
displayed in a graph of response or resonance units (RU) versus time. 
Collagen I was immobilised on the surface of CM5 sensor chips (2331 RU of collagen I). 
SPARC FS-EC and EC proteins were then passed over the sensor chip surface at 
concentrations ranging of 0 to 40 µM. The qualitatively observed rapid rates of 
association and dissociation indicate weak interactions (Figure 5.11A), hence 
interactions were measured under steady-state conditions and analysed by fitting the 
plateau values at equilibrium to a simple 1:1 Langmuir binding model (Figure 5.11B). 
dSPARC FS-EC bound collagen I with a half-maximal binding (K0.5) of 14.6 ± 1.4 µM (Figure 
5.11). As expected, dSPARC EC showed comparatively lower collagen binding, K0.5 = 
39.5 ± 7.0 µM (Figure 5.12).  
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Figure 5.11 SPR (Biacore) analysis of dSPARC FS-EC NHis-myc and collagen I interaction. 
A. The sensorgrams were obtained by dSPARC concentrations ranging from 0-40 µM. The y-axis 
shows the response difference i.e. the difference between experimental and control flow cells, in 
resonance units (RU). B. Plot of the equilibrium binding response versus concentration. Data 
were fitted by a simple 1:1 Langmuir binding model to derive dissociation constants (K0.5).  
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Figure 5.12 SPR (Biacore) analysis of dSPARC EC NHis-myc and collagen I interaction. A. 
The sensorgrams were obtained by dSPARC concentrations ranging from 0-40 µM. The y-axis 
shows the response difference i.e. the difference between experimental and control flow cells, in 
resonance units (RU). B. Plot of the equilibrium binding response versus concentration. Data 
were fitted by a simple 1:1 Langmuir binding model to derive dissociation constants (K0.5).  
 
145 
 
It is possible to carry out kinetic analysis of SPR data, when the association and 
dissociation rates are small. However, erroneous interpretation of this type of data can 
be made due to factors such as neglect of mass transport, steric hindrance and/or the 
possibility of more-complex binding schemes (Schuck and Minton, 1996). Therefore, 
comparing data from equilibrium and kinetic analyses is a good way to test the validity 
of the experimental data. 
The kinetic evaluation procedure determines association and dissociation constants by 
fitting the experimental data to a 1:1 interaction model. At equilibrium, association 
balances dissociation. For a simple bimolecular interaction, A + B ↔ AB, the equilibrium 
dissociation constant, K0.5 = [A][B]/[AB], is measured by plotting equilibrium binding 
level against concentration. Both kinetic and equilibrium analyses were carried out on 
the dataset derived for hSPARC FS-EC binding to collagen I. For kinetic analysis, the 
experimental data were fitted by a 1:1 Langmuir binding isotherm (A + B ↔ AB) (Figure 
5.14). Visual inspection of the fitted curves overlaid on the experimental data indicates 
good fit. A dissociation constant, K0.5, of 22.7 µM was obtained (χ2 = 1.9). This value is in 
excellent agreement with that obtained from equilibrium analysis of the data (Figure 
5.13), where a K0.5 of 23.9 ± 0.9 µM was obtained. hSPARC EC binding to collagen I 
yielded a similar K0.5 value of 26.2 ± 0.8 µM (Figure 5.15).  
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Figure 5.13 Kinetic SPR analysis of hSPARC FS-EC NHis-myc and collagen I interaction. 
The sensorgrams were obtained with hSPARC concentrations ranging from 0-40 µM. The y-axis 
shows the response difference i.e. the difference between experimental and control flow cells, in 
resonance units (RU). The coloured traces are the experimental data and the grey traces are 
best fits of the kinetic model. Data analysis performed using the BIAevaluation 4.1.1 software. 
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Figure 5.14 SPR (Biacore) analysis of hSPARC FS-EC NHis-myc and collagen I interaction. 
A. The sensorgrams were obtained with hSPARC concentrations ranging from 0-40 µM. The y-
axis shows the response difference i.e. the difference between experimental and control flow 
cells, in resonance units (RU). B. Plot of the equilibrium binding response versus concentration. 
Data were fitted by a simple 1:1 Langmuir binding model to derive dissociation constants (K0.5).  
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Figure 5.15. SPR (Biacore) analysis of hSPARC EC NHis-myc and collagen I interaction. A. 
The sensorgrams were obtained with hSPARC concentrations ranging from 0-40 µM. The y-axis 
shows the response difference i.e. the difference between experimental and control flow cells, in 
resonance units (RU). B. Plot of the equilibrium binding response versus concentration. Data 
were fitted by a simple 1:1 Langmuir binding model to derive dissociation constants (K0.5).  
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cSPARC FS-EC showed very weak binding to collagen I (compared to other invertebrate 
SPARCs) with an estimated K0.5 value of 109 ± 37 µM (Figure 5.16). These data do not 
allow reliable analysis since the curve does not plateau at the highest concentration 
used (20 µM). The interaction of collagen I with cSPARC EC would be weaker still so this 
was not tested.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 SPR (Biacore) analysis of cSPARC FS-EC NHis-myc and collagen I interaction. 
A. The sensorgrams were obtained with cSPARC concentrations ranging from 0-40 µM. The y-
axis shows the response difference i.e. the difference between experimental and control flow 
cells, in resonance units (RU). B. Plot of the equilibrium binding response versus concentration. 
Data were fitted by a simple 1:1 Langmuir binding model to derive dissociation constants (K0.5).  
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I was unable to study the binding of SPARC proteins to collagen IV using SPR as the CM5 
sensor surface immobilised with collagen IV could not be regenerated.  
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Chapter 6: Discussion 
Interaction of SPARC with collagen 
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6. Discussion 
 
6.1 Biological implications of SPARC – collagen interactions 
SPARC is an important matricellular glycoprotein that is highly expressed in tissues 
undergoing development and remodelling. Several studies have shown SPARC binds to 
a number of ECM proteins including collagen types I, III, IV and V (Termine et al., 1981, 
Sage et al., 1989, Mayer et al., 1991, Maurer et al., 1995). The biological significance of 
SPARC – collagen interactions is poorly understood but can be deduced from knockout 
mouse models, which exhibit grossly normal phenotype but have fragile skin and 
develop cataracts (Norose et al., 1998). Tissues from SPARC-null mice contain less 
collagen than those from WT mice (Bradshaw et al., 2003) in part due to abnormal ECM 
assembly, indicating that SPARC is involved in the supramolecular assembly and 
stability of both fibrillar and network-forming collagen. Studies in invertebrates have 
showed that SPARC is required for collagen IV deposition in the BM during embryonic 
development. Defects in collagen deposition have also been observed in mammals, in 
the absence of SPARC expression. Based on these observations, it has been proposed 
that SPARC acts in concert with molecular chaperones such as Hsp47 to stabilise the 
collagen triple helix and restrict the lateral aggregation of procollagen molecules prior 
to export from the ER (Martinek et al., 2007).  Trombetta-Esilva and Bradshaw (2012) 
have suggested a hypothetical model of cellular mechanisms of SPARC which is shown 
in Figure 6.1. 
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Figure 6.1 Function of SPARC in procollagen deposition and assembly. SPARC is secreted 
from the cell bound to procollagen, thus preventing procollagen binding to cell-surface 
receptors such as DDR2. In the absence of SPARC, procollagen molecules fail to accumulate into 
fibrils as they get tethered to the cell surface, resulting in less total collagen and thinner collagen 
fibrils. From Trombetta-Esilva and Bradshaw (2012).  
 
It has been hypothesised that SPARC and related proteins such as SC1/hevin can 
compensate functionally for each other in vertebrates (Brekken and Sage, 2000). SC1 
has been shown to bind collagen (Hambrock et al., 2003) and the collagen binding 
residues are conserved in both SPARC and SC1. However, SPARC/SC1 double knockout 
mice show similar phenotype to SPARC-null mice (Barker et al., 2005), indicating that 
SPARC is more important than SC1 in collagen assembly and maturation.  
Invertebrate SPARCs also bind collagens through their EC domain but lacking helix αB, 
they have a shorter connection between helices αA and αD (Appendix 1). Therefore, it 
can be hypothesised that invertebrate SPARCs may exist in an activated form i.e. they do 
not require proteolytic cleavage of helix αC to make the collagen binding site on helix αA 
accessible (Sasaki et al., 1998). To test this hypothesis, I expressed vertebrate and 
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invertebrate SPARC to be able to perform structural studies and investigate SPARC 
binding to collagen. 
 
6.2 Structural studies 
Structural characterisation of proteins by X-ray crystallography may be highly 
informative but presents two major bottlenecks: production of soluble proteins and 
growth of diffraction-quality crystals (Chang et al., 2007). SPARC proteins were 
recombinantly expressed in embryonic kidney HEK-293 c18 cells to ensure correct 
folding and post-translational modifications. The first construct considered for 
structural studies was the dSPARC EC domain, which contains a potential N-linked 
glycosylation site at Asn214. Glycosylated proteins are often difficult to crystallise due 
to heterogeneity and conformational flexibility of the carbohydrate moiety, leading to 
inhibition of formation of an ordered crystal lattice (Baker et al., 1994). Hence, 
enzymatic deglycosylation was achieved by PNGase F digestion, which cleaves between 
the Asn-oligosaccharide bond, and deglycosylation was confirmed by SDS-PAGE. 
However, the SEC profile showed the sample was not monodisperse (presence of 
monomer and dimer), and this might explain why the protein failed to yield crystals.  
I attempted to crystallise dSPARC FS-EC, also treated with PNGase F to facilitate 
crystallography. The SEC profile showed the presence of mixed species – presumed 
monomeric and dimeric. Although deglycosylation was easily achieved on a small-scale 
analytical preparation of this protein, it did not work equally well for a large scale 
preparation, even after overnight incubation with PNGase F at relatively high 
concentration. SDS-PAGE showed the presence of two bands with reduced molecular 
weight compared with the native protein, indicating that some but not all carbohydrates 
had been removed. Following PNGase F digestion, the protein was incubated with 
lectins, but this treatment also failed to remove residual carbohydrates. The difference 
in level of deglycosylation between EC and FS-EC proteins could be due to accessibility 
of the glycosylation sites. PNGase F cleaves between the innermost GlcNAc and Asn 
residues, and the cleavage site on the glycan in the FS domain (Asn126) might be less 
accessible to PNGase F than the one in the EC domain (Asn214). 
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A dSPARC double mutant, with mutations in the 2 putative glycosylation sites (Asn126 
and Asn214 to Gln), also failed to yield crystals. 
At this stage, a SPARC homologue from another invertebrate species, C. elegans, was 
considered for structural studies. Some proteins do crystallise with full N-linked glycans 
(Mesters and Hilgenfeld, 2007), hence crystallisation trials of cSPARC FS-EC and EC 
were set up in their native states. Both proteins failed to crystallise in their fully 
glycosylated states.  
It may be possible and worthwhile to deglycosylate invertebrate SPARC proteins using 
other approaches. One strategy is to express the proteins in the presence of the α-
mannosidase inhibitor, kifunensine, purify them and then treat them with enzymes such 
as endoglycosidase F (Endo F). The glycoform profiles of proteins depend on the cell 
lines used to express these proteins. For example, glycoproteins expressed in insect 
cells are mainly oligomannans such as Man9GlcNAc2 whereas mammalian cell lines 
produce mainly complex bi-antennary N-glycans, built on a core of Man3GlcNAc2. 
Kifunensine acts downstream of the N-glycosylation biosynthetic pathway, i.e. it allows 
initial glycosylation and folding but inhibits mannosidase I enzyme in the ER (Elbein, 
1991), thus leaving the proteins with high-mannose Man9GlcNAc2 oligosaccharides, 
which are more homogeneous than hybrid glycan structures and susceptible to cleavage 
by Endo F. To ensure complete deglycosylation, lectin treatment can be performed 
following enzymatic digestion of SPARC proteins, since commonly used lectins such as 
concanavalin A (ConA) bind oligomannose-type N-glycans with much higher affinity 
than complex-type biantennary N-glycans (Cummings and Etzler, 2009). These 
treatments could potentially lead to successful crystallisation of invertebrate SPARC 
proteins due to removal of heterogeneity.  
 
6.3 Functional studies 
We felt it was important to compare how vertebrate and invertebrate SPARCs differ in 
their ability to bind collagens type I and IV. In solid phase and surface plasmon 
resonance assays, dSPARC binds most strongly to collagen I, followed by hSPARC and 
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cSPARC. The solid assay yielded dissociation constants for dSPARC and hSPARC FS-EC 
that are an order of magnitude lower (i.e. tighter binding) than those obtained from SPR 
studies. This discrepancy may be due to differences in assay formats. Solid phase assays 
are not ideal for determination of dissociation constants due to surface effects and non-
linearity of detection signals. In such assays, high surface density means several 
adsorbed molecules may be recognised by a multivalent ligand leading to apparent 
higher affinities. Very early saturation is observed at low ligand concentrations; at 
higher concentrations, steric hindrances between large antibodies result in non-
linearity of detection signals, yielding affinities that can be up to 1000 fold too high 
(Tangemann and Engel, 1995). Our data also show that some of the dissociation 
constants are an order of magnitude higher than previously published binding data 
(Sasaki et al., 1997, Maurer et al., 1997). SPARC EC proteins could not be studied using 
solid phase assays possibly because in many cases, low affinity binding fails to be 
detected in these assays due to the long incubation times and several wash steps. In SPR 
studies, hSPARC FS-EC and EC proteins showed similar binding affinities to collagen I 
indicating a single binding site, as reported previously (Sasaki et al., 1997). SPR data for 
dSPARC FS-EC and EC and collagen interactions showed rapid rates of association and 
dissociation and could not be analysed kinetically. The binding profiles for dSPARC – 
collagen interactions indicate that the dissociation constants derived might not be best 
explained by a single-site model; the dissociation phase does not follow a 1:1 interaction 
model, therefore, the calculated K0.5 value might be a combination of K0.5 values 
corresponding to high- and low-affinity binding sites for dSPARC on collagen I.  
In solid phase assays with immobilised collagen IV, hSPARC binds tightly with a K0.5 of 
2.6 µM, which is in agreement with previously reported values  (Maurer et al., 1997). 
dSPARC shows relatively lower binding and cSPARC exhibits very little binding to 
collagen IV. One of the drawbacks of our study of invertebrate SPARC – collagen 
interactions is that it involves the use of mammalian collagens I and IV (from rat tail and 
human placenta, respectively). Unfortunately, collagen from invertebrates is not 
available commercially. The Collagen Toolkit, developed in the Farndale lab, consists of 
sets of overlapping collagen-derived-triple-helical peptides (Raynal et al., 2006). This 
has been used in several studies for mapping ligand binding sites on fibrillar collagens II 
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and III. No such toolkit exists for heterotrimeric collagens (e.g. type I and IV) due to 
technical challenges involved in the synthesis of these peptides. 
Alanine mutagenesis studies of the collagen binding epitope of hSPARC have previously 
indicated the presence of five crucial amino acid residues for collagen binding: R149 
and N156 in helix αA, L242, M245 and E246 in a loop region connecting the two EF-
hands of SPARC (Sasaki et al., 1998). These essential residues are conserved in 
vertebrates. However, small differences are seen in invertebrates; an N156Q 
substitution is found in C. elegans and a M245L substitution found in Drosphila. These 
minor substitutions should not have a significant effect on the structure and function of 
the EC domain.  However, despite the conservation of 3 of the 5 key collagen binding 
amino acids, our data shows that C. elegans SPARC has a lower collagen binding affinity 
compared with other SPARCs. Further studies are needed to understand invertebrate 
SPARC – collagen IV interactions in more detail and it may be possible do so in future if 
technological advances lead to the development of peptide libraries from heterotrimeric 
collagens.  
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7. Conclusions and Future Directions 
 
Decorin 
 
Decorin, the prototypical small leucine-rich repeat proteoglycan, has a broad binding 
repertoire ranging from collagens to growth factors and RTKs. Consequently, it 
regulates a host of cellular processes in the ECM such as fibrillogenesis and the control 
of cell proliferation. 
 
Decorin is a major component of connective tissues and has been shown to bind various 
collagens including types I, II, II and VI (Bidanset et al., 1992, Scott and Orford, 1981, 
Vogel et al., 1984). Decorin is also known to bind and inhibit the activity of TGF-β, a 
powerful profibrotic cytokine (Yamaguchi et al., 1990). Decorin deficient mice are viable 
and grossly normal but have fragile skin with reduced skin tensile strength as a result of 
abnormal collagen fibrils of irregular diameter (Danielson et al., 1997).  
 
Much work remains to be done to better understand the biological role of decorin in 
collagen fibrillogenesis and to exploit its potential as a therapeutic agent for various 
connective tissue and fibrous disorders involving collagen deposition, control and 
repair such as wound healing, tendon and ligament repair, etc. (Reed and Iozzo, 2002). 
Future therapies will rely on the Dcn -/- mouse model and double knockout studies to 
understand the molecular mechanisms through which decorin and other SLRPs operate 
in maintaining the integrity of connective tissues (Reed and Iozzo, 2002). My work has 
resolved the controversy about the physiological relevance of the decorin dimer by 
showing that dimerisation is reversible and that the concave face of decorin is involved 
alternatively in dimerisation or collagen binding. In addition, I have shown that wild-
type and monomeric decorin have similar thermal stabilities. Most studies so far have 
focussed on only a few SLRPs, especially decorin, biglycan, lumican, and ﬁbromodulin, 
with research concerning the other SLRPs trailing far behind (Nastase et al., 2014). 
Biophysical studies including characterisation of the functional oligomeric statuses and 
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stabilities of these other SLRPs warrant further studies as they help us better 
understand the roles these molecules play in several disease states.  
 
Among SLRPs, the biological role of decorin in cancer progression has been extensively 
studied. Numerous studies have shown that decorin acts as a natural anticancer agent 
so enhancement of decorin gene expression should halt tumour growth (Bi and Yang, 
2013). It is anticipated that decorin will garner more interest in the future due to its 
potential therapeutic and prognostic value. The concave face of decorin seems to be able 
to bind a myriad of ECM proteins with no obvious structural similarities, but having 
versatile effects in health and disease. Therefore, my findings detailed in this thesis, that 
the functional oligomeric state of decorin is monomeric and the concave face of decorin 
is available for ligand binding, are of importance in understanding core-protein 
mediated interactions of decorin and can be extended to study other binding partners, 
such as growth factors and RTKs in the ECM. One of the challenges of future research 
would be to identify the leucine-rich repeats of decorin that harbour specific 
bioactivities since these can be used in adjuvant peptide therapies or can be engineered 
to bind to specific receptors in the treatment of cancer (Neill et al., 2012). 
 
 
SPARC 
 
SPARC is multifunctional matricellular glycoprotein that is able to bind several proteins 
in the ECM, modulate the activity of growth factors, and alter cell shape due to its 
counteradhesive properties. High levels of SPARC are observed during development. In 
adult tissues, SPARC expression is usually restricted to sites of ECM turnover. The 
SPARC sequence is highly conserved among species, as diverse as C. elegans and 
humans, indicating the importance of this protein in multicellular life (Bradshaw, 2009).  
 
It has been shown that SPARC is required for normal embryonic development in 
invertebrates. Inactivation of SPARC in C. elegans and Xenopus leads to embryonic 
lethality (Fitzgerald and Schwarzbauer, 1998, Purcell et al., 1993). In Drosophila 
embryos, haemocyte-derived collagen IV is not observed in the basal laminae in the 
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absence of SPARC, leading to decreased basal lamina stability (Martinek et al., 2008). 
Hence, the role of SPARC – collagen interactions has important consequences for our 
understanding of development in invertebrates.  
 
The high conservation of collagen binding residues between vertebrate and 
invertebrate SPARC sequences suggests that all SPARCs bind collagen in a similar 
manner. However, invertebrate SPARCs do not undergo proteolytic activation similar to 
human SPARC since they do not contain an inhibitory loop which is present in 
mammalian SPARC. The studies outlined in this thesis have made some progress in 
understanding the differences in collagen binding between vertebrate and invertebrate 
SPARC in terms of binding affinities. Multiple SPARC binding sites along the collagen IV 
triple helix have been observed under electron micrographs (Mayer et al., 1991) but 
their precise locations remains to be elucidated. This would require the development of 
heterotrimeric peptide libraries the synthesis of which has so far proven to be 
technically challenging.  
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Appendix I 
 
 
 
 
Sequence alignments of selected SPARC EC domains. The sequences are of human SPARC 
(SwissProt P09486), human SPARC-like/hevin (Q14515), Xenopus laevis SPARC (P36378), 
Drosophila melanogaster SPARC (O97365) and Caenorhabditis elegans SPARC (P34714). 
Conserved residues are highlighted in yellow and cysteines are in red. Residues involved in 
calcium and collagen binding to human SPARC are indicated by pink circles and black inverted 
triangles, respectively. The sequence numbering and α-helices A-G of human SPARC are 
indicated above the alignment. From (Hohenester et al., 2008)
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Background: In the crystal structure of decorin, the concave faces of two monomers interact to form a tight dimer.
Results: The decorin dimer in solution is in equilibrium with stable monomers, and mutations on the concave face abolish
collagen binding.
Conclusion: Decorin binds collagen as a monomer.
Significance: These findings help resolve the controversy about the functional oligomeric state of decorin.
Decorin, the prototypical small leucine-rich proteoglycan,
binds to collagen and thereby regulates collagen assembly
into fibrils. The crystal structure of the decorin core protein
revealed a tight dimer formed by the association of twomono-
mers via their concave faces (Scott, P. G., McEwan, P. A.,
Dodd, C. M., Bergmann, E. M., Bishop, P. N., and Bella, J.
(2004) Proc. Natl. Acad. Sci. U.S.A. 101, 15633–15638).
Whether decorin binds collagen as a dimer has been contro-
versial. Using analytical ultracentrifugation, we determined a
dissociation constant of 1.37 0.30M for themouse decorin
dimer. Dimerization could be abolished by engineering gly-
cosylation sites into the dimer interface; other interface
mutants remained dimeric. The monomeric mutants were as
stable as wild-type decorin in thermal unfolding experiments.
Mutations on the concave face of decorin abolished collagen
binding regardless of whether the mutant proteins retained
the ability to dimerize or not. We conclude that the concave
face of decorin mediates collagen binding and that the dimer
therefore must dissociate to bind collagen.
The small leucine-rich proteoglycans (SLRPs)2 comprise a
diverse family of secreted glycoproteins that have in com-
mon a core protein consisting of multiple leucine-rich
repeats (LRRs) flanked by cysteine-rich cap regions. One or
several glycosaminoglycan chains are attached to the canon-
ical SLRPs; other family members have acidic regions or are
modified by tyrosine sulfation (1, 2). Decorin is the proto-
typical SLRP. It has a well characterized role in regulating
collagen fibrillogenesis (2, 3) and additionally modulates the
activity of various growth factors and receptor tyrosine
kinases (4). Ultrastructural studies of tissue-derived collagen
fibrils have revealed decorin binding sites within the gap
region of the D-period (5–7). A unique decorin binding site
near the C terminus of the triple helix has been identified
using type I procollagen produced in cell culture (8). Decorin
inhibits collagen fibrillogenesis in vitro (9) and has a pro-
found effect on the ultrastructure of the resulting fibrils (10).
Decorin-deficient mice are viable and grossly normal but
have fragile skin due to abnormal collagen fibrils (11). Mice
lacking decorin and the related SLRP biglycan have a much
more severe skin phenotype (12) and a severely disrupted
collagen fibril architecture in the cornea (13).
The crystal structure of the decorin core protein revealed
that the 12 LRRs form a curved solenoid; the concave face of the
solenoid is a parallel -sheet, and the convex back consists of
irregular loops and single helical turns (14). In this crystal struc-
ture, two decorin monomers were found to interact through
their concave faces, burying a large amount of decorin surface
(see Fig. 1A). A strong tendency of decorin and other SLRPs
to form dimers in solution was observed in several biophys-
ical studies (15–17). Some even claimed that folded mono-
meric decorin cannot exist in solution (18), whereas others
concluded that the crystallographic decorin dimer is an arti-
fact (19). To complicate matters further, mutagenesis (20–
22) and molecular modeling studies (23, 24) have implicated
the concave face, which is largely buried in the decorin
dimer, in collagen binding.
We felt that itwas important to resolve the controversy about
the oligomeric state of decorin and how it relates to collagen
binding. Here, we show that decorin dimerization is relatively
weak and reversible and thatmutants that are stablemonomers
in solution can be obtained. Mutations on the concave face of
decorin abolished collagen binding regardless of whether they
disrupted the dimer or not. Thus, the same region of decorin
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mediates dimerization and collagen binding, and the decorin
dimer must dissociate to bind collagen.
EXPERIMENTAL PROCEDURES
Expression Constructs—DNA coding for residues 45–354 of
mouse decorin (UniProt P28654) was amplified by PCR from a
full-length cDNA clone (OriGene) and inserted into amodified
pCEP-Pu vector (25). After cleavage of the vector-encoded
BM-40 signal peptide, vector-encoded APLA and AAAHHH-
HHH sequences are present at the N and C termini of the
mature protein, respectively. The mutations were intro-
duced by overlap extension PCR. All expression constructs
were verified by sequencing.
Protein Production—The proteins were produced in human
embryonic kidney HEK293 c18 cells (ATCC). The cells were
grown at 37 °C with 5% CO2 in Dulbecco’s modified Eagle’s
medium/F-12 (Invitrogen) containing 10% fetal bovine serum,
2 mM glutamine, 10 units/ml penicillin, 100 g/ml streptomy-
cin, and 250 g/ml Geneticin. The cells were transfected with
the pCEP-Pu expression plasmid using FuGENE (Roche Diag-
nostics) and selected with 1g/ml puromycin (Sigma). Conflu-
ent cells in a HYPERFlask (Corning) were washed twice with
phosphate-buffered saline (PBS; Invitrogen) and incubated
with serum-free medium for 3–4 weeks with weekly medium
exchanges. The pooled and filtered conditioned medium was
loaded onto a 5-ml HisTrap column (GE Healthcare) using an
A¨KTA Purifier (GE Healthcare). The protein was eluted with
300 mM imidazole in PBS, concentrated using a Vivaspin cen-
trifugal device (Sartorius), and further purified on a Superdex
200 16/60 size exclusion chromatography column (GE Health-
care) with Tris-buffered saline (TBS; 20mMTris, 150mMNaCl,
pH 7.5) as the running buffer. The fractions containing pure
protein were pooled and concentrated to 2–3 mg/ml, and ali-
quots were flash frozen in liquid nitrogen. All experimentswere
performed with freshly thawed proteins. For analytical pur-
poses, the N-linked glycan was removed by peptide N-glycosi-
dase F treatment under denaturing conditions according to the
manufacturer’s protocol (New England Biolabs).
Analytical Size Exclusion Chromatography with Laser Light
Scattering—Wild-type and mutant decorin samples at a con-
centration of 3 mg/ml (83 M) were injected onto a Superdex
200 10/30 column (GEHealthcare) connected to a 1260 Infinity
HPLC (Agilent Technologies). The running buffer was TBS,
and the flow ratewas 0.2ml/min. Light scattering and refractive
index changes were monitored using in-lineWyatt Mini Dawn
and Optilab T-rEX detectors (Wyatt Technology Corp.). The
data were analyzed with the Wyatt ASTRA V software using
dn/dc values of 0.185 and 0.145 ml/g for the polypeptide and
polysaccharide fractions of the glycoproteins, respectively.
Each consensus site for N-linked glycosylation was assumed to
add 2 kDa ofmolecular mass. Themass of the polypeptide frac-
tion of the glycoproteins was determined by the three-detector
method (26) using an extinction coefficient of 24,961M1 cm1
for the decorin protein.
Analytical Ultracentrifugation—Sedimentation velocity ex-
periments were performed at 20 °C using a Beckman XL-I ana-
lytical ultracentrifuge at a rotor speed of 40,000 rpm. The
instrument was equippedwith an eight-hole AnTi50 rotor with
double sector cells with column heights of 12 mm. Sedimenta-
tion was monitored using absorbance (280 nm) and interfer-
ence optics. Decorin proteins were dialyzed extensively against
PBS and studied at concentrations ranging from 0.028 (0.77
M) to 3.4 mg/ml (94 M). The sedimentation boundaries were
analyzed using direct boundary Lamm fits using the program
SEDFIT (version 14.1) (27). A partial specific volume of 0.7289
ml/gwas calculated from the amino acid and carbohydrate con-
tent. The buffer density and viscosity were taken to be 1.00543
g/ml and 1.02 centipoises, respectively, based on theoretical
values provided by the program SEDNTERP. The continuous
c(s) size distribution algorithm assumes that all species have the
same frictional ratio f/f0 in each fit. The final SEDFIT analyses
used a fixed resolution of 200 and optimized the c(s) fit by float-
ing the meniscus, bottom of the cell, base line, and f/f0 ratio
until the overall root mean square deviation and visual appear-
ance of the fits were deemed satisfactory. The relative amounts
of monomer and dimer were derived using the c(s) integration
function. The dimer dissociation constants were obtained by
fitting the ratio of monomer and dimer with Equation 1 using
SigmaPlot 12.0 software (Systat Software Inc.).
y  1 
Kd2  8Kd x  Kd
4x
(Eq. 1)
where y is the dimer fraction, x is the total protein concentra-
tion, andKd is the dissociation constant. For a derivation of this
equation, see Benfield et al. (28). HYDROPRO (29) was used to
calculate s20,w0 values for the decorin monomer and dimer. The
models were based on the crystal structure of dimeric bovine
decorin core (14). Biantennary oligosaccharide chains, each
consisting of a GlcNAc2Man3 core and two GlcNAc-Gal-
NeuNAc antennae (30), were added at each of the four pre-
dicted glycosylation sites of mouse decorin, and the hydration
shell was represented by an atomic element radius of 0.31 nm
for all atoms (29).
Differential Scanning Calorimetry—The experiments were
performed using a Calorimetry Systems Nano III calorimeter.
Wild-type and mutant decorin samples at a concentration of 3
mg/ml (83 M) were dialyzed extensively against PBS. 1-ml ali-
quots of sample and dialysis buffer were degassed for 15 min.
Following an equilibration period of 10min, initial scans from 5
to 20 °C were repeated until a stable base line was obtained.
Scans were then performed from 5 to 65 °C at a heating rate of
1 °C/min.
Differential Scanning Fluorimetry—The experiments were
performed using a Stratagene Mx3005p qPCR instrument
essentially as described (31). 10-l aliquots of wild-type and
mutant decorin in PBS at a concentration of 0.362 mg/ml (10
M) were mixed with 10 l of SYPRO Orange solution (Invit-
rogen) diluted 1:250 and heated from 25 to 95 °C at a heating
rate of 1 °C/min. The excitation wavelength was 492 nm, and
fluorescence was monitored at 610 nm.
Collagen Fibrillogenesis Assay—A 1.05 mg/ml stock solution
of mouse type I collagen (isolated from tendon, treated with
pepsin, and precipitated using NaCl) in 50 mM acetic acid was
neutralized at 4 °C by diluting it 33-fold with 150 mM sodium
phosphate, 150mMNaCl, pH 7.8 and immediately placed into a
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Shimadzu UV-2501PC spectrophotometer equipped with a
water-jacketed cuvette holder maintained at 37 °C. The turbid-
ity arising from collagen fibril formation was recorded as
absorbance at 400 nm over 100 min. In the inhibition experi-
ments, the decorin proteinswere added at a concentration of 50
g/ml (1.38 M).
Solid-phase Binding Assay—A 1 mg/ml stock solution of rat
tail type I collagen (Sigma) in 0.1 M acetic acid was diluted 1:40
with 50 mM Tris, 100 mM NaCl, pH 8.5 immediately prior to
use.NuncMaxisorp 96-wellmicrotiter plateswere coated over-
night at 4 °C with 1.25 g of collagen per well. The wells were
washed oncewith PBS and blocked for 2 h at room temperature
with 150 l of 0.1 mg/ml bovine milk -casein (Sigma) in PBS
containing 0.05% Tween 20 (incubation buffer). The cleared
wells were incubated for 3 h with 50 l of decorin proteins
diluted in incubation buffer. After six washes with incubation
buffer, thewellswere incubated for 1 hwith 50l of anti-His tag
antibody conjugated to horseradish peroxidase (Miltenyi Bio-
tec; 1:500 dilution in incubation buffer). After three washes
with incubation buffer and three washes with PBS, the assay
was developed using 75l of o-phenylenediamine dihydrochlo-
ride substrate (Sigma) per well for 20min, and the reaction was
stopped with 50 l of 3 M H2SO4 per well. Absorbance was
measured at 492 nm using a Tecan Sunrise microplate reader.
RESULTS
Mutational Disruption of the Decorin Dimer Interface—We
created an expression construct formouse decorin core protein
(referred to as decorin from here on) that corresponds to the
ordered residues in the crystal structure of bovine decorin core
protein (14). This construct spans residues 45–354 (the num-
bering scheme includes the signal peptide) and contains a His6
tag at the C terminus. The C-terminal cap is not involved in the
dimer interface of bovine decorin (Fig. 1A), and the His6 tag is
therefore not expected to interfere with dimerization. We
designed four mutations that might disrupt the dimer interface
in mouse decorin (Fig. 1A). The Y51A/R52A/Q54A triple
mutation in the N-terminal cap removes three side chains that
are prominently involved in the interface (corresponding to
Phe-27, Arg-28, and Gln-30 in the bovine decorin structure),
the R151E mutation in LRR5 (Arg-127 in the bovine decorin
structure) reverses a charge in the network of polar interactions
that accounts for most of the interface, the Q61N mutation
(Gln-37 in the bovine decorin structure) introduces a consen-
sus site for N-linked glycosylation into LRR1, and the Y130N
mutation (Tyr-106 in the bovine decorin structure) introduces
a consensus site forN-linked glycosylation into LRR4. Analysis
by the NetNGlyc server predicted glycosylation potentials of
0.60 and 0.72 for asparagines at positions 61 and 130, respec-
tively, indicating a high probability that the engineered glyco-
sylation sites would be modified.
Wild-typemouse decorin and all fourmutantswere obtained
with good yields from episomally transfected HEK293 cells and
purified to homogeneity (Fig. 1B and data not shown). The
wild-type protein (calculated molecular mass, 36.2 kDa) ran as
a single band of 43 kDa on reducing SDS-PAGE, consistent
with the presence of four consensus sites forN-linked glycosyl-
ation in the mouse decorin sequence. The Q61Nmutant ran as
a broader band at higher molecular mass, demonstrating that
the engineered glycosylation site at position 61 is modified by a
glycan. In contrast, the electrophoretic mobility of the Y130N
mutant resembled more closely that of the wild-type protein,
indicating that the engineered glycosylation site at position 130
is either unmodified or that the attached glycan is not detecta-
ble by SDS-PAGE. Removal of the N-linked glycans by peptide
N-glycosidase F digestion resulted in identical sharp bands at
30 kDa for the wild-type construct and the two mutants with
engineered glycosylation sites (Fig. 1B).
Oligomeric States of Wild-type and Mutant Decorin—To
determine the oligomeric states of mouse decorin and its dimer
interfacemutants, we first used size exclusion chromatography
with multiangle light scattering (SEC-MALS). Wild-type
mouse decorin injected at 3 mg/ml concentration (83 M)
eluted in an asymmetric peak with a pronounced tail (Fig. 2).
The molecular mass of the protein without modifications was
determined to be 64.4 kDa (Table 1). This value is much closer
to the calculated mass of a dimer (72.4 kDa) than that of a
monomer (36.2 kDa). The dimer appears to dissociate quite
readily, however, giving rise to an asymmetric peak and an aver-
age mass that is slightly lower than that of a dimer. The molec-
ular mass of the glycoprotein (i.e. protein plus carbohydrate
modifications) was determined to be 83.5 kDa (Table 1), which
is in excellent agreement with the reportedmass of 84.6 kDa for
dimeric bovine decorin core glycoprotein (17). The elution pro-
files and molecular masses of the Y51A/R52A/Q54A and
R151Emutants resembled those of the wild-type protein (Fig. 2
and Table 1), indicating that thesemutations had not disrupted
the mouse decorin dimer. In contrast, the Q61N and Y130N
mutants eluted later thanwild-type decorin and displayed sym-
metric peak profiles with molecular masses closely matching
those of amonomer (Fig. 2 and Table 1). For the Q61Nmutant,
the disruption of the dimer could be attributed unequivocally to
an engineered glycan as there is clear evidence for an additional
modification in SDS-PAGE (Fig. 1B). For the Y130N mutant,
the presence of a disruptive glycan could only be inferred from
the observation that this mutant is monomeric. It is possible,
although unlikely, that introduction of an unmodified aspara-
gine at position 130 disrupts the decorin dimer. Because our
FIGURE 1. Mouse decorin mutants. A, location of mutations in mouse
decorin mapped onto the crystal structure of the bovine decorin dimer (14).
The dimer is viewed along its symmetry axis, and the N and C termini are
labeled in one subunit. B, reducing SDS-PAGE of wild-type (WT) mouse
decorin and the Q61N and Y130N mutants before and after digestion with
peptide N-glycosidase F (PNGase F) (Coomassie Blue stain). The positions of
selected molecular mass markers are indicated on the left.
Mutational Analysis of Decorin Dimerization
35528 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 49•DECEMBER 6, 2013
objectivewas to obtainmonomeric decorinmutants, we did not
further investigate the presumed modification in the Y130N
mutant.
The SEC-MALS experiment suggested that wild-typemouse
decorin might exist in a concentration-dependent monomer-
dimer equilibrium. To investigate themonomer-dimer equilib-
rium quantitatively, we used analytical ultracentrifugation.
Using atomic models based on the crystal structure of bovine
decorin (14) with appropriate carbohydrate modifications, we
calculated s20,w0 values of 3.0 and 4.7 S for monomeric and
dimeric mouse decorin (for details, see “Experimental Proce-
dures”).We collected sedimentation velocity data at seven con-
centrations of wild-type decorin ranging from 0.028 to 3.4
mg/ml (0.77–94 M) (Fig. 3A). The c(s) distributions derived
from these data are characterized by two peaks, one at 3.6 S and
one at 4.7–5.3 S, the relative proportions of which varied with
the protein concentration (Fig. 3B). These peaks were inter-
preted to correspond to monomers and dimers, respectively,
and their relative areas were used to derive a dissociation con-
stant of 1.37 0.30 M for the mouse decorin dimer (Fig. 3C).
Analogous experiments with the Y51A/R52A/Q54A and R151E
mutants yielded comparable dimerdissociation constants of 2.3
0.8 and 0.47 0.09M, respectively (Fig. 4).
Stability of Wild-type and Mutant Decorin—The experi-
ments described so far show that wild-type mouse decorin
exists in a monomer-dimer equilibrium and that mutants can
be obtained that behave as pure monomers in SEC-MALS. To
quantify the thermal stabilities of selected proteins, we used
differential scanning calorimetry. Wild-type mouse decorin
and the monomeric Q61N mutant unfolded in single transi-
tions with melting temperatures of 50 and 52 °C, respectively
(Fig. 5A), which compare with a reported melting temperature
of 46 °C for bovine decorin (18). Unfolding was only partially
reversible as the signals on a second up-scan were reduced by
90% (data not shown). To extend the analysis to the remain-
ing mutants, we used differential scanning fluorimetry, which
monitors thermal unfolding using a hydrophobic dye and
requires only small amounts of protein (31). The unfolding
curves of all decorin proteins were very similar with inflection
points ranging from 49 to 51 °C (Fig. 5B). As in the differential
scanning calorimetry experiment, the monomeric mutants
with engineered glycosylation sites (Q16N and Y130N) were
marginallymore stable thanwild-type decorin. A positive effect
of glycans on protein stability is well documented and fre-
quently exploited in the pharmaceutical industry (32).
Collagen Binding by Wild-type and Mutant Decorin—An
important aim of the present study was to resolve the contro-
versy whether decorin binds to collagen as a monomer or as a
dimer (14, 19, 24). We first assessed collagen binding indirectly
by measuring the inhibition of collagen fibrillogenesis, which is
the classic assay for decorin activity (9). Wild-type mouse
decorin robustly delayed fibrillogenesis of type I collagen (Fig.
FIGURE 2. SEC-MALS analysis of WT mouse decorin and the dimer inter-
facemutants. The proteins were injected onto a Superdex S200 column at a
concentration of 3 mg/ml and run in TBS. The solid lines represent the refrac-
tive index (RI) detector signal (left y axis), and the dashed lines represent the
molecularmassof theglycoproteinpolypeptide fraction (right yaxis) asdeter-
mined by the three-detector method (26).
TABLE 1
Molecular masses of mouse decorin and its mutants as determined by SEC-MALS
The relative errors of the experimentally determined masses are5%.
Protein
Calculated
molecular mass
N-Linked
glycosylation sites
Peak elution
volume
Experimental mass
of glycoproteina
Experimental mass of
polypeptide fractionb
kDa ml kDa kDa
WT 36.2 4 14.5 83.5 64.4
Y51A/R52A/Q54A 36.2 4 14.1 85.3 65.3
Q61N 36.2 5 15.5 52.1 37.6
Y130N 36.2 5 15.1 51.5 36.7
R151E 36.2 4 14.1 88.4 68.4
a Derived from the refractive index and light scattering signals.
b Derived from the absorbance, refractive index, and light scattering signals (26).
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6A) as reported previously for bovine and human decorin (10,
13, 14, 19, 22). Of the four dimer interface mutants, only the
Y51A/R52A/Q54 mutant delayed fibrillogenesis similarly to
wild-type protein. TheQ61N, Y130N, andR151Emutants were
completely inactive (Fig. 6A). We also attempted to measure
collagen binding directly using a solid-phase assay with immo-
bilized type I collagen (22, 33) but were frustrated by high and
variable levels of nonspecific binding regardless of the blocking
agent (albumin and casein) or detection method used (anti-
mouse decorin antibody, anti-His tag antibody, biotinylation,
and detection by avidin). Despite these problems, we consis-
tently observed stronger collagen binding by wild-type mouse
decorin and the Y51A/R52A/Q54A mutant than by any of the
single point mutants (Fig. 6B). These observations corroborate
the findings obtained with themore robust fibrillogenesis assay
and indicate that decorin residues 61, 130, and 151 are impor-
tant for collagen binding.
DISCUSSION
Decorin and the related SLRPs biglycan, lumican, and fibro-
modulin play amajor role in regulating collagen fibril formation
in the extracellular matrix (2, 3), but how they bind to collagen
has been unclear. A sterically plausible binding mode involves
one or several collagen triple helices interacting with the con-
cave face of the curved SLRPmolecule (23, 24), which also hap-
pens to be the most highly conserved surface region (14). How-
ever, in crystal structures of decorin and biglycan, the concave
face forms the interface of a seemingly tight dimer (14, 18),
leading to controversy about the physiological relevance of the
dimers (16–19). Here, we have resolved this controversy by
FIGURE3.Sedimentationvelocityanalysisofwild-typemousedecorin.Sevenconcentrations from0.028 to3.4mg/mlwereanalyzed inPBSat a rotor speed
of 40,000 rpm.A, scan boundaries (black) and their fits (red) at the highest and lowest protein concentration. Only every third (3.4mg/ml) or fifth (0.028mg/ml)
scan is shown for clarity. B, four continuous size distributions obtained from fitting the scan boundaries with the Lamm equation. The peaks assigned to
monomeric (m) and dimeric (d) decorin are labeled. C, determination of the dimer dissociation constant. The dimer fractions were obtained by integration of
the monomer and dimer peaks in the c(s) distributions. The solid line is a non-linear least square fit of the data by the equation describing a monomer-dimer
equilibrium (see “Experimental Procedures”).
FIGURE 4. Determination of the dimer dissociation constants of decorin
mutants Y51A/R52A/Q54A and R151E by sedimentation velocity analy-
sis. The dimer fractions were obtained by integration of the monomer and
dimer peaks in the c(s) distributions. The solid lines are non-linear least square
fits of thedata by the equationdescribing amonomer-dimer equilibrium (see
“Experimental Procedures”).
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showing that dimerization is reversible and that the concave
face of decorin is involved alternatively in dimerization or col-
lagen binding (Table 2).
Using analytical ultracentrifugation, we determined a disso-
ciation constant of 1.37 M for the mouse decorin dimer. A
similar study of biglycan dimerization determined a dissocia-
tion constant of 4.5 M (calculated from a free energy of asso-
ciation of7.3 kcal/mol) (15). Thus, at the high concentrations
typically used in solution scattering (17, 18) and crystallization
experiments (14, 18), decorin and biglycan are dimers, but at
plausible physiological concentrations, dimers will dissociate
into monomers. In unfolding experiments with decorin and
biglycan, denaturation coincideswith a transition from (folded)
dimer to (unfolded) monomer (17, 18). This finding has been
interpreted as evidence that folded monomers cannot exist
(18). By engineering glycosylation sites into the dimer interface,
we have created decorin mutants (Q61N and Y130N) that
remainmonomeric at high concentration. The thermal stability
of these mutants slightly exceeded that of wild-type decorin,
likely due to a commonly observed stabilizing effect of engi-
neered glycans (32). Thus, dimerization clearly is not essential
to stabilize the decorin fold. Proteins that are structurally
related to decorin and are stable monomers, such as Nogo
receptor (34, 35) or LRR domain 3 of Slit (36), exist. Other
proteins that dimerize similarly to decorin, such as LRRdomain
4 of Slit (37) or AMIGO-1 (38), also exist. In contrast to our
findings with decorin, mutation of interface residues in
AMIGO-1 affected protein folding and secretion (38). Thus,
the possibility remains that some SLRPs do not dissociate into
stable monomers, but we believe that this is no longer a tenable
scenario for decorin.
FIGURE 5. Thermal stabilities ofWT andmutantmouse decorin. A, unfold-
ing transitions obtained by differential scanning calorimetry at a protein con-
centration of 3 mg/ml in PBS. The melting temperatures derived from the
peak maxima are 50 (WT) and 52 °C (Q61N), respectively. B, unfolding transi-
tions obtainedbydifferential scanning fluorimetry at a protein concentration
of 0.181mg/ml in PBS. Themelting temperatures derived from the inflection
points of the curves are 49 (R151E), 50 (WT and Y51A/R52A/Q54A), and 51 °C
(Q61N and Y130N), respectively. Shown is a representative of two independ-
ent experiments carried out in triplicate. A.U., arbitrary units.
FIGURE 6. Collagen binding by WT and mutant mouse decorin. A, inhibi-
tion of collagen fibrillogenesis by WT and mutant mouse decorin. Type I col-
lagen (32g/ml) was incubated at pH 7.8 and 37 °C, and the turbidity arising
from fibril formation was recorded as absorbance at 400 nm. The decorin
proteins were added at a concentration of 50 g/ml. Shown is a representa-
tive of three independent experiments. B, collagen binding by WT and
mutantmouse decorin. Type I collagenwas immobilized onmicrotiter plates
and incubatedwith varying amounts of decorin proteins. Bounddecorin pro-
teins were detected as absorbance at 492 nm using an antibody-linked color
reaction. The solid lines are fits of the data by an equation describing single
site binding. Shown is a representative of three independent experiments
carried out in duplicate.
TABLE 2
Summary of results obtained with mouse decorin and its mutants
Protein
Location of
mutated residue(s)
Oligomeric
statea
Collagen
bindingb
WT Monomer-dimer
equilibrium
Yes
Y51A/R52A/Q54A N-terminal cap Monomer-dimer
equilibrium
Yes
Q61N LRR1 Monomer No
Y130N LRR4 Monomer No
R151E LRR5 Monomer-dimer
equilibrium
No
a Determined by SEC-MALS (Fig. 2) and analytical ultracentrifugation (Figs. 3
and 4).
b Determined by inhibition of collagen fibrillogenesis and solid-phase binding
(Fig. 6).
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Engineering glycosylation sites into LRR1 (Q61N mutant)
and LRR4 (Y130N mutant) or reversing the charge of a key
residue in LRR5 (R151Emutant) abolished the ability of decorin
to inhibit collagen fibrillogenesis and reduced collagen binding
in a solid-phase binding assay. In contrast, a drastic triplemuta-
tion in theN-terminal cap region (Y51A/R52A/Q54A) had only
a modest effect on collagen binding. Previous mutagenesis
studies additionally implicate LRR6 (21) and LRR7 (22) in col-
lagen binding. Thus, the picture that is emerging is that a large
part of the concave surface of monomeric decorin may be
involved in collagen binding. In agreement with this view, a
recent modeling study using the experimentally derived struc-
ture of fibrillar type I collagen (39, 40) concluded that the
decorin monomer could interact with up to six triple helices at
the fibril surface (24).
An alternative interpretation of our results is that the mono-
meric decorin mutants Q61N and Y130N are inactive because
collagen binding requires an intact decorin dimer (14). If this
were the case, the R151E mutant, which dimerizes similarly to
wild-type decorin, would be expected to bind collagen, but this
is not the case. Using Equation 1 and the experimentally deter-
mined dimer dissociation constants, we estimate that 50% of
wild-type decorin and 34% of the R151Emutant are available as
monomers in the fibrillogenesis assay. This modest difference
cannot explain the complete loss of collagen binding resulting
from theR151Emutation. The simplest explanation is thatArg-
151 (and the concave face as a whole) is directly involved in the
binding of monomeric decorin to collagen fibrils. The ultimate
proof for this model would require a mutant that is monomeric
and binds collagen like wild-type decorin. Such mutants may
well be elusive given that the dimer interface is formed precisely
by the region most likely responsible for collagen binding.
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